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analysis in a cost-effective manner.  Trimethoprim was an effective inhibitor of rosiglitazone 
metabolism in vitro and it increased rosiglitazone concentrations in vivo by 31%.  In addition, 
there was a strong relationship (r2=0.97, p=0.0021) between trimethoprim plasma concentration 
and fold inhibition in subjects who did not carry the CYP2C8*3 allele, suggesting genotype 
influences the extent of CYP2C8 inhibition.  Administration of St. John’s wort increased 
rosiglitazone clearance by 35%, but CYP2C8 genotype did not affect the magnitude of induction.  
Finally, genotype did not affect basal rosiglitazone metabolism.  Since changes have been 
observed with other CYP2C8 metabolized drugs, polymorphic effects of CYP2C8 may be 
substrate dependent.  In conclusion, these results support the use of rosiglitazone as an in vivo 
probe of CYP2C8 activity, as it is affected by CYP2C8 inhibitors and inducers.  The clinical 
benefits of CYP2C8 substrates may be influenced by these and other CYP2C8 modulators and 
therefore rosiglitazone could serve as a probe to detect these interactions.    
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 Chapter 1 
Introduction and Background 
 
 
 1
 Cytochrome P450 Superfamily 
The Cytochrome P450 (CYP) superfamily of enzymes is responsible for the breakdown of 
numerous xenobiotics as well as endogenous compounds (Bertz and Granneman, 1997; Rendic, 
2002), including an estimated 60% to 80% of medications prescribed in the United States (Fisher 
et al., 2001; Venkatakrishnan et al., 2001).  CYP enzymes catalyze Phase I biotransformation 
reactions, which include oxidation (e.g., hydroxylation), reduction (e.g., nitroreduction), and 
hydrolysis (e.g., ester hydrolysis) (Rendic, 2002).  CYP enzymes are hemoproteins primarily 
found in the smooth endoplasmic reticulum of hepatocytes with extrahepatic expression in the 
intestine, lungs, kidneys, and brain (Venkatakrishnan et al., 2001).  These enzymes are stratified 
into families, subfamilies, and individual isoforms using a nomenclature system originally 
proposed by Nebert et al., (1987), in which the name begins with the root “CYP,” followed by an 
Arabic number indicating the family (>40% amino acid sequence homology), a letter designating 
the subfamily (>55% sequence homology), and an Arabic number indicating the individual gene, 
e.g., CYP2C8 (Nelson et al., 1996). 
 To date there are more than 270 different CYP gene families, 18 recorded in mammals, 
which encode for 57 CYP genes in humans (Nebert and Russell, 2002).  Although there are a 
large number of CYP genes, the CYP1, CYP2, and CYP3 families are the primary groups 
involved in drug metabolism, facilitating the breakdown of drugs and endogenous compounds 
such as arachidonic acid and eicosanoids (Nebert and Russell, 2002).  The CYP1 family 
preferentially metabolizes polycyclic aromatic hydrocarbons, arylamines, and N-heterocyclics 
(Nebert and Russell, 2002).  The CYP2 family is the largest of the mammalian CYP families as it 
consists of 13 subfamilies and metabolizes nearly half of all frequently prescribed drugs (Nebert 
and Russell, 2002).  Finally, the CYP3 family consists of four enzymes, of which CYP3A4 and 
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 CYP3A5 are the most abundantly expressed CYP enzymes in the liver (Nebert and Russell, 
2002) and metabolize approximately 50% of all of the drugs broken down by CYP enzymes 
(Bertz and Granneman, 1997).   
 Genetic polymorphisms, which occur at a frequency of 1% or greater in the population 
(Nebert, 1999), are of increasing importance in drug metabolism and have been found in every 
major CYP gene.  CYP variants are named according to the guidelines published by Shows et al., 
(1987), which recommended that gene and allele (designated by Arabic numerals), are separated 
by an asterisk, e.g. CYP2C9*2 (Shows et al., 1987).  If allelic variants share key mutations but 
differ in respect to other base changes, they are given the same Arabic number (allele group) 
followed by a capitalized letter (allele subgroup), e.g. CYP2C19*2A (Daly et al., 1996).  The 
first consensus or reference sequence is designated as *1, and subsequent variants (i.e., *2, 
*3,…) are sequentially named as they are approved by the Human Cytochrome P450 Allele 
Nomenclature Committee (http://www.imm.ki.se/CYPalleles/) (Ingelman-Sundberg et al., 2000; 
Nebert, 2000).  Polymorphisms occur primarily from single nucleotide polymorphisms (SNPs), 
which may be synonymous, present with no change in amino acid sequence, or nonsynonymous, 
exhibit variation of the amino acid sequence through substitution, addition, or deletion.  
Nonsynonymous SNPs may cause the creation of an alternative splice site, a frameshift mutation, 
gene deletion, or premature stop codon, causing non-functional alleles, e.g., CYP2C19*3.  
Alternatively, these SNPs may alter the amino acid sequence producing an allele with decreased 
metabolic activity, e.g., CYP2C9*3. 
 Interest in CYP activity continues to intensify due to the large number of xenobiotics and 
endogenous compounds metabolized by these enzymes and the influence of genetic 
polymorphism.  Some of these enzymes, such as CYP3A, are responsible for the breakdown of 
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 many compounds and are well studied; whereas the in vivo activity of other enzymes, such as 
CYP2C8, are relatively unknown, but are of growing importance as new substrates continue to 
be discovered.  The purpose of the following body of work is to better characterize the role of 
CYP2C8 in vivo and to learn how modulators of CYP2C8 activity influence drug metabolism by 
this enzyme. 
CYP2C Subfamily 
The CYP2C subfamily is part of the largest family of CYP enzymes, CYP2 (Nebert and Russell, 
2002), and constitutes approximately 20% of all CYP enzymes expressed in the liver (Shimada 
et al., 1994).  CYP2C enzymes contribute to the metabolism of approximately 20% of all drugs 
metabolized by the CYP superfamily of enzymes (Bertz and Granneman, 1997).  Members of the 
CYP2C subfamily include CYP2C8, CYP2C9, CYP2C18, and CYP2C19.  A listing of important 
inhibitors, inducers, and substrates for each enzyme in this subfamily is shown in Table 1.  The 
list includes some drugs that are known to be selectively metabolized by these enzymes, such as 
rosiglitazone (CYP2C8) (Baldwin et al., 1999), S-warfarin (CYP2C9) (Rettie et al., 1994), and 
S-mephenytoin (CYP2C19) (Goldstein et al., 1994).  To date, no substrates have been found for 
CYP2C18. 
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 Table 1 Substrates, inhibitors, and inducers of CYP2C8, CYP2C9 and CYP2C19 
 
CYP2C8(a) CYP2C9(b) CYP2C19(c) 
 Substrates  
rosiglitazone  
paclitaxel 
repaglinide 
amodiaquine 
chloroquine 
morphine N-demethylation  
R-(-)-ibuprofen 
Amiodarone 
S-warfarin 
tolbutamide 
phenytoin 
losartan 
diclofenac 
piroxicam 
S-(+)-ibuprofen 
R-(-)-ibuprofen 
glipizide 
irbesartan 
 
S-mephenytoin 
omeprazole 
propranolol 
imipramine 
proguanil activation to 
cycloguanil 
 Inhibitors(d)  
trimethoprim 
gemfibrozil 
quercetin 
ketoconazole 
amiodarone 
fluconazole 
fluvoxamine 
sulfamethoxazole 
modafinil 
 
fluoxetine 
fluvoxamine 
ticlopidine 
modafinil 
 Inducers(d)  
rifampin 
hyperforin 
phenobarbital 
rifampin 
hyperforin 
phenobarbital 
rifampin 
hyperforin 
phenobarbital 
(a) From references: Rahman et al., 1994, Hamman et al., 1997, Baldwin et al., 1999, Ohyama et al., 2000, Li et al., 2002, 
Bidstrup et al., 2003, Projean et al., 2003a, and Projean et al., 2003b.  
(b) From references: Goldstein and de Morais, 1994, Rettie et al., 1994, Sullivan-Klose et al., 1996, Hamman et al., 1997, 
Bourrie et al., 1999, Kidd et al., 1999, Kidd et al., 2001, Yasar et al., 2001. 
(c) From references: Ward et al., 1989, Ward et al., 1991, Goldstein et al., 1994, Chang et al., 1995, and Koyama et al., 1997. 
(d) Adapted from http://medicine.iupui.edu/flockhart/table.htm 
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CYP2C gene structure and regulation  
The CYP2C subfamily is encoded on chromosome 10q24 in a cluster of 500 kb oriented in the 
Cen-CYP2C18-CYP2C19-CYP2C9-CYP2C8-Tel direction (Figure 1) (Gray et al., 1995).  The 
CYP2C8 gene, which is comprised of nine exons ( ), is the smallest of the CYP2C 
subfamily, spanning approximately 31 kb (Klose et al., 1999).   In comparison, the CYP2C9 and 
CYP2C18 genes each span more than 50 kb, and CYP2C19 more than 90 kb (de Morais et al., 
1993; Klose et al., 1999).  The nucleotide and amino acid sequences of the CYP2C subfamily are 
highly conserved as members share greater than 80% homology (Table 2) (Goldstein and de 
Morais, 1994).  
Figure 2
 
 
CYP2C18 CYP2C19 CYP2C9 CYP2C8
 
 
Figure 1 Schematic representation of the CYP2C subfamily locus on chromosome 10q24.  Adapted from Gray 
et al., 1995 and NCBI (http://www.ncbi.nlm.nih.gov/).  Arrows indicate direction of transcription. 
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5’                
              3’ 1 2  3  4  5  6  7  8 9 
2450 bp 2300 bp 6000 bp 2700 bp 3800 bp 11500 bp 
1560 bp 1540 bp 
 171 bp 
 
Figure 2 Schematic representation of the CYP2C8 locus.  Exons are indicated by number above block and 
lengths of intronic regions are shown by numbers below the figure.  Adapted from Dai et al., 2001. 
 
 
 
Table 2 Nucleotide and amino acid percent homology of CYP2C cDNA. The upper value represents the 
nucleotide homology and the lower represents amino acid homology.  Adapted from Goldstein and de 
Morais, 1994. 
 
 CYP2C8 CYP2C9 CYP2C18 CYP2C19 
CYP2C8 
--- 
--- 
82.8 
89.4 
83.7 
88.7 
82.6 
90.6 
CYP2C9 
82.8 
89.4 
--- 
--- 
85.6 
92.7 
93.9 
95.7 
CYP2C18 
83.7 
88.7 
85.6 
92.7 
--- 
--- 
85.7 
92.7 
CYP2C19 
82.6 
90.6 
93.9 
95.7 
85.7 
92.7 
--- 
--- 
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 Similar to nucleotide and amino acid sequence conservation, the regulatory and upstream regions 
of the CYP2C subfamily have significant homology.  The regulatory region is well conserved 
between CYP2C8 and CYP2C9 as the 5’-flanking regions share 75% homology, but these 
sequences share only ~44% homology with the CYP2C18 regulatory region (de Morais et al., 
1993; Goldstein and de Morais, 1994).  One consensus sequence found in the upstream regions 
of the CYP2C8, CYP2C9, and CYP2C18 genes is the HepG2-specific factor 1 (HPF-1) 
(Venepally et al., 1992), which serves as a binding region for hepatocyte nuclear factor 4 (HNF-
4) (Sladek et al., 1990; Chen et al., 1994).  HPF-1 has been implicated in the hepatic regulation 
of CYP2C genes in rabbit (Chen et al., 1994) and is the principal cis-acting element in positive 
regulation of the CYP2C9 promoter (Ibeanu and Goldstein, 1995).  Binding sites for hepatic 
nuclear factor 3γ (HNF-3γ) have also been found in this 5’-flanking region of CYP2C genes 
(Bort et al., 2004).  Other liver-enriched transcription factors that regulate CYP2C transcription 
such as the CCAAT/enhancer binding protein (C/EBP), hepatocyte nuclear factor 1 (HNF-1), 
and activating protein 1 (AP-1), have been found in the promoter regions of CYP2C8, CYP2C9, 
and CYP2C18 (de Morais et al., 1993; Klose et al., 1999).     
 Analysis of the promoter region of the CYP2C genome has revealed binding sites for the 
orphan nuclear receptors, a class of nuclear receptors involved in the regulation of drug 
metabolizing enzymes.  Nuclear receptors are ligand-activated transcription factors that are 
loosely categorized into two groups based on ligand status, classical and orphan nuclear 
receptors (Mangelsdorf and Evans, 1995; Mangelsdorf et al., 1995; Giguere, 1999).  Receptors 
of known endocrine ligands, such as the hormones Vitamin D and all-trans-retinoic acid were 
identified as classical members, while receptors cloned, which had no known ligands were 
referred to as orphan nuclear receptors (Giguere, 1999).  Two of the most notable orphan nuclear 
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 receptors involved in the regulation of drug metabolism are the pregnane X receptor (PXR) and 
the constitutive androstane receptor (CAR) (Waxman, 1999; Fuhr, 2000; Moore et al., 2002).   
Ligands of the orphan nuclear receptors, such as rifampin (a) bind to the nuclear receptor (PXR) 
causing (b) a translocation of the ligand-receptor complex into the nucleus, (c) 
heterodimerization of this ligand-receptor to the retinoid X receptor-α (RXRα), where the 
heterodimer (d) binds to the DNA binding region, leading to (e) increased expression of the 
target protein ( ) (Giguere, 1999). Figure 3
Figure 3 Mechanism of CYP activation in via the orphan nuclear receptors.  (a) An exogenous ligand, such as 
rifampin, binds to PXR, which causes a (b) translocation into the nucleus and (c) heterodimerization 
with RXRα, followed by (d) the binding of the heterodimeric complex to the PXR response element 
(PXR-RE) in the promoter region of the DNA resulting in (e) an increase in transcription of the 
target protein(s). 
 
 
Ligand 
(a) RXR(b) (c)
Nucleus 
Nuclear 
Receptor   
(PXR) (d) (e)
Cell Cytosol DNA
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 Binding regions for the orphan nuclear receptors, known as response elements (RE) for PXR, 
CAR, and the glucocorticoid receptor (GR), PXR-RE, CAR-RE and GRE, respectively, have 
been found in the upstream regions for CYP2C8 (Ged and Beaune, 1991), CYP2C9 (de Morais et 
al., 1993; Ferguson et al., 2002; Chen et al., 2004), and CYP2C19 (Chen et al., 2003).  The GR 
ligand dexamethasone is a weak inducer of the CYP2C subfamily having modest effects on 
CYP2C8 and CYP2C19, and little effect on CYP2C9 activity (Gerbal-Chaloin et al., 2001; 
Raucy et al., 2002).  Known ligands for PXR (e.g., rifampin) and CAR (e.g., phenobarbital) 
increase CYP2C8, CYP2C9, and CYP2C19 mRNA and protein expression in hepatocyte 
cultures (Gerbal-Chaloin et al., 2001; Raucy et al., 2002; Chen et al., 2003).  Further, the 
induction of CYP2C8 by rifampin is similar to patterns observed with CYP3A induction (Raucy 
et al., 2002).  Hyperforin, a major constituent of the herbal supplement St. John’s wort, is 
another PXR ligand that induces CYP enzymes, including CYP2C8 (Moore et al., 2000; 
Wentworth et al., 2000; Chen et al., 2004; Komoroski et al., 2004).  In vivo, rifampin induces 
CYP2C19, CYP2C9, and CYP2C8 activity and significantly decreases exposure of the substrates 
mephenytoin (Feng et al., 1998), glipizide (Niemi et al., 2001a), and rosiglitazone (Park et al., 
2004a), respectively.  Further, St. John’s wort increases clearance of the CYP2C9 substrate 
warfarin (Jiang et al., 2004), and the CYP2C19 substrate mephenytoin (Wang et al., 2004b). 
Human CYP2C Expression and Distribution 
Expression of the CYP2C subfamily is age dependent as protein concentrations are not found in 
fetal tissue, but rise quickly after birth, reaching approximately 50% of adult expression after one 
year.  During this stage of development, CYP2C9 is the major isoform detected (Treluyer et al., 
1997).  The CYP2C subfamily is primarily distributed in the liver and small intestine, but 
CYP2C8 and CYP2C9 exhibit a wide array of extrahepatic distribution ( ).   Table 3
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 Table 3 Human distribution of CYP2C subfamily member mRNA and protein.  Observations determined by 
Zeldin et al., 1995, Hukkanen et al., 1997, Mace et al., 1998, McFayden et al., 1998, Klose et al., 1999, 
Glaeser et al., 2002, Lapple et al., 2003, and Enayetallah et al., 2004. 
 
 CYP2C8 CYP2C9 CYP2C18 CYP2C19 
mRNA     
Liver +++ ++++ ++ + 
Small Intestine + +++ +++ ++ 
Kidney ++ + + - 
Brain ++ - + - 
Ovaries + + - - 
Lung* 
BAM 
BM/PL 
 
+ 
++ 
 
+ 
+ 
 
++ 
++ 
 
+ 
- 
Adrenal gland + + - - 
Mammary gland + - + - 
Uterus + + - - 
Testes - + - - 
Prostate - + - - 
Protein     
Liver +++ ++++ - ++ 
Small Intestine + +++ - ++ 
Kidney ++ +++ NE NE 
Adrenal gland + ++ NE NE 
Uterus - + NE NE 
Prostate - + NE NE 
Salivary glands + ++ NE NE 
Stomach - ++ NE NE 
Spleen - ++ NE NE 
Large intestine ++ ++ NE NE 
Epidermis - + NE NE 
Lymph nodes - + NE NE 
Endometrium - + NE NE 
Tonsils + + NE NE 
Key: +: Relative abundance versus CYP2C enzymes; -: not detected in tissue; NE: not examined 
  * BAM: Bronchoalveolar macrophages; BM: Bronchial Mucosa; PL: Peripheral Lung Tissue  
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 Hepatic mRNA expression of the CYP2C subfamily presents in the rank order of CYP2C9 > 
CYP2C8 > CYP2C18 > CYP2C19.  Hepatic protein expression is similar, but CYP2C18 is not 
detectable (Lapple et al., 2003).  CYP2C9 and CYP2C18 mRNA are equally expressed in the 
small intestine (distal duodenum and proximal jejunum), followed by CYP2C19 and CYP2C8.  
As for intestinal protein expression, CYP2C9 is the most abundant, followed by CYP2C19, 
CYP2C8 (found below the limits of quantification), and CYP2C18 (not detectable) (Klose et al., 
1999; Glaeser et al., 2002; Lapple et al., 2003).   Relative expression of the CYP2C enzymes is 
tissue specific as CYP2C9 protein is 10 fold greater in the liver compared to the kidney, and 
CYP2C8 mRNA is approximately 25 fold greater in the liver than the intestine (Lapple et al., 
2003).  Further, CYP2C8 and CYP2C9 have significantly greater activity in the liver than the 
intestine and their activities correlate with protein expression (Lapple et al., 2003). 
 Extrahepatic expression of the CYP2C subfamily occurs in the bronchoalveolar 
macrophages and lymphocytes, and peripheral lung tissue (Hukkanen et al., 1997; Mace et al., 
1998).  In the bronchial mucosa, CYP2C8 and CYP2C18 are the primary mRNA expressed 
followed by CYP2C9 (low) and CYP2C19 (none) (Mace et al., 1998).  CYP2C8 and CYP2C9 
mRNA have been detected in the kidney, with CYP2C8 being the predominant isoform (Zeldin 
et al., 1995; Klose et al., 1999).  Regional distribution of CYP2C8 and CYP2C9 in the kidney 
occurs in the proximal and distal tubules and collecting ducts, but not in the glomeruli 
(Enayetallah et al., 2004).  In the brain, CYP2C8 mRNA is detected in the cerebellum, midbrain, 
basal ganglia, and frontal and temporal cortices (McFayden et al., 1998).  CYP2C8 and CYP2C9 
mRNA expression in other tissues of interest includes mammary gland, testes, adrenal gland, 
prostate, uterus, and ovaries (Klose et al., 1999).  Finally, immunohistochemical staining reveals 
CYP2C8 protein in salivary glands, large intestine, and tonsils and CYP2C9 protein in the 
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 salivary glands, stomach, pancreas, tonsils, spleen, lymph nodes, epidermis, and endometrium 
(Enayetallah et al., 2004).  Overall, the CYP2C subfamily is primarily distributed in the liver but 
is detected in numerous tissues including the small intestine, kidney, and brain. 
Polymorphic Expression of the CYP2C subfamily 
Within the CYP2C subfamily considerable polymorphic expression exists, which influences the 
metabolism of a number of compounds.  All enzymes of the CYP2C subfamily have 
demonstrated polymorphic expression with the primary focus on CYP2C9 and CYP2C19.   
CYP2C19   
The anticonvulsant mephenytoin was one of the first drugs noted to exhibit variable metabolism, 
which lead to the investigation of polymorphic expression of CYP2C19.  CYP2C19, originally 
designated P-450MP, has 19 allelic variants (Table 4) and mediates the 4’-hydroxylation of S-
mephenytoin (Goldstein et al., 1994).  The bioconversion of S-mephenytoin serves as a 
phenotypic trait measure of CYP2C19 and is used to distinguish, extensive metabolizers (EMs), 
and carriers of variant alleles, poor metabolizers (PMs) (Desta et al., 2002).  PMs are commonly 
found in the Asian population with a frequency of 12 to 23% (Bertilsson et al., 1992; Desta et 
al., 2002); however, the frequency of PMs in the Caucasian population is approximately 1 to 6% 
(Goldstein et al., 1997; Xie et al., 1999; Desta et al., 2002).  The PM phenotype is associated 
with decreased metabolism of S-mephenytoin (de Morais et al., 1994b), omeprazole (Chang et 
al., 1995), and diazepam (Wan et al., 1996).  Further the PM phenotype has been implicated in 
pharmacodynamic response as cure rates of Helicobacter pylori are significantly better in PMs 
than EMs (Furuta et al., 1998; Tanigawara et al., 1999).   
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Table 4 CYP2C19 allele nomenclature.  Adapted from Human Cytochrome P450 (CYP) Allele Nomenclature 
Committee (http://www.imm.ki.se/CYPalleles/) 
 
Change Enzyme effect CYP2C19 
Genotype Exon Nucleotide Amino Acid In vitro In vivo 
*1A -- None None Normal Normal 
*1B 7 99C>T; 991A>G Ile331Val Normal Normal 
*1C 7 991A>G Ile331Val Normal Normal 
*2A 5 *1B and 681G>A; 990C>T splicing defect Inactive Inactive 
*2B 5 *1B and 276G>C; 681G>A; 990C>T 
splicing defect; 
Glu92Asp Inactive Inactive 
*3 4 *1C and 636G>A; 1251A>C Stop Codon Inactive Inactive 
*4 1 *1B and 1A>G GTG Initiation Codon ND Inactive 
*5A 9 1297C>T Arg433Trp Inactive Inactive(a) 
*5B 9 *1B and 1297C>T Arg433Trp Inactive Inactive(a) 
*6 3 *1B and 395G>A Arg132Gln Inactive Inactive(a) 
*7 - IVS5+2T>A Splicing defect ND Inactive(a) 
*8 3 358T>C Trp120Arg Decreased Inactive(a) 
*9 3 *1B and 431G>A Arg144His Decreased TBD 
*10 5 *1B and 680C>T; Pro227Leu Decreased TBD 
*11 3 *1B and 449G>A Arg150His Normal TBD 
*12 9 *1B and 1473A>C Stop
491Cys (26 extra 
amino acids) Unstable TBD 
*13 8 *1C and 1228C>T Arg410Cys Normal TBD 
*14 1 *1B and 50T>C Leu17Pro ND TBD 
*15 1 *1C and 55A>C Ile19Leu ND TBD 
*16 9 1324C>T Arg442Cys TBD TBD 
 
Key: Decreased: Decreased activity versus CYP2C19*1/*1; Increased: Increased activity versus CYP2C19*1/*1; 
TBD: To be determined; Inactive: Inactive enzyme is produced; ND: Not determined; (a) Observed in n = 1. 
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 The PM phenotype is primarily due to two alleles, CYP2C19*2 and CYP2C19*3, which account 
for greater than 99% of PMs in the Asian population and approximately 88% of PMs in the 
Caucasian population (de Morais et al., 1994a; de Morais et al., 1994b; Goldstein et al., 1997).   
CYP2C19*2, originally designated CYP2C19m1 (de Morais et al., 1994b), is present in 
frequencies of 0.25, 0.13, 0.32, and 0.23 in the African-American, Caucasian, Chinese, and 
Japanese populations, respectively (Goldstein et al., 1997).   Direct sequencing of CYP2C19 led 
to the discovery of a mutation at 276G>C in 15% of individuals carrying the CYP2C19*2 allele 
and was designated CYP2C19*2B, while the original allele was named CYP2C19*2A (Ibeanu et 
al., 1998b).  CYP2C19*3, which accounts for approximately 25% of PMs, is primarily found in 
the Asian population (de Morais et al., 1994a).  The mutation occurs from the 636G>A 
transversion and produces a premature stop codon and truncated CYP2C19 protein (de Morais et 
al., 1994a).  The CYP2C19*4 allele is due to a deficient GTG initiation codon (1A>G), which 
produces an inactive enzyme, and has an allele frequency of 0.006 in the Caucasian population, 
(Ferguson et al., 1998).  CYP2C19*5A and CYP2C19*5B were each found in a single subject 
and causes reduced enzyme activity due to the 1297C>T mutation in the heme binding domain of 
CYP2C19.  The combined allelic frequencies of CYP2C19*5A and CYP2C19*5B are 0.0025 and 
< 0.009 in the Chinese (Bai ethnic group) and Caucasian populations, respectively (Ibeanu et al., 
1998a).  CYP2C19*6 and CYP2C19*7 have deficient catalytic activities in vitro, and were found 
in approximately 1.4% of previously studied PMs; however these alleles are extremely rare as 
they were not detected in a large sample of French Caucasians (n = 344) (Ibeanu et al., 1998b; 
Ibeanu et al., 1999).   CYP2C19*8 demonstrates 11 fold lower activity in vitro versus 
CYP2C19*1B and was demonstrated to have an allelic frequency of 0.007 in French Caucasian 
lung cancer patients (Ibeanu et al., 1999).  Of the remaining alleles, only CYP2C19*9, 
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 CYP2C19*10, and CYP2C19*12, which are found in the African (African American and African 
Pygmies) population at allele frequencies ranging from 0.01 to 0.02, appear to have decreased in 
vitro enzyme activity (Blaisdell et al., 2002).  Of note, CYP2C19*12 produces an unstable 
enzyme as the CYP2C19*1 stop codon is replaced with 491Cys and 26 additional amino acids 
(Blaisdell et al., 2002).   
 While numerous CYP2C19 allelic variants have been discovered, the variants 
CYP2C19*2 and CYP2C19*3 account for the majority of PM phenotypes in the population.  
Further, the alleles CYP2C19*1 through CYP2C19*8 account for approximately 99.7% of the 
PM phenotype, allowing genotyping procedures to be specific (Wedlund, 2000).  Other alleles, 
such as CYP2C19*10 and CYP2C19*12, should be investigated in vivo to determine their 
contribution to the PM phenotype. 
CYP2C9  
Thirteen allelic variants of CYP2C9 have been discovered to date ( ), with CYP2C9*2 and 
CYP2C9*3 being the primary focus of investigations.  CYP2C9*2 has an allele frequency of 
approximately 0.13 in the Caucasian population (Stubbins et al., 1996; Dickmann et al., 2001), 
varies from 0.01 to 0.025 in the African American population, and is rarely expressed in the 
Asian population (Sullivan-Klose et al., 1996; Dickmann et al., 2001).  Similarly, CYP2C9*3 
has an allelic frequency of approximately 0.08 in the Caucasian population and 0.0125 in the 
African American population (Sullivan-Klose et al., 1996; Dickmann et al., 2001).  Both of these 
alleles decrease CYP2C9 activity in vitro (Rettie et al., 1994; Crespi and Miller, 1997; Yamazaki 
et al., 1998; Takanashi et al., 2000), but the CYP2C9*3 allele has a more profound effect as it 
reduces the intrinsic clearance of S-warfarin (Sullivan-Klose et al., 1996; Yamazaki et al., 1998), 
flurbiprofen (Yamazaki et al., 1998), losartan (Yasar et al., 2001), and tolbutamide (Sullivan-
Table 5
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 Klose et al., 1996; Inoue et al., 1997) to a much greater extent.  Similar results were observed 
with in vivo studies demonstrating that the CYP2C9*3 allele has a greater impact on the 
metabolism of losartan (Babaoglu et al., 2004), flurbiprofen (Lee et al., 2003a), and tolbutamide 
(Kidd et al., 1999) than the CYP2C9*2 allele.  Further the CYP2C9*2 and CYP2C9*3 alleles 
affect the pharmacodynamic response of warfarin as carriers require lower daily maintenance 
doses and experience a greater number of bleeding complications than wild-type patients 
(Higashi et al., 2002). 
 
Table 5 CYP2C9 allele nomenclature.  Adapted from Human Cytochrome P450 (CYP) Allele Nomenclature 
Committee (http://www.imm.ki.se/CYPalleles/) 
 
Change Enzyme effect CYP2C9 
Genotype Exon Nucleotide Amino Acid In vitro In vivo 
*1 -- None None Normal Normal 
*2 3 430C>T Arg144Cys Decreased - 
*3 7 1075A>C Ile359Leu Decreased Decreased 
*4 7 1076T>C Ile359Thr Decreased TBD 
*5 7 1080C>G Asp360Glu Decreased Decreased 
*6 5 818delA Frameshift ND Inactive(a) 
*7 1 55C>A Leu19Ile Normal TBD 
*8 3 449G>A Arg150His Increased TBD 
*9 5 752A>G His251Arg Normal TBD 
*10 5 815A>G Glu272Gly Normal TBD 
*11 7 1003C>T Arg335Trp Decreased TBD 
*12 9 1465C>T Pro489Ser Decreased TBD 
*13 2 269T>C Leu90Pro ND Decreased(a) 
 
Key:  Decreased: Decreased activity versus CYP2C9*1/*1; Increased: Increased activity versus CYP2C9*1/*1; 
TBD: To be determined; Inactive: Inactive enzyme is produced; ND: Not determined; (a) Observed in n = 1. 
* Promoter region mutations have been omitted to simplify the table 
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 The CYP2C9*4 allele has reduced CYP2C9 activity in vitro and is present in the Japanese 
population at an allele frequency of 0.02 (Ieiri et al., 2000; Imai et al., 2000).  The CYP2C9*5 
allele is present in 0.017 of the African American population, has lower in vitro activity 
(Dickmann et al., 2001), and carriers of this allele appear to demonstrate lower losartan 
clearance versus wild type subjects (Allabi et al., 2004).  A null allele, CYP2C9*6 is detectable 
in the African American population at an allelic frequency of 0.006, and like CYP2C9*5, is not 
observed in Caucasian or Asian populations (Kidd et al., 2001).  This allele appears to cause a 
decrease in phenytoin clearance with associated toxicity (Kidd et al., 2001) and a decrease in the 
clearance of losartan (Allabi et al., 2004).  Blaisdell et al.,(Blaisdell et al., 2004) recently 
identified allelic variants designated CYP2C9*7 through CYP2C9*12, which have allele 
frequencies ranging from 0.006 to 0.03 in African populations.  Of these variants, the 
CYP2C9*8, CYP2C9*11, and CYP2C9*12 alleles have altered in vitro metabolic activities in 
comparison with the wild-type allele (Blaisdell et al., 2004).  The final allele, CYP2C9*13, was 
identified in a Chinese population with an allele frequency of 0.01 and was associated with 
decreased CYP2C9 activity (Si et al., 2004). 
 To date it appears that CYP2C9*2 and CYP2C9*3 are the most relevant CYP2C9 alleles 
in the Caucasian population.  Further investigation is necessary to determine the in vivo 
relevance the other CYP2C9 variants in various populations. 
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 CYP2C8 
The importance of CYP2C8 in drug metabolism has increased over the last decade as new 
substrates for this enzyme have been discovered.  The 6′-hydroxylation of paclitaxel has served 
as the classical in vitro marker of CYP2C8 activity (Rahman et al., 1994; Dai et al., 2001; Dierks 
et al., 2001).  Several CYP2C8 allelic variants that cause nonsynonymous changes in the protein 
have been identified (Table 6 and Figure 4).   
 
 
Table 6 CYP2C8 allele nomenclature.  Adapted from Human Cytochrome P450 (CYP) Allele Nomenclature 
Committee (http://www.imm.ki.se/CYPalleles/) 
 
Change Enzyme effectCYP2C8 
Genotype Exon Nucleotide Amino Acid In vitro 
*1 -- None None Normal 
*1B -- -271C>A N/A Normal 
*1C -- -370T>G N/A Normal 
*2 5 805A>T Ile269Phe Decreased 
*3 
3 
8 
416G>A 
1196A>G 
Arg139Lys  
Lys399Arg Decreased 
*4 5 792C>G Ile264Met Normal 
*5 3 475delA Frameshift Inactive 
Key: Decreased: Decreased activity versus CYP2C8*1/*1 ; Increased: Increased activity versus CYP2C8*1/*1 ; 
TBD: To be determined; Inactive: Inactive enzyme is produced. 
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Figure 4 Schematic representation of the CYP2C8 gene with known polymorphisms.  Arrows indicate 
polymorphisms and respective single nucleotide polymorphisms.  Adapted from Nakajima et al., 
2003. 
 
The CYP2C8*2 allele is primarily expressed in the African American population at an allele 
frequency of 0.18.  This variation results from an 805A>T mutation and reduces the intrinsic 
clearance of paclitaxel (Dai et al., 2001).  The CYP2C8*3 allele is primarily detected in the 
Caucasian population at an allele frequency ranging from 0.13 to 0.17 (Dai et al., 2001; Martinez 
et al., 2004) and is produced by two separate single nucleotide polymorphisms, 416G>A in exon 
3 and 1196A>G in exon 8, which decrease paclitaxel turnover (Dai et al., 2001; Soyama et al., 
2001).  In vivo, the CYP2C8*3 allele appears to increase the clearance of repaglinide (Niemi et 
al., 2003c), but decrease the clearance of R-(-)-ibuprofen (Martinez et al., 2004).   Since the 
pharmacokinetic results are quite different for these compounds, further investigation of the 
CYP2C8*3 allele in vivo is warranted.  CYP2C8*3 is also linked to the CYP2C9*2 allele as 96% 
of subjects presenting with the CYP2C8*3 variant express CYP2C9*2 (Yasar et al., 2002).  The 
contribution of each of these variants is apparent on the metabolism of racemic ibuprofen, 
(Garcia-Martin et al., 2004) and together may influence the metabolism of other substrates 
*2 – 792C>G  
1 2  3  4  5  6  7  8 9 
2450 bp 2300 bp 6000 bp 2700 bp 3800 bp 11500 bp 
1560 bp 1540 bp 
 171 bp *5 475delA 
*3 – 1196A>G 
*3 – 416G>A *4 – 805A>T 
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 metabolized by both CYP2C8 and CYP2C9.  The CYP2C8*4 allele, a 792C>G transversion, is 
found in Caucasians at an allelic frequency of approximately 0.075 (Bahadur et al., 2002).  The 
metabolism of paclitaxel (Bahadur et al., 2002) in vitro and repaglinide in vivo (Niemi et al., 
2003c) are not significantly different than metabolism by the wild type allele, suggesting that this 
variant does not alter CYP2C8 activity.  However, it should be noted that in the repaglinide 
evaluation, only three subjects genotyped as CYP2C8*1/*4 were compared to nineteen 
CYP2C8*1/*1 subjects and there was large variability in clearance.  A larger and more balanced 
study design may be needed to determine the in vivo relevance of carrying the CYP2C8*4 allele.  
The deletion of adenine at position 475 produces a rare frameshift mutation, CYP2C8*5, that has 
an allele frequency of approximately 0.0025 in the Japanese population (Nakajima et al., 2003).  
This deletion is thought to cause the initiation of a stop codon at codon 177 (Soyama et al., 
2002b), and has been implicated in toxicity associated with the CYP2C8 substrate cerivastatin 
(Nakajima et al., 2003; Ishikawa et al., 2004).  Two other variants are found upstream of the 
CYP2C8 translation region, CYP2C8*1A and CYP2C8*1B, which have no effect on CYP2C8 
expression (Bahadur et al., 2002).  To date the CYP2C8*2, CYP2C8*3, and CYP2C8*4 alleles 
have been investigated in vitro, but the in vivo effects are not completely understood.  To 
investigate the significance of these mutations, a probe drug of CYP2C8 activity would be 
useful. 
 
Probe Drugs 
Substrates metabolized primarily by an individual enzyme are useful for estimating enzyme 
activity.  When used for in vitro investigations, these substrates may be drugs, paclitaxel 
(CYP2C8) (Baldwin et al., 1999; Masimirembwa et al., 1999), endogenous compounds, 
testosterone (CYP3A) (Masimirembwa et al., 1999), or chemical entities synthesized to be 
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 enzyme selective, 7-ethoxy-4-trifluoromethylcoumarin (CYP2B6) (Jinno et al., 2003).  When 
used for in vivo investigations, synthesized chemical entities and endogenous compounds (e.g., 
testosterone) have many substantial drawbacks, the most important being safety.  These 
compounds may not be approved for human use or safe to administer to specific groups, such as 
women or children.  One approach to estimate in vivo CYP activity is to employ a probe drug, a 
substrate primarily metabolized by an individual enzyme.  A probe drug ideally would possess 
the following characteristics: safety, a relatively short half-life, metabolism exclusively mediated 
by the pathway of interest (and that pathway is the major route of metabolism), and rapid 
excretion of the metabolite (Watkins, 1994).  To evaluate hepatic CYP activity, considerations 
for a probe substrate include a low extraction ratio, the lack of first pass metabolism, and lack of 
interindividual variability of the volume of distribution and protein binding (Watkins, 1994).  
Several examples of probe drugs include caffeine (CYP1A2) (Sharma et al., 2004), S-
mephenytoin and omeprazole (CYP2C19) (Chang et al., 1995; Frye et al., 1997; Chainuvati et 
al., 2003), tolbutamide (CYP2C9) (Lee et al., 2003b), metoprolol (CYP2D6) (Sharma et al., 
2004), chlorzoxazone (CYP2E1) (Frye et al., 1997; Poloyac et al., 1999), and midazolam 
(CYP3A) (Lee et al., 2002).   
 Several candidate drugs exist to evaluate in vivo CYP2C8 activity including 
rosiglitazone, repaglinide, and paclitaxel.  Although paclitaxel is commonly used to assess in 
vitro activity (Dai et al., 2001), it is an antineoplastic agent that can not be administered safely to 
healthy volunteers (Sonnichsen et al., 1995).  Repaglinide is a safer alternative to paclitaxel, but 
it is metabolized into several metabolites, which are produced by both CYP2C8 and CYP3A 
(Bidstrup et al., 2003).  Since repaglinide is metabolized by CYP3A, drug interactions related to 
CYP2C8 and CYP3A, such as induction by rifampin (Raucy et al., 2002), would complicate 
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 interpretation.  Rosiglitazone may be suitable for use as an in vivo CYP2C8 probe since it has a 
favorable safety and pharmacokinetic profile and it is primarily metabolized by CYP2C8 
(Baldwin et al., 1999). 
Rosiglitazone  
Rosiglitazone (Avandia®) is an antihyperglycemic medication used in the treatment of type 2 
diabetes mellitus, and is a member of the thiazolidinedione class of drugs, which are commonly 
referred to as “the glitazones” (Wagstaff and Goa, 2002).  Members of this class of 
antihyperglycemic agents include rosiglitazone, pioglitazone, and troglitazone ( ); 
(troglitazone was withdrawn from the market by the U.S. Food and Drug Administration (FDA) 
due to hepatic toxicity).  Thiazolidinedione medications exert their clinical effect through the 
Peroxisome Proliferator-Activated Receptor-γ (PPARγ).  Activation of this receptor by the 
thiazolidinediones leads to increased glucose utilization and metabolism, increased fatty acid 
utilization, decreased endogenous glucose production, and decreased tissue resistance to glucose 
(Mayerson et al., 2002).  This class of medications does not trigger the pancreas to secrete 
insulin like other antihyperglycemic agents, such as the sulfonylureas (e.g., glipizine or 
tolbutamide), and therefore does not cause hypoglycemia in healthy volunteers (Cox et al., 2000; 
Inglis et al., 2001; Miller et al., 2002). 
Figure 5
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Figure 5 Structures of the thiazolidinedione class of antihyperglycemic agents. 
 
 
For the treatment of type 2 diabetes mellitus, the standard dosage begins at 4 mg daily, but can 
be increased to 8 mg daily.  Rosiglitazone can be used as monotherapy as well as adjuvant 
therapy with insulin or metformin (Wagstaff and Goa, 2002).  The most common adverse events 
associated with daily rosiglitazone administration include upper respiratory tract infection, 
injury, and headache (Wagstaff and Goa, 2002); however, peripheral edema is a concern after 
repeated administration (Thomas and Lloyd, 2001; Niemeyer and Janney, 2002; Idris et al., 
2003).  Unlike the hepatic problems that plagued troglitazone, very few cases of liver failure 
have been reported (Al-Salman et al., 2000; Lee et al., 2002) and the incidence of elevated 
transaminase levels is low (Wagstaff and Goa, 2002).  Further, retrospective analysis of over 
6000 patients and subjects that received rosiglitazone in controlled trials concluded that no major 
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 cases of hepatic toxicity occurred (Lebovitz et al., 2002).  Rosiglitazone pharmacokinetic 
parameters are as follows: half-life of approximately 3 to 4 hours, albumin protein binding of 
0.99, and bioavailability of approximately 0.99 (Wagstaff and Goa, 2002).  Administration in the 
presence of food can prolong the time until peak plasma concentration, but there is no effect on 
oral bioavailability (Freed et al., 1999).  End stage renal disease and age do not affect 
rosiglitazone absorption and disposition (Thompson-Culkin et al., 2002; Wagstaff and Goa, 
2002).  Rosiglitazone is completely metabolized, primarily, into two major metabolites, para-
hydroxyrosiglitazone and N-desmethylrosiglitazone (Figure 6).  The sulfate conjugate of the 
former, para-O-sulfate rosiglitazone, and N-desmethylrosiglitazone account for > 80% of all 
metabolites isolated in plasma.  After single dose administration, para-O-sulfate rosiglitazone 
accounts for approximately 16% of the dose excreted in the urine and no unchanged parent drug 
is found (Cox et al., 2000).  In terms of PPARγ activation, rosiglitazone metabolites are 55% less 
potent than the parent compound (Wagstaff and Goa, 2002).  
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Figure 6  Metabolism of rosiglitazone into two major metabolites.  Biotransformation of rosiglitazone to 
para-hydroxyrosiglitazone and N-desmethylrosiglitazone is performed primarily by CYP2C8, with 
a minor contribution of CYP2C9 (Baldwin et al., 1999).  
 
     
Drug interaction studies have demonstrated that rosiglitazone pharmacokinetic parameters were 
not influenced by acarbose (Miller et al., 2001), ranitidine (Miller et al., 2002), sucralfate (Rao et 
al., 2002), and metformin (Di Cicco et al., 2000a).  However, the CYP inhibitors ketoconazole 
and gemfibrozil decrease the clearance of rosiglitazone (Niemi et al., 2003a; Park et al., 2004b) 
and the CYP inducer rifampin substantially increases rosiglitazone clearance (Park et al., 2004a).  
Contrary to in vitro studies that implicate the thiazolidinediones, troglitazone, pioglitazone and 
rosiglitazone, as inducers of CYP3A activity (Sahi et al., 2003), rosiglitazone has no clinical 
effect on the metabolism of CYP3A substrates, nifedipine (Harris et al., 1999), ethinylestradiol, 
and norethindrone (Inglis et al., 2001).  Further, rosiglitazone does not affect exposure to 
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 metformin (Di Cicco et al., 2000a), or the P-glycoprotein substrate, digoxin (Di Cicco et al., 
2000b).  Therefore, based on the safety and pharmacokinetic profile, rosiglitazone may serve as a 
good CYP2C8 probe. 
Summary and Introduction to Dissertation 
CYP2C is an important enzyme subfamily in drug metabolism as it is widely distributed in the 
body, metabolizes approximately 20% of known CYP substrates, and is influenced by a number 
of CYP inhibitors and inducers.  While a multitude of studies have investigated CYP2C9 and 
CYP2C19 activity in vivo, little work has focused on CYP2C8.  Since rosiglitazone is primarily 
metabolized by CYP2C8 and has a favorable pharmacokinetic and safety profile, it would be 
advantageous to investigate its utility as an in vivo probe of CYP2C8 activity.   
 The following research will evaluate rosiglitazone as a CYP2C8 probe through the 
development of assay methods instrumental in determining CYP2C8 genotype and plasma 
concentrations of rosiglitazone and trimethoprim, as well as clinical studies to evaluate 
rosiglitazone disposition in the presence of trimethoprim (inhibitor), St. John’s wort (inducer), 
and CYP2C8 allelic variants.  The aim of Chapter 2 was to develop a simplified method to 
determine rosiglitazone concentrations in human plasma.  Development of an improved method 
for the determination of trimethoprim concentrations in human plasma is presented in Chapter 3.  
The goal of Chapter 4 was to utilize Pyrosequencing technology as a means to determine 
CYP2C8 genotype in a high-throughput design.  The aim of Chapter 5 was to investigate the 
effect of the CYP2C8 inhibitor trimethoprim on rosiglitazone metabolism in vitro and in vivo.  
The objective of Chapter 6 was to evaluate the effect of the herbal supplement, St. John’s wort, 
on the in vivo metabolism of rosiglitazone.  The goal of Chapter 7 was to characterize the 
pharmacokinetics of rosiglitazone in subjects carrying the variant alleles, CYP2C8*2, 
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 CYP2C8*3, and CYP2C8*4.  The work herein was performed to demonstrate the utility of 
rosiglitazone as an in vivo probe of CYP2C8 activity, through the evaluation of rosiglitazone 
metabolism in the presence of genetic and non-genetic factors that affect CYP2C8 activity. 
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 Chapter 2 
Simplified Method for Determination of Rosiglitazone in Human Plasma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Hruska MW and Frye RF.  Simplified Method for Determination of Rosiglitazone in Human 
Plasma.  J Chromatogr B 2004;803(2): 317-20.] 
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 Abstract 
Rosiglitazone is a thiazolidinedione antihyperglycemic drug used in the treatment of type 2 
diabetes mellitus.  Rosiglitazone is extensively metabolized by cytochrome P450 2C8 and may 
have some utility as an in vivo probe for this enzyme.  A liquid chromatographic method using 
sensitive fluorescence detection and simplified sample processing involving protein precipitation 
with acetonitrile was developed.  The isocratic mobile phase consisted of 10 mM sodium 
acetate-ACN (pH 5; 60:40, v/v) and was delivered at a flow rate of 1 ml/min to an Alltima 
phenyl column (250 mm x 4.6 mm, 5 micron).  Detection was by fluorescence at (EX/EM) 
247/367 for rosiglitazone and 235/310 for the internal standard betaxolol.  Intra- and inter-day 
precision ranged from 3.1% – 8.5% and 2.3% – 5.7%, respectively.  No endogenous interference 
was observed with either rosiglitazone or the internal standard.  The assay is simple, economical, 
precise, and is directly applicable to human pharmacokinetic studies involving single dose 
rosiglitazone administration. 
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 Introduction 
Rosiglitazone (Figure 7) is a thiazolidinedione antihyperglycemic drug used in the treatment of 
type 2 diabetes mellitus.  Thiazolidinedione antihyperglycemic agents exert their effect through 
the Peroxisome Proliferator-Activated Receptorγ (PPARγ), which facilitates the expression of 
genes responsible for glucose and lipid metabolism (Balfour and Plosker, 1999).  Rosiglitazone 
has a half-life in humans of approximately 3 to 4 hours, a volume of distribution of 
approximately 18 liters, and it is 99.8% bound to plasma proteins (Balfour and Plosker, 1999). 
Rosiglitazone undergoes extensive metabolism with essentially no parent drug excreted 
unchanged in the urine.  The two major metabolites of rosiglitazone isolated via microsomal and 
animal studies are para-hydroxyrosiglitazone and N-desmethylrosiglitazone, both of which are 
produced by cytochrome P450 (CYP) 2C8 (Bolton et al., 1996; Baldwin et al., 1999). 
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Figure 7  Structures of (A) Rosiglitazone and (B) Betaxolol (internal standard). 
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 Since rosiglitazone is predominantly metabolized by CYP2C8, it may have potential use as an in 
vivo probe of this enzyme.  Availability of a simple method for determination of rosiglitazone in 
human plasma would aid in the evaluation of rosiglitazone as a CYP2C8 probe.  Several methods 
have been published but each has drawbacks limiting ease of use.  Muxlow, et al., developed a 
method using the automated sequential trace enrichment of dialysates (ASTED) system 
combined with fluorescence detection (Muxlow et al., 2001).  A drawback of this method is that 
it requires a specialized extraction system (ASTED) and it uses a synthesized internal standard, 
both of which are not readily available.  Also, the linear standard curve range extended only to 
100 ng/ml, which is not ideal for human pharmacokinetic studies of rosiglitazone.  After a single 
dose of rosiglitazone, maximum plasma concentrations exceed 600 ng/ml (Cox et al., 2000).  
Mamidi et al., reported a method that is linear up to 1000 ng/ml, but uses an internal standard 
that is not commercially available (Mamidi et al., 2002).  The method of Kolte et al., utilizes 
HPLC linked to ultraviolet detection and a commercially available compound (pioglitazone) as 
the internal standard (Kolte et al., 2003).  However, the method requires a large sample volume 
(1 ml) and a prolonged analysis time of 25 min per sample.  Thus, the goal of this work was to 
establish a method that has a simple and inexpensive extraction method, requires a small plasma 
sample volume, and has a readily available internal standard.  In this paper, we introduce an 
HPLC fluorescence method with simplified sample processing to quantify rosiglitazone in 
human plasma.  The method was used to determine rosiglitazone plasma concentrations after 
single-dose administration. 
 32
 Experimental 
Chemicals and Reagents 
Rosiglitazone reference standard (≥ 98%) was purchased from Cayman Chemical Company 
(Ann Arbor, MI, USA).  Betaxolol reference standard (100%) was obtained from United States 
Pharmacopeia (Rockville, MD, USA).  Sodium Acetate and acetonitrile (ACN) were purchased 
from Fisher Scientific (Pittsburgh, PA, USA).  Blank human plasma was purchased from the 
Central Blood Bank of Pittsburgh (Pittsburgh, PA, USA).  HPLC grade deionized water was 
obtained from an in-house Millipore (Billerica, MA, USA) water system. 
Instrumentation and Chromatographic Conditions 
   The HPLC system consisted of a Waters 501 Pump coupled with a Waters model 2475 
fluorescence detector (Waters Corp., Milford, MA).  Detection and quantification was performed 
using Millennium32 software version 3.1 (Waters Corp., Milford, MA).  Separation was 
achieved with a 250 mm x 4.6 mm, 5µm Alltima phenyl column (Alltech Associates Inc., 
Deerfield, IL) and an isocratic mobile phase of 10 mM sodium acetate (pH 5)-ACN (60:40, v/v) 
delivered at a flow rate of 1 ml/min.  Rosiglitazone was monitored at λex of 247, λem of 367 and 
betaxolol was monitored at λex of 235 and λem of 310.  During each sample run, λex = 247 and 
λem = 367 was monitored from 0 to 7 and 10 to 15 minutes, and λex = 235 and λem = 310 was 
monitored from 7 to 10 minutes.  The total run time was 15 min. 
Standard Preparation 
Rosiglitazone stock solution was prepared at a concentration of 1 mg/ml in ethanol.  Dilutions 
that were prepared in ethanol at concentrations of 200ng/ml, and 2, 10, and 20 µg/ml were used 
to prepare calibration standards and quality control (QC) samples.   The internal standard (IS) 
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 betaxolol was dissolved in methanol to prepare a 25 µg/ml stock solution.  Blank plasma was 
spiked with appropriate stock solutions and brought up to 200 µL prior to processing. 
Sample Preparation 
IS (10 µL or 250 ng) was added to plasma samples (200 µL) in microcentrifuge tubes and 
vortexed briefly.  ACN (600 µL) was then added to each sample, vortexed for 2 min, and 
centrifuged at 3,000 g for 10 min.  Supernatant was evaporated using nitrogen gas in a heating 
block set at 45°C.  Dried samples were reconstituted with 200 µL of mobile phase and a 75 µL 
aliquot was injected onto the column. 
Calibration and Linearity 
Calibration curves consisted of seven standard concentrations of rosiglitazone in human plasma: 
5, 10, 50, 100, 250, 500, and 1000 ng/ml.  Duplicate calibration curves were analyzed daily for 3 
days, with the lowest concentration (5 ng/ml) prepared in triplicate.  For each curve, the 
rosiglitazone peak height to IS peak height ratio was calculated and plotted against nominal 
rosiglitazone concentrations.  Calibration curves for rosiglitazone were constructed by weighted 
(1/y2) linear regression analysis. 
Precision and Accuracy 
Precision and accuracy were determined by the analysis of rosiglitazone QC samples spiked at 
concentrations of 40, 400, and 750 ng/ml.  Replicate QC samples (n = 12) were analyzed on Day 
1 to determine intra-day precision and accuracy.  Inter-day precision and accuracy were 
determined by replicate QC samples on Day 1 (n =12), Day 2 (n = 6), and Day 3 (n= 6), for a 
total of n = 24 QC samples at each concentration.  Mean, standard deviation, and relative 
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 standard deviation (RSD) were calculated from QC values and used in the estimation of intra- 
and inter-day precision.  Accuracy (bias) is expressed as the percent difference between the 
calculated mean concentration relative to the nominal concentration. 
Selectivity and Stability 
Selectivity was assessed by processing six separate sources of blank plasma.  Blank plasma 
samples were processed in duplicate and compared to plasma spiked with the lowest 
rosiglitazone standard.  Sample carryover was determined by inserting vials of blank mobile 
phase in random positions throughout the third validation.  Batches of high and low QCs were 
prepared and subjected to three freeze-thaw cycles (-80°C to room temperature) prior to 
processing and analysis.  After each freeze thaw cycle, aliquots were extracted and analyzed.  To 
determine stability of processed samples, high and low QC samples were prepared and subjected 
to repeated analysis over a 24 h period post-extraction. 
Extraction Efficiency 
Extraction efficiency was determined by comparing the response obtained from extracted QC 
samples versus the response observed after direct injection of reference samples.  Reference 
samples consisted of water spiked with appropriate amounts of rosiglitazone.  Responses 
obtained from reference samples were defined as 100%. 
Application to plasma sampling 
Rosiglitazone pharmacokinetics were evaluated in a healthy volunteer.  The protocol was 
approved by the University of Pittsburgh Institutional Review Board and signed informed 
consent was obtained.  Rosiglitazone 8mg (Avandia, GlaxoSmithKline, Philadelphia, PA, 
USA) was administered orally with 8 ounces of water after an overnight fast.  Plasma was 
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 collected for 24 h, and stored at -20°C until analyzed.  Plasma concentrations of rosiglitazone 
were determined as described above.  The maximum observed rosiglitazone concentration 
(Cmax) and the time at which Cmax was observed (Tmax) are reported.  The terminal 
elimination rate constant (λz) was estimated by nonlinear least squares regression analysis of the 
terminal portion of the concentration-time curve.  The apparent elimination half-life was 
calculated as 0.693/λz. 
Results 
Chromatography 
Representative chromatograms of plasma samples are depicted in Figure 8.  Figure 8A depicts a 
blank plasma sample and a plasma sample spiked with rosiglitazone 5 ng/ml (LOQ); Figure 8B 
shows a plasma sample obtained 1 h after a single dose of rosiglitazone 8 mg.  Retention times 
were approximately 7.9 min and 13.2 min for IS and rosiglitazone, respectively.  The peaks of 
interest were well separated and free from interference with endogenous substances. 
Precision, Linearity, and Accuracy 
Linear calibration curves were obtained for rosiglitazone over the concentration range of 5 – 
1000 ng/ml; the mean regression equation was: Y = [0.0058 ± 0.0020]X + [0.0022 ± 0.0018].  
The correlation coefficients calculated for each run were > 0.99.  Intra- and inter- day precision 
(RSD) was ≤ 8.5% and accuracy was within ± 11.1% (Table 7).  The signal to noise ratios for 
rosiglitazone at 5 ng/ml and the I.S. at 250 ng were greater than 5:1 (Figure 8A). 
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Figure 8 Representative chromatographs of (A) extracted blank plasma (----) and plasma spiked (    ) at LOQ 
concentration of rosiglitazone 5 ng/ml (offset = 0.05mV); (B) rosiglitazone in plasma at 1 hour after 
single dose rosiglitazone 8 mg administration (concentration 210.2 ng/ml); Peaks (1) I.S., (2) 
Rosiglitazone. 
 37
  
 
 
Table 7 Intra- and inter-day precision and accuracy of rosiglitazone in plasma. 
 
 Concentration (ng/ml) 
 Spiked Observed 
(mean ± S.D.) 
 
% RSD 
 
 
% Bias 
Intra-assay Precision (n = 12) 
 
Quality Controls 
  
 40 38.5 ± 1.2 3.1 -3.8 
 400 367.2 ± 18.9 5.1 -8.2 
 750 759.6 ± 64.6 8.5 1.3 
Inter-assay Precision (n = 24) 
 
Quality Controls 
   
 40 38.1 ± 0.9 2.3 -4.8 
 400 355.8 ± 16.1 4.5 -11.1 
 750 706.0 ± 40.5 5.7 -5.9 
Standards     
 5 5.1 ± 0.3 6.0 1.1 
 10 10.0 ± 0.6 5.8 -0.4 
 50 50.5 ± 2.5 4.9 1.0 
 100 98.7 ± 3.9 4.0 -1.3 
 250 246.4 ± 5.6 2.3 -1.5 
 500 531.6 ± 43.8 8.2 6.3 
 1000 982.1 ± 28.2 2.9 -1.8 
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 Selectivity, Stability, and Recovery 
No endogenous interference with rosiglitazone or IS was observed in six different sources of 
blank plasma.  There was no evidence of sample carryover.  Rosiglitazone and IS were both 
stable in the injection solvent at room temperature for at least 24 h prior to injection.  Samples 
subjected to three freeze-thaw cycles showed no degradation of rosiglitazone.  Extraction 
recovery determined at the three QC concentrations was ~100% (Table 8). 
 
 
 
 
 
Table 8 Extraction recovery of rosiglitazone and internal standard from human plasma (n = 3). 
 
Spiked Concentration  
 
% Recovery 
  
 
% RSD  
Rosiglitazone (ng/ml)   
40 105.7 ± 5 4.68 
400 113.8 ± 2 1.36 
750 105.6 ± 1 0.94 
Internal Standard (µg/ml)   
25  96.7 ± 6 6.40 
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 Plasma Sampling 
The log concentration-time profile for a healthy subject administered rosiglitazone 8 mg as a 
single dose is illustrated in .  The observed Cmax was 697.3 ng/ml, which occurred at a 
tmax of 0.5 h; the observed t1/2 was 3.9 h.   
Figure 9
Figure 9 Log-concentration – time profile for subject administered single dose rosiglitazone (8 mg). 
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 Discussion 
The method presented here allows for simple and economical detection of rosiglitazone in small 
volumes of human plasma, using protein precipitation coupled with sensitive fluorescent 
detection.  The extraction technique does not require additional expensive solid phase extraction 
equipment such as the ASTED system (Cox et al., 2000; Muxlow et al., 2001).  Further, this 
method uses a commercially available fluorescent compound as an internal standard, rather than 
a synthesized thiazolidinedione-like structure as an internal standard (Cox et al., 2000; Mamidi 
et al., 2002).  Although the method developed by Muxlow et al. (Muxlow et al., 2001), was 
utilized in the clinical development of rosiglitazone, the standard range had a maximum 
concentration of 100 ng/ml.  Single dose rosiglitazone yields maximum plasma concentrations 
well above a threshold of 100 ng/ml, as shown by the data in  and other studies (Cox et 
al., 2000; Mamidi et al., 2002), so an additional dilution step would be required to fit within this 
standard curve range.  A more recent method described by Kolte et al. (Kolte et al., 2003), used 
a commercially available product as an internal standard but required a much larger volume of 
plasma due to less sensitive ultraviolet detection.  In the method presented here, smaller volumes 
of plasma can be analyzed since we used fluorescence detection, which has greater sensitivity 
than ultraviolet detection.  By extracting smaller plasma samples, less organic solvents may be 
used in extraction, yielding less cost and less time drying extracted samples.  The analysis time is 
also much shorter in this assay, 15 min versus 25 min, which cuts down on overall time of 
sample analysis.  Since there is no endogenous interferences in the regions where rosiglitazone 
and the IS elute (Figure 8), the analysis time could be decreased even further by using a shorter 
column. 
Figure 9
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 In this paper, we have introduced a simplified HPLC fluorescence method to quantify 
rosiglitazone in human plasma.  The method provides an economical, simple alternative to the 
methods previously published and is suitable for the determination of rosiglitazone plasma 
concentrations after single-dose administration. 
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 Chapter 3 
Determination of Trimethoprim in Low-Volume  
Human Plasma by Liquid Chromatography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Hruska MW and Frye RF. Determination of Trimethoprim in Low-Volume Human Plasma by 
Liquid Chromatography. J Chromatogr B 2004;807(2): 301-5.] 
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 Abstract 
 
Trimethoprim is an anti-infective agent used in the treatment of urinary and respiratory tract 
infections and mild to moderate pneumocystis carinii pneumonia.  Trimethoprim is also a 
selective in vitro inhibitor of cytochrome P450 2C8 and may have utility as an in vivo inhibitor 
of this enzyme.  A simplified high performance liquid chromatography (HPLC) method was 
developed to determine trimethoprim in human plasma.  Samples are processed by protein 
precipitation with perchloric acid and separation is achieved on a Synergi Polar-RP column (4 
micron, 150 mm x 4.6 mm) using a mobile phase consisting of 50 mM ammonium formate-
acetonitrile-methanol (pH = 3.0; 90:6:4, v/v/v).  Detection is monitored at 280 nm.  Intra- and 
inter-day precision ranged from 1.1% – 1.9% and 0.9% – 4.1%, respectively.  The assay is 
simple, economical, precise, and is directly applicable to human studies involving steady state 
trimethoprim pharmacokinetics. 
 44
 Introduction 
Trimethoprim (Figure 10), a dihydrofolate reductase inhibitor, is an anti-infective agent used 
predominantly in the treatment of urinary and respiratory tract infections (Dollery, 1999).  
Trimethoprim is also used in combination with sulfamethoxazole or dapsone to treat mild to 
moderate cases of pneumocystis carinii pneumonia (PCP) (Korraa and Saadeh, 1996).  Treatment 
of PCP requires trimethoprim doses of 15 - 23 mg/kg/day, which yields mean plasma 
concentrations of 6.7 to 18.4 µg/ml (23.1 – 63.4 µM) (Lee et al., 1989; Klinker et al., 1998).  
The frequency of severe adverse effects including neutropenia and thrombocytopenia increases 
when trimethoprim plasma concentrations exceed 8 µg/ml (Klinker et al., 1998).  Trimethoprim 
is well-absorbed after oral administration (bioavailability ~95%) and achieves peak plasma 
concentrations 1-4 hours after single dose administration.  It has a half-life of ~10 hours, protein 
binding of 44%, a volume of distribution ranging from 70 -100 L, and it is extensively eliminated 
in the urine as unchanged drug (Dollery, 1999). 
 In addition to its therapeutic applications, trimethoprim is a selective in vitro inhibitor of 
cytochrome P450 (CYP) 2C8 (Ki = 32 µM; 1µM = 290.3 µg/L) (Wen et al., 2002), and may be 
useful as an in vivo inhibitor of this enzyme.  Peak plasma concentrations after trimethoprim 200 
mg given twice daily are approximately 20 µM (Moore et al., 1996).  Wen et al. (2002), 
predicted based on expected plasma concentrations, that in vivo inhibition of CYP2C8 would be 
approximately 80% assuming that hepatic trimethoprim concentrations would be approximately 
130 µM, which is based on the liver to plasma partitioning ratio of 6.5:1 observed in monkeys 
(Craig and Kunin, 1973).  These observations suggest that trimethoprim may be useful as a 
selective enzyme inhibitor in vivo, but further study is required.
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Figure 10 (A) Trimethoprim (B) Sulfamethazine, Internal Standard (IS) 
 
There is a need to measure trimethoprim in plasma to ensure effective concentrations are 
achieved in patients being treated for PCP and also to aid in the evaluation of trimethoprim as an 
in vivo inhibitor of CYP2C8.  Thus, a simple, efficient method for determination of trimethoprim 
in plasma is desired.  Several methods for the determination of trimethoprim in human plasma 
have been reported (Gochin et al., 1981; DeAngelis et al., 1990; Laizure et al., 1990; Avgerinos 
et al., 1991; Pokrajac et al., 1998; Ronn et al., 1999).  In general they require large (1 ml) sample 
volumes (Gochin et al., 1981; Avgerinos et al., 1991; Pokrajac et al., 1998), involve a multi-step, 
lengthy extraction process or solid-phase extraction (DeAngelis et al., 1990; Ronn et al., 1999) 
or require the use of an ion-pairing agent for suitable chromatography with a C18 column 
(Laizure et al., 1990).  A large sample volume (e.g., 1 ml) is a problem in certain populations 
such as pediatric AIDS patients requiring trimethoprim therapy for PCP (Ronn et al., 1999).  
Ronn, et al. improved the applicability to special populations by decreasing the sample volume 
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 to 125 µL, but the sample preparation involved multiple steps including protein precipitation, 
transfer of supernatant and subsequent dilution with mobile phase (Ronn et al., 1999).  
Therefore, the goal of this work was to establish a method that uses a small sample volume and 
an efficient, economical extraction method.  In this paper, we introduce an HPLC method with 
simplified sample processing and ultraviolet wavelength detection to determine trimethoprim in 
human plasma.  The method was used to determine steady-state trimethoprim plasma 
concentrations in healthy human subjects. 
Experimental 
Chemicals 
 
Trimethoprim (≥ 98 %) reference standard and sulfamethazine (≥ 99%) (internal standard, IS) 
were purchased from Sigma-Aldrich (St. Louis, MO, USA).  Acetonitrile and methanol were 
obtained from Fisher Scientific (Pittsburgh, PA, USA).  Perchloric Acid was purchased from J.T. 
Baker (Phillipsburg, NJ, USA). Ammonium formate and formic acid were obtained from Sigma-
Aldrich (St. Louis, MO, USA).  Blank human plasma was purchased from the Central Blood 
Bank of Pittsburgh (Pittsburgh, PA, USA).  Deionized water was obtained from an in-house 
Millipore (Billerica, MA, USA) water system. 
HPLC Separation 
The HPLC system consisted of a Waters 2695 separation module and a Waters 486 Tunable 
Absorbance Detector (Waters, Corp., Milford, MA, USA).   Detection and quantification were 
performed using Millenium32 software version 3.1 (Waters, Corp., Milford, MA, USA).  
Separation was achieved with a Synergi Polar-RP 4µ 150 mm x 4.6 mm column (Phenomenex, 
Torrance, CA, USA) heated to 30°C and an isocratic mobile phase of ammonium formate (pH 
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 3.0; 50 mM)-acetonitrile (ACN)-methanol (MeOH) (90:6:4, v/v/v), delivered at a flow rate of 1 
ml/min.  The monitoring wavelength was set at 280 nm, with a run time of 14 minutes. 
Standard Preparation 
Trimethoprim stock solution was prepared at a concentration of 1 mg/ml in methanol.  Dilutions 
prepared in methanol at concentrations of 250 and 50 µg/ml were used to prepare calibration 
standards and quality control (QC) samples.  The internal standard (IS) sulfamethazine was 
dissolved in methanol to prepare a 50 µg/ml stock solution.  Standards and QC samples were 
prepared at the beginning of the validation experiment by spiking batches of blank human 
plasma and dispensing into 200 µL aliquots.  Aliquots were stored at –20°C until analysis was 
performed. 
Plasma Sample Preparation 
Aliquots of plasma (200 µL) were placed in microcentrifuge tubes, IS (10 µL or 500 ng) was 
added, and the tubes were briefly vortexed.  Perchloric acid (25 µL) was added to each sample, 
which was then vortexed for 2 minutes, and centrifuged at 3000 g for 10 minutes.  The 
supernatant was transferred to HPLC vials, and capped.  A 75-µL aliquot was injected onto the 
HPLC system for analysis. 
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 Calibration and Linearity 
Calibration curves consisted of seven non-zero standard concentrations of trimethoprim in 
human plasma: 0.5, 1, 2.5, 5, 7.5, 10, 20 µg/ml.  Duplicate calibration curves were assayed daily 
for 3 days, with the lowest concentration (0.5 µg/ml) prepared in triplicate.  For each curve, the 
trimethoprim to IS peak height ratios were calculated and plotted against the nominal 
trimethoprim concentration.  Calibration curves for trimethoprim were constructed by weighted 
(1/y2) linear regression analysis. 
Precision and Accuracy 
Precision and accuracy were determined by the analysis of trimethoprim QC samples spiked at 
concentrations of 2, 8, and 16 µg/ml.  Replicate QC samples (n = 12) were analyzed on Day 1 to 
determine intra-day precision and accuracy.  Inter-day precision and accuracy was determined 
from replicate QC samples analyzed on Day 1 (n = 12), Day 2 (n = 6), and Day 3 (n = 6) for a 
total of 24 QC samples at each concentration.  Mean, standard deviation and relative standard 
deviation (RSD) were calculated from the QC values and used in the estimation of intra- and 
inter-day precision.  Accuracy (bias) is expressed as the percent deviation between the mean 
concentration relative to the nominal concentration. 
Selectivity and Stability 
Selectivity was analyzed by processing six different sources of blank plasma. Blank plasma 
samples were processed in duplicate and compared to plasma spiked with the lowest 
trimethoprim standard.  Sample carryover was determined by inserting vials of blank mobile 
phase in various positions throughout the third validation run.  Batches of high and low QC 
samples were prepared and subjected to three freeze-thaw cycles prior to processing and 
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 analysis.  After each freeze thaw cycle, aliquots were extracted and analyzed and determined 
acceptable at > 95% peak height of control samples not exposed to the freeze-thaw cycles.  The 
stability of processed samples was determined by repeated analysis of high and low QC samples 
for over 24 hours post-extraction.  The limit of quantitation (LOQ) was defined as the lowest 
standard value having a signal to noise (S:N) ratio of at least 10:1 and acceptable precision and 
accuracy (i.e., within 15%).  The limit of detection (LOD) was defined as the smallest detectable 
peak having a S:N ratio of at least 3:1. 
Extraction Efficiency 
Extraction recovery of trimethoprim was calculated by comparing the response obtained from 
extracted QC samples versus the response observed after direct injection of reference samples.  
Reference samples consisted of water spiked with appropriate amounts of trimethoprim 
standards.  Responses obtained from the reference samples were defined as 100%. 
Application to Plasma Sampling 
Trimethoprim pharmacokinetics were determined in eight healthy volunteers.  The protocol was 
approved by the University of Pittsburgh Institutional Review Board and signed informed 
consent was obtained from each subject.  Trimethoprim, 2 × 100 mg tablets (Watson 
Pharmaceuticals, Corona, California, USA), were administered every 12 hours for a total of 5 
days.  Multiple plasma samples were collected for 48 hours after reaching steady state on Day 4 
and stored at –20°C until analyzed.  Plasma trimethoprim concentrations were determined as 
described above. 
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 Results 
Chromatographic Separation 
Representative chromatograms of plasma samples are shown in Figure 11.  Figure 11A depicts a 
double-blank sample (no IS) and a sample spiked with trimethoprim 0.5 µg/ml (LOQ) and IS.  
B shows a subject plasma sample obtained at steady-state during trimethoprim 200 mg 
twice daily administration.  Retention times were approximately 7.1 and 12.2 minutes for 
trimethoprim and IS, respectively.  The peaks of interest were well separated and free from 
interference with endogenous peaks.  Sulfamethoxazole eluted at approximately 9 minutes (data 
not shown) and did not interfere with either peak of interest. 
Figure 11
Precision, Linearity, and Accuracy 
Linear calibration curves were obtained for trimethoprim over the concentration range of 0.5 to 
20 µg/ml; the mean regression equation was: Y = 0.2083 ± 0.0013 X + 0.0033 ± 0.0002.  The 
correlation coefficients calculated for each run were >0.999.  Response remained linear at all 
concentrations with no saturation of signal.  Intra- and inter-day precision were within ± 5% and 
accuracy was within ± 6.25% (Table 9). 
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Figure 11 Representative chromatograms of (A) extracted double blank plasma (----) and plasma sample 
spiked (      ) with trimethoprim 0.5 µg/ml (LOQ) and IS and (B) Subject plasma sample after 
administration of trimethoprim 200 mg twice daily at steady state (concentration of 2.89 µg/ml); 
Peaks are (1) Trimethoprim and (2) IS. 
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 Table 9 Intra- and Inter-day precision and accuracy of trimethoprim in human plasma 
 
  
Concentration (µg/ml) 
 Spiked Observed 
(mean ± S.D.) 
 
% RSD 
 
% 
Deviation 
Intra-assay Precision 
Quality Controls 
  
 2.00 2.15 ± 0.04 1.7 7.5 
 8.00 7.52 ± 0.14 1.9 -6.0 
 16.0 15.3 ± 0.2 1.1 -4.4 
Inter-assay Precision 
Quality Controls 
   
 2.00 2.12 ± 0.04 1.9 6.0 
 8.00 7.64 ± 0.19 2.4 -4.5 
 16.0 15.3 ± 0.4 2.7 -4.4 
Standards     
 0.50 0.50 ± 0.01 1.4 -0.0 
 1.00 1.01 ± 0.02 2.0 1.0 
 2.50 2.55 ± 0.04 1.6 2.0 
 5.00 4.99 ± 0.08 1.6 -0.2 
 7.50 7.48 ± 0.07 0.9 -0.3 
 10.0 10.2 ± 0.3 2.9 2.0 
 20.0 19.5 ± 0.8 4.1 -3.0 
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 Selectivity, Stability, and Recovery 
No endogenous interference with trimethoprim or IS was observed in six extracted blank plasma 
samples and there was no evidence of sample carryover.  The signal to noise ratio of 
trimethoprim at 0.5 µg/ml and IS at 50 µg/ml were greater than 10:1.  The LOQ was 0.5 µg/ml 
and the LOD was 0.1 µg/ml with a S:N ratio of 5:1.   Trimethoprim and the IS were stable in 
processed samples at room temperature for at least 24 hours prior to analysis.  Samples subjected 
to three freeze-thaw cycles showed no sign of degradation.  Extraction efficiency determined at 
the three QC concentrations was approximately 76 to 80% ( ). Table 10
Table 10 Extraction recovery of trimethoprim and internal standard in human plasma (n = 3) 
Application to Plasma Sampling 
Eight healthy subjects received trimethoprim 200 mg twice daily for 5 days.  The mean (SD) 
steady-state concentration vs. time profile for all eight subjects on Day 4 is depicted in Figure 12.  
The concentrations observed were similar to those reported previously in HIV-infected subjects 
receiving trimethoprim 200 mg twice daily (Lee et al., 1996). 
 
 
 
 
Spiked Concentration Recovery (%) RSD (%) 
Trimethoprim (µg/ml)   
2.0 80.5 ± 0.9 1.14 
8.0 76.9 ± 0.7 0.96 
16.0 79.6 ± 1.1 1.41 
Internal Standard (µg/ml)   
50.0 90.7 ± 1.0 1.12 
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Figure 12 Mean ± SD concentration-time data at steady-state (Day 4) from 8 subjects after administration of 
trimethoprim 200 mg twice daily for 5 days. 
 
Discussion 
The method presented provides simplified and economical detection of trimethoprim in small 
volumes of human plasma, using protein precipitation coupled with ultraviolet detection.  We 
used protein precipitation to extract trimethoprim, which is less time consuming than liquid-
liquid extraction (Gochin et al., 1981) and less expensive than solid phase extraction (DeAngelis 
et al., 1990; Laizure et al., 1990).  Use of the phenyl Polar-RP column with a mobile phase 
containing a mixture of organic solvents yielded separation from endogenous interference and 
symmetrical peaks without the need for an ion-pairing agent.  Further, sulfamethoxazole, an 
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 agent commonly co-administered with trimethoprim, does not interfere with either peak of 
interest, so with modification this method could be used for pharmacokinetic studies involving 
the combination product.  This method allows unbiased detection of trimethoprim and is directly 
applicable to trimethoprim steady-state pharmacokinetic studies.   
   Trimethoprim is most commonly administered in combination with sulfamethoxazole (e.g., 
Bactrim), but the single drug formulation is used for selected applications.  Trimethoprim and 
sulfamethoxazole have been shown in vitro to selectively inhibit CYP2C8 and CYP2C9 activity, 
respectively; however, sulfamethoxazole loses selectivity and inhibits CYP2C8 activity at 
relatively high concentrations (Wen et al., 2002).  Therefore, to evaluate trimethoprim as a 
CYP2C8 inhibitor in vivo, the trimethoprim only formulation must be administered.  The 
trimethoprim only formulation is also used in combination with dapsone as an alternative 
treatment for PCP in patients who can not tolerate sulfamethoxazole.  Monitoring plasma 
concentrations of trimethoprim during PCP treatment may be helpful to verify therapeutic 
concentrations or to help avoid severe concentration-related adverse events, since increased 
neutropenia, thrombocytopenia, and severe adverse events has been associated with plasma 
concentrations greater than 8 µg/ml (Klinker et al., 1998). 
   In summary, the method presented here uses a simple extraction method, has consistent 
recovery efficiency, and is applicable for analyzing trimethoprim plasma concentrations in 
steady-state pharmacokinetic studies or patients receiving high dose trimethoprim therapy. 
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 Chapter 4 
A Pyrosequencing Method for Genotyping Cytochrome P450 2C8 and 2C9 Enzymes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Hruska MW, Frye RF, and Langaee TY. A Pyrosequencing Method for Genotyping 
Cytochrome P450 2C8 and 2C9 Enzymes. Clin Chem 2004;50(12):2392-5.] 
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 Introduction 
The cytochrome P450 enzymes CYP2C8 and CYP2C9 play important roles in drug metabolism 
(Dai et al., 2001; Goldstein, 2001; Bahadur et al., 2002).  Single nucleotide polymorphisms that 
have been identified in the genes encoding for these enzymes may contribute to variability in 
drug response due to alterations in metabolism.  CYP2C8 expression includes five alleles, 
CYP2C8*1 (wild type), CYP2C8*2, CYP2C8*3 (Dai et al., 2001), CYP2C8*4 (Bahadur et al., 
2002), and CYP2C8*5 (Soyama et al., 2001).  The variant alleles CYP2C8*2 and CYP2C8*3 
have been shown to have decreased enzyme activity in vitro (Dai et al., 2001), while CYP2C8*4 
expression appears to cause decreased CYP2C8 activity (Bahadur et al., 2002).  The allele 
frequency of CYP2C8*2 is 0.18 in the African-American population, while CYP2C8*3 and 
CYP2C8*4 are primarily expressed in the Caucasian population at frequencies of 0.13 and 0.075, 
respectively (Dai et al., 2001; Bahadur et al., 2002). 
Thirteen alleles of CYP2C9 have been identified to date and the majority of studies on 
these have focused on the importance of CYP2C9*2 (Crespi and Miller, 1997) and CYP2C9*3 
(Sullivan-Klose et al., 1996).  CYP2C9*4 is expressed in the Asian population at an allele 
frequency of 0.02, but does not appear to be expressed in Caucasians or African-Americans 
(Imai et al., 2000).  CYP2C9*5 and CYP2C9*6 are found primarily in African Americans at 
frequencies of 0.017 (Dickmann et al., 2001) and 0.006 (Kidd et al., 2001), respectively.  
Blaisdell et al. (Blaisdell et al., 2004) recently identified variants designated as CYP2C9*7 
through CYP2C9*12, which have allele frequencies ranging from 0.006 to 0.03 in African 
populations.  The CYP2C9*8, CYP2C9*11, and CYP2C9*12 alleles have altered in vitro 
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 metabolic activities in comparison with the wild-type allele CYP2C9*1 (Blaisdell et al., 2004)..  
Finally, CYP2C9*13 was identified in a Chinese population with an allele frequency of 0.01 and 
was associated with decreased CYP2C9 activity (Si et al., 2004).           
 Given the importance of these enzymes in the metabolism of multiple drugs, a reliable 
genotyping method that is amenable to high throughput applications would help facilitate 
research in this area.  Several restriction fragment length polymorphism (RFLP) methods have 
been developed to identify CYP2C8 and CYP2C9 alleles (Sullivan-Klose et al., 1996; Crespi and 
Miller, 1997; Dai et al., 2001; Bahadur et al., 2002).  These methods are reliable, but have 
several disadvantages that include the time required for enzymatic digestion, lack of feasible 
high throughput applications, potential for incomplete digestion, and increased cost per sample 
(Aquilante et al., 2004).  Other methods using the LightCycler (Burian et al., 2002) and tetra-
primer (Ye et al., 2001) technologies offer advantages over RFLP, but do not provide researchers 
with direct sequencing data. 
 Pyrosequencing is a less laborious process that relies on the release of pyrophosphate 
upon incorporation of a nucleotide into a DNA sequence to provide direct sequencing data, is 
ideal for the determination of allelic variants and by utilizing Multiplex Pyrosequencing 
numerous target DNA sequences may be analyzed in a single tube (Ronaghi, 2001; Pourmand et 
al., 2002).  We previously developed a Pyrosequencing method for CYP2C9 genotyping, but the 
original method only determines the two major variants found in Caucasian and 
African-American populations, CYP2C9*2 and CYP2C9*3 (Aquilante et al., 2004).  An 
improvement to our previous reported method is necessary in order to evaluate CYP2C9*4 and 
CYP2C9*5, which are located on the same exon as CYP2C9*3.   
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 The purpose of this study is to introduce an analytical method that determines all of the major 
CYP2C8 variants and the major CYP2C9 variants expressed in the population, CYP2C9*2, and 
in a single reaction, CYP2C9*3, CYP2C9*4, and CYP2C9*5. 
Methods 
DNA extraction and isolation:  
For DNA extraction and isolation, blood samples were collected from fifty consecutively 
identified healthy volunteers who signed informed consent.  The study was approved by the 
Institutional Review Board at the University of Florida.  Ethnicity was self-reported as 
African-American, 4 (0.08), Asian, 2 (0.04), Caucasian, 36 (0.72), and Hispanic, 8 (0.16).  
Approximately 10 ml of blood was withdrawn from each subject and DNA was extracted with a 
QIAamp® DNA Mini Kit (Qiagen) according to the manufacturer instructions.  Samples were 
stored at -20°C after extraction.  
Primers and PCR Conditions:  
Primers used for the PCR reactions and Pyrosequencing are shown in .  PCR reactions 
(25 µL) consisted of 12.5 µL HotStarTaq Master Mix (Qiagen), 1.5 µL DMSO, PCR primers 
(10 pmol), 7 µL of H2O, and 40 ng DNA.  PCR conditions were as follows: 95°C for 15 
minutes, 40 cycles consisting of (1) denaturation at 94°C for 30 seconds, (2) annealing at 56°C 
(55°C for CYP2C9; 58°C for CYP2C8 Exon 8) for 30 seconds, and (3) extension at 72°C for 45 
seconds, followed by final extension at 72°C for 7 minutes. 
Table 11
Pyrosequencing:  
Genotyping was performed using the previously described protocol (Aquilante et al., 2004).  
Briefly, PCR products (10 µl) were immobilized with streptavidin-coated Sepharose beads.  
Beads were isolated and treated with 70% ethanol, denaturation buffer, and wash buffer and 
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 released into a mixture of annealing buffer and 10 pmol sequencing primer (Table 11), heated at 
80°C for 2 minutes, and cooled to room temperature.  Pyrosequencing was performed for 
sequence determination and allele designation using a Biotage PSQ HS 96 System and data was 
captured on PSQ HS 96 SNP software.  The sequence of ten random subjects was determined in 
triplicate to verify robustness of the assay. 
Results 
Figure 13(a) depicts the predicted histograms and subject pyrograms for CYP2C8 Exon 5 in 
subjects presenting with the following genotypes: (i) CYP2C8*1/*1 , (ii) CYP2C8*1/*2 , (iii) 
CYP2C8*2/*2, (iv) CYP2C8*1/*4, and (v) CYP2C8*4/*4.  The predicted histogram and 
resultant pyrogram of a subject presenting as CYP2C9*1/*3 is illustrated in Figure 13(b).  The 
allelic frequencies of the sample population are listed in Table 11.  There were no allelic variants 
found in the Asian subjects and CYP2C9*4 and CYP2C9*5 were not found in the population 
studied.  Linkage disequilibrium was apparent between CYP2C8*3 and CYP2C9*2 as 7 of the 8 
(87.5%) subjects expressing the CYP2C8*3 allele also expressed CYP2C9*2.  Re-analysis of ten 
randomly selected samples in triplicate produced the same genetic sequence information. 
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 Figure 13 CYP2C8 Exon 5 sequence, predicted histograms and pyrograms. 
(a) CYP2C8 Exon 5 sequence used to determine genotypes for CYP2C8*2 (805A>T, indicated by left box) and CYP2C8*4 
(792C>G, indicated by the right box).  Beneath those are predicted histograms and pyrograms of subjects presenting as (i) 
homozygous wild type, CYP2C8*1/*1  (A/A and C/C) (ii) CYP2C8*1/*2  (A/T and C/C) (iii) CYP2C8*2/*2 (T/T and C/C) (iv) 
CYP2C8*1/*4 (A/A and C/G) and (v) CYP2C8*4/*4 (A/A and G/G) genotypes. (b) Predicted histogram and pyrogram of a 
subject with CYP2C9*1/*3 (A/C) genotype.  Allelic variation of CYP2C9 Exon 7 is determined from left to right as 
CYP2C9*5 (1080C>G), CYP2C9*4 (1076T>C), and CYP2C9*3 (1075A>C).  The order of nucleotide dispensation is located 
at the bottom of each pyrogram. 
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 Discussion 
The Pyrosequencing method presented here is directly applicable to studies involving genetic 
determination of CYP2C8 and CYP2C9 polymorphisms in a large sample population as our 
laboratory has used this assay to genotype several hundred samples (unpublished data) from a 
variety of sources including whole blood, urine, buccal swab, and mouthwash rinse.  A key 
advantage of Pyrosequencing is that the direct sequence data for each subject DNA is obtained.  
By obtaining the DNA sequence, little interpretation is necessary versus other methods such as 
RFLP where incomplete digestion may complicate data analysis.  Further, the time and cost per 
sample using Pyrosequencing is less than RFLP analysis (Aquilante et al., 2004).  A method 
using real-time PCR to determine CYP2C8 allelic variants was recently reported (Weise et al., 
2004).  The PCR method offers an advantage over RFLP in that it can be modified for high 
throughput applications, but it does not provide a direct sequence of DNA and therefore still 
requires some data interpretation.  Further, this RT-PCR method does not involve the 
determination of CYP2C9 genotype, which is important as a linkage between the allelic variants 
CYP2C8*3 and CYP2C9*2 exists (Yasar et al., 2002).  The data gathered in our investigation 
supports the previous report as similar frequencies of CYP2C8*3 and CYP2C9*2 linkage were 
found, but further investigation with a larger sample is necessary.  The method is also novel as it 
allows the genotyping of three separate allelic variants in one PCR reaction.  Unfortunately, we 
were unable to detect CYP2C9*4 and CYP2C9*5 carriers as the respective Asian and 
African-American population sample sizes were small.  A larger sample of these populations 
would be required to identify individuals carrying these alleles.  Additionally, with the recent 
discovery of other CYP2C9 allelic variants (Blaisdell et al., 2004; Si et al., 2004), adaptations of 
this method should allow detection of these variants.  
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 Chapter 5 
The Effect of Trimethoprim on CYP2C8 Mediated Rosiglitazone Metabolism  
in Human Liver Microsomes and Healthy Subjects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Hruska MW, Amico JA, Langaee TY, Ferrell RE, Fitzgerald SM, and Frye RF. The Effect of 
Trimethoprim on CYP2C8 Mediated Rosiglitazone Metabolism in Human Liver Microsomes 
and Healthy Subjects. Br J Clin Pharmacol  2005;59(1):70-9.] 
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 Abstract 
Aims: Rosiglitazone, a thiazolidinedione antidiabetic medication used in the treatment of Type 2 
diabetes mellitus, is predominantly metabolized by the cytochrome P450 (CYP) enzyme 
CYP2C8.  The anti-infective drug trimethoprim has been shown in vitro to be a selective 
inhibitor of CYP2C8.  The purpose of this study was to evaluate the effect of trimethoprim on 
the CYP2C8 mediated metabolism of rosiglitazone in vivo and in vitro. 
Methods:  The effect of trimethoprim on the metabolism of rosiglitazone in vitro was assessed 
in pooled human liver microsomes.  The effect in vivo was determined by evaluating 
rosiglitazone pharmacokinetics in the presence and absence of trimethoprim.  Eight healthy 
subjects (4 men and 4 women) completed a randomized, cross-over study.  Subjects received 
single dose rosiglitazone (8 mg) in the presence and absence of trimethoprim 200 mg given twice 
daily for 5 days. 
Results:  Trimethoprim inhibited rosiglitazone metabolism both in vitro and in vivo.  Inhibition 
of rosiglitazone para-hydroxylation by trimethoprim in vitro was found to be competitive with 
apparent Ki and IC50 values of 29 µM and 54.5 µM, respectively.  In the presence of 
trimethoprim, rosiglitazone plasma AUC was increased by 31% (p = 0.01) from 2774 +/- 645 µg 
l(-1) hr to 3643 +/- 1051 µg l(-1) hr (95% confidence interval (CI) for difference 189, 1549), and 
half-life was increased by 27% (p = 0.006) from 3.3 +/- 0.5 to 4.2 +/- 0.8 hours (95% CI for 
difference 0.36, 1.5).  Trimethoprim reduced the para-O-sulfate rosiglitazone/rosiglitazone and 
the N-desmethylrosiglitazone/rosiglitazone AUC(0-24) ratios by 22% and 38%, respectively.    
Conclusions:  These results indicate that trimethoprim is a competitive inhibitor of CYP2C8-
mediated rosiglitazone metabolism in vitro and that trimethoprim administration increases 
plasma rosiglitazone concentrations in healthy subjects. 
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 Introduction 
The significance of cytochrome P450 (CYP) 2C8 to drug elimination is expanding due to its 
relative distribution, polymorphic expression, and the rapidly increasing knowledge of its role in 
drug metabolism.  CYP2C8 is primarily distributed in the liver (Klose et al., 1999), and it is the 
second most abundant member of the CYP2C subfamily expressed in this organ (Lapple et al., 
2003).  CYP2C8 is also found in the lung (Mace et al., 1998), kidney, adrenal gland, mammary 
gland, brain, uterus, and ovary tissue (Klose et al., 1999).  CYP2C8 is polymorphically 
expressed with five allelic variants identified to date, CYP2C8*2 (Ile269Phe), CYP2C8*3 
(Arg139Lys, Lys399Arg) (Dai et al., 2001), CYP2C8*4 (Ile264Met) (Bahadur et al., 2002), and 
CYP2C8*5 (frame shift mutation) (Nakajima et al., 2003).  Altered in vitro activity has been 
demonstrated for the CYP2C8*2 and CYP2C8*3 variant alleles (Dai et al., 2001; Bahadur et al., 
2002; Nakajima et al., 2003).  The CYP2C8*2 allele is found mainly in African-Americans, has 
a frequency of 0.18, and is associated with decreased affinity for paclitaxel and a two-fold lower 
intrinsic clearance of 6α-hydroxypaclitaxel (due to a two-fold higher apparent Km with no 
change in Vmax).  The CYP2C8*3 allele has a frequency of 0.13, is found primarily in 
Caucasians, and is associated with decreased paclitaxel turnover (Dai et al., 2001).  These 
genetic polymorphisms may play a role in the pharmacokinetic and pharmacodynamic response 
to drugs metabolized by CYP2C8, which includes paclitaxel (Rahman et al., 1994), amodiaquine 
(Li et al., 2002), repaglinide (Bidstrup et al., 2003), morphine (Projean et al., 2003b), and 
rosiglitazone (Bolton et al., 1996; Baldwin et al., 1999; Cox et al., 2000). In addition, CYP2C8 
metabolizes retinoic acid (Nadin and Murray, 1999) and arachidonic acid (Zeldin et al., 1995; 
Dai et al., 2001) and so may have an important physiological role. 
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     Rosiglitazone is a thiazolidinedione antihyperglycemic agent used in the treatment of 
type 2 diabetes (Baldwin et al., 1999; Cox et al., 2000).  Thiazolidinediones exert their clinical 
effects via the peroxisome proliferator-activated receptor γ (PPAR γ), which facilitates the 
expression of genes responsible for glucose and lipid metabolism (Balfour and Plosker, 1999).  
Rosiglitazone undergoes extensive metabolism with essentially no parent drug excreted 
unchanged in the urine (Cox et al., 2000).  Rosiglitazone is primarily metabolized by CYP2C8, 
with CYP2C9 contributing to a minor extent (Baldwin et al., 1999).  The two major metabolites 
of rosiglitazone produced by CYP2C8 are para-hydroxyrosiglitazone and N-
desmethylrosiglitazone (Bolton et al., 1996; Baldwin et al., 1999), which account for >80% of 
all metabolic products isolated in human plasma after rosiglitazone administration (Cox et al., 
2000).  The sulfate conjugate of para-hydroxyrosiglitazone, para-O-sulfate-rosiglitazone is the 
major plasma metabolite (Cox et al., 2000).  Based on these characteristics, conversion of 
rosiglitazone to para-O-sulfate-rosiglitazone may be a useful index of CYP2C8 activity.   
 It has been suggested that one means by which an enzyme-selective probe drug can be 
validated is to evaluate its pharmacokinetics in subjects who are treated with an inhibitor of the 
target enzyme (Watkins, 1994).  The nonspecific CYP2C8 and CYP2C9 inhibitor gemfibrozil 
has been shown to adversely affect the pharmacokinetics of rosiglitazone causing a 2.3-fold 
increase in the area under the concentration-time curve (Niemi et al., 2003a).  The effect of a 
selective CYP2C8 inhibitor on rosiglitazone pharmacokinetics has not been evaluated.  The 
antibiotic trimethoprim, which is commonly used in the treatment of respiratory and urinary tract 
infections, has been shown in vitro to selectively inhibit CYP2C8 at concentrations ranging from 
5 to 100 µM (Ki = 32 µM) (Wen et al., 2002).  Trimethoprim administered at a dose of 200 mg 
twice daily achieves peak plasma concentrations of approximately 20 µM (Watson et al., 1983).  
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 Based on the liver/plasma concentration ratio of 6.5 to 1 observed in monkeys (Craig and Kunin, 
1973), it has been proposed that this plasma concentration would produce approximate hepatic 
concentrations of 130 µM, which would yield greater than 80% inhibition of CYP2C8 (Watson 
et al., 1983; Wen et al., 2002).  Trimethoprim was recently shown to inhibit the metabolism of 
the CYP2C8 and CYP3A4 substrate repaglinide, causing a 61% increase in the area under the 
curve (Niemi et al., 2004b).  The effect of trimethoprim administration on the CYP2C8-mediated 
metabolism of rosiglitazone has not been determined.  Therefore, the purpose of these studies 
was to evaluate the in vitro and in vivo inhibitory effect of trimethoprim on the metabolism of 
this drug. 
Methods 
Clinical Study 
Human Subjects:   
The study was approved by the Institutional Review Board at the University of Pittsburgh.  Eight 
healthy non-smoking subjects (4 men and 4 women) provided written informed consent prior to 
the study.  Subjects were determined to be healthy on the basis of past medical history, a 
physical examination and routine clinical laboratory tests.  Subjects were excluded if they had 
any evidence of abnormal renal or hepatic function, had a BMI > 31 kg m-2, had preexisting 
medical conditions, or used any medications other than oral contraceptives or hormone 
replacement therapy.  Women of child bearing age were tested for pregnancy prior to enrollment 
and on admission to each study phase for exclusionary purposes.  Subject age, weight, and body 
mass index were 28.3 ± 11.9 years (21 – 57), 72.2 ± 16.6 kg (50.9 – 101), and 23.6 ± 3.0 kg m-2 
(19.5 – 28.0), respectively (Mean ± SD (range)).  Seven subjects were Caucasian and one was 
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 African-American.  One of the female subjects was taking oral contraceptives and none of the 
subjects took complimentary medicine or over the counter medications during the study visits.   
Study Design:   
The study had a randomized cross-over design in which subjects received: 1) rosiglitazone 8 mg 
and 2) rosiglitazone 8 mg and trimethoprim 200 mg twice daily for five days.  Study visits were 
separated by a washout period of 1 week.  Subjects abstained from alcohol and caffeine 
containing foods and beverages for 24 hours, and from grapefruit or grapefruit juice and over-
the-counter medications for 48 hours prior to each study visit.  After an overnight fast, subjects 
were administered rosiglitazone 8 mg (Avandia, GlaxoSmithKline, Research Triangle Park, 
NC, USA) with 8 oz (240 ml) of water at approximately 8:00 AM.  Subjects fasted for 
approximately 2 hours after rosiglitazone dosing.  Blood samples (10 ml) were obtained before 
and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24 hours after drug administration.  In the 
other phase of the study, trimethoprim (200 mg) was administered for five days at approximately 
7:30 AM and 7:30 PM.  Rosiglitazone was administered at approximately 8:00 AM on the fourth 
day of trimethoprim dosing.  Blood samples were obtained as above with additional samples 
collected at 13 hours prior to and 30, 36, and 48 hours after rosiglitazone administration.  Blood 
samples were drawn in EDTA tubes, kept on ice, and centrifuged within two hours of collection 
at 2500 g, 4oC, for 15 minutes.  Plasma was harvested and stored at -70oC until analysis.     
Drug and Metabolite Analysis: 
Rosiglitazone:   
Concentrations of rosiglitazone were determined as described previously (Hruska and Frye, 
2004b).  Briefly, the internal standard, betaxolol (250 ng), was added to plasma (200 µl), and 
proteins were precipitated with 600 µl acetonitrile.  Analysis was performed by HPLC with 
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 fluorescence detection.  Rosiglitazone was monitored at an excitation wavelength (λex) of 247 
nm and an emission wavelength (λem) of 367 nm and betaxolol was monitored at a λex of 235 nm 
and a λem of 310 nm.  Separation was achieved with an Alltima Phenyl 5µ 250 mm × 4.6 mm 
column (Alltech Associates Inc., Deerfield, IL, USA), and an isocratic mobile phase of 10 mM 
sodium acetate (pH 5): acetonitrile (60:40) delivered at a flow rate of 1 ml min-1.  Intra- and 
inter-day precision ranged from 3.1% – 8.5% and 2.3% – 5.7%, respectively.  
Rosiglitazone metabolites:   
Plasma (100µl) was added to 96-well 0.45µ Captiva® filter plates (Varian Inc, Lake Forest, CA, 
USA) preloaded with 300 µl of acetonitrile.  The plates were vortex-mixed for 30 seconds, 
inverted for 5 minutes, and filtered under a vacuum.  Water (300 µL) was added to the filtrate, 
and plates were briefly vortex-mixed.  Aliquots (10 µl) were injected onto a Surveyor HPLC 
system connected to a TSQ Quantum MS/MS system (Thermo, Woburn, MA, USA).  
Chromatographic separation was performed using a Symmetry C8 5µm, 2.1 × 150 mm column 
(Waters Corp., Milford, MA, USA).  The mobile phase consisted of (A) 0.1% formic acid in 
water and (B) 0.1% formic acid in methanol delivered at a flow rate of 200 µl min-1.  Gradient 
elution was achieved with mobile phase that started at 80% A, ramped to 40% A over 2 minutes, 
changed to 10% A from 2.5 to 6.0 minutes, and then ramped back to 80% A over the next 0.2 
minutes.  Conditions were held at 80:20 for 1.3 minutes for a total run time of 8.5 minutes.  
Detection was achieved with positive electrospray ionization and data output was captured with 
Xcalibur® software (Thermo, San Jose, CA, USA).  Precursor and product ions [M + H]+ 
detected were m/z 358.2/135, 374.2/151, and 344.2/121, for rosiglitazone, para-O-sulfate-
rosiglitazone, and N-desmethylrosiglitazone, respectively (Bolton et al., 1996; Cox et al., 2000).  
Since the sulfate group is lost in the mass spectrometer source, the mass detected is that of the 
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para-hydroxy metabolite.  The internal standard was detected with single ion monitoring [M + 
H]+ at 308.3.  Metabolite concentrations were calculated in arbitrary units (U l-1) relative to the 
maximum peak concentration (Cmax) determined from the chromatographic output.    
Trimethoprim:   
Concentrations of trimethoprim were determined as previously reported (Hruska and Frye, 
2004a).  Briefly, the internal standard sulfamethazine (500 ng) was added to plasma (200 µl) and 
proteins were precipitated with perchloric acid (25 µl).  Samples were vortex-mixed and then 
centrifuged at 3000 g for 10 minutes.  The supernatant was transferred to injector vials and an 
aliquot (75 µl) was injected onto the HPLC system.  Separation was achieved using a Synergi 
4µ Polar-RP 150 mm × 4.6 mm column (Phenomenex, Torrance, CA, USA) heated to 30°C.  The 
mobile phase, which consisted of ammonium formate (pH 3.0; 50 mM)-acetonitrile-methanol 
(90:6:4, v/v/v), was delivered isocratically at a flow rate of 1 ml min-1.  Detection was at an 
ultraviolet wavelength of 280 nm.  Intra- and inter-day precision ranged from 1.1% – 1.7% and 
1.9% – 2.7%, respectively. 
Determination of CYP2C8 Genotype:   
Pyrosequencing assays were developed to genotype the CYP2C8*2, CYP2C8*3, and CYP2C8*4 
alleles.  PCR reaction mixtures (25 µl) consisted of 12.5 µl HotStarTaq® Master Mix (Qiagen, 
Valencia, CA, USA), 1.5 µl DMSO, PCR primers (10 pmol each), 7 µl of water, and 40 ng 
DNA.  PCR Primer sequences are shown in .  PCR conditions were as follows: 95°C for 
15 minutes, 40 cycles consisting of (1) denaturation at 94°C for 30 seconds, (2) annealing at 
56°C (58°C for Exon 8) for 30 seconds, and (3) extension at 72°C for 45 seconds, followed by 
Table 12
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 final extension at 72°C for 7 minutes.  Genotyping was performed using manufacturer protocol 
(Biotage AB, Uppsala, Sweden).  Briefly, PCR products (10 µl) were immobilized with 
streptavidin-coated Sepharose beads and incubated.  Beads were isolated and treated with 70% 
ethanol, denaturation buffer, and wash buffer.  Beads were released into a mixture of annealing 
buffer and 10 pmol sequencing primer ( ), heated at 80°C for 2 minutes and cooled to 
room temperature (Ronaghi, 2001; Haglund et al., 2004).  Genotyping analysis was carried out 
using a PSQ HS 96 System (Biotage AB, Uppsala, Sweden) and data was captured with PSQ HS 
96 SNP software (Biotage AB, Uppsala, Sweden). 
Table 12
Table 12 PCR Primers and Sequencing Primers for CYP2C8*2, CYP2C8*3, and CYP2C8*4 
 
 
 
Exon PCR Primers Sequencing Primers 
3 
F: B-5’-GTGTTCTCCCAGTTTCTGCCC-3’ 
R: 5’-GACGCAGAGTAGAGTCACCCAC-3’ 
5’-CGGTCCTCATGCTC-3’ 
5 
F: B-5’-CAGGCTTGGTGTAAGATACATA-3’ 
R: 5’-CAGAAGGATTCGATGAATCA CAA-3’ 
5’-CTTACCTGCTCCATTTTGA-3’ 
8 
F: 5’-CTCCTCACTTCTGGACTTCTTTA-3’ 
R: B-5’-CCTTTAAATACAAATGGAAACGAG-3’ 
5’-CGTGCTACATGATGACA-3’ 
 
 
Data Analysis: 
The rosiglitazone concentration-time data were analyzed by noncompartmental methods.  The 
terminal elimination rate constant (λz) was estimated by linear least squares regression analysis 
of the terminal portion of the log concentration-time data.  Apparent elimination half-life was 
calculated from the expression 0.693 λz-1.  The area under the concentration time curve (AUC) 
was determined using the linear trapezoidal rule with extrapolation to infinity.  The apparent oral 
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 volume of distribution (Vd/F) was calculated from the expression Dose (λz × AUC)-1.  The 
maximum concentration (Cmax) was determined from the experimental data.  Tmax was the time at 
which Cmax was observed.  For both rosiglitazone metabolites, the area under the concentration 
time curve (AUC) was calculated by the linear trapezoidal rule from 0 to 24 hours.   
Pharmacokinetic calculations were performed using WinNonlin 2.1 (Pharsight Corp., Mountain 
View, CA, USA). 
    The trimethoprim concentration-time data were analyzed by non-compartmental 
methods.  The AUC was calculated for the 48 hour period (four 12-hour dosing intervals) after 
rosiglitazone administration by the linear trapezoidal rule.  The maximum steady state 
concentration (Cssmax) and the minimum steady state concentration (Cssmin) were those observed 
over all four dosing intervals.  The average steady state concentration (Cssave) was calculated by 
dividing the AUC(0-48) of trimethoprim by the total time (48 hours).  All calculations were 
performed with WinNonlin 2.1 (Pharsight Corp., Mountain View, CA, USA). 
 Rosiglitazone pharmacokinetic parameters were log-transformed where appropriate and 
compared by paired t-test unless specified otherwise.  Confidence intervals (95%) on mean 
differences were calculated.  Tmax was compared using the Wilcoxon matched pairs test.  A 
two-sided p ≤ 0.05 was considered significant and all calculations were performed using PRISM 
software version 4.0 (GraphPad Software, Inc., San Diego, CA, USA). 
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 Microsomal Inhibition Studies 
Human Liver Microsomes:  
Pooled human liver microsomes (n = 29 donors) were purchased from BD Biosciences 
Discovery Labware (Bedford, MA, USA), who state that collection and processing of human 
tissue was conducted in compliance with all current regulatory and ethical requirements.  
Rosiglitazone was obtained from Cayman Chemical (Ann Arbor, MI, USA) and gemfibrozil was 
purchased from Sigma-Aldrich (St. Louis, MO, USA). All other reagents were of analytical 
grade or higher. 
Incubation conditions:   
Metabolite formation was linear with respect to time (r2 > 0.98) and protein concentration (r2 > 
0.97).  Optimal incubation conditions were 0.2 mg microsomal protein (0.8 mg ml-1) incubated 
for 10 minutes at 37.0°C.  Incubations were performed in duplicate and consisted of 1.3 mM 
NADP+, 3.3 mM glucose-6-phosphate, 0.2 U glucose-6-phosphate dehydrogenase, 3.3 mM 
magnesium chloride, and 0.2 mg of microsomal protein in 250 µl phosphate buffer pH = 7.4.  
Incubations were started by addition of glucose-6-phosphate dehydrogenase.  Reactions were 
terminated by the addition of 400 µl of ice cold acetonitrile and samples were vortexed 
immediately, and centrifuged for 10 minutes at 3000 g.  Supernatant (75 µl) was injected onto 
the column and analyzed as described above.  The ratio of para-hydroxyrosiglitazone peak area 
to rosiglitazone peak area was used as a marker of CYP2C8 activity.  The Km for the reaction 
was determined using substrate concentrations of 0, 5, 10, 25, 50, 75 and 100 µM. 
Inhibition experiments:  
To determine IC50, rosiglitazone (10µM) was incubated in the presence of trimethoprim (0, 1, 5, 
10, 25, 50, 100 µM) and gemfibrozil (0, 5, 10, 25, 50, 100, 250 µM).  To determine Ki, 
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 rosiglitazone was added to the microsomal suspension at varying concentration (5, 10, 25, 50 
µM) in the presence of trimethoprim (0, 25, 50, 100 µM) and gemfibrozil (0, 25, 50, 100, 250 
µM).  Enzyme activity was plotted against nominal rosiglitazone concentration and the apparent 
Km was determined by fitting the Michaelis-Menten model to the untransformed data using non-
linear regression.  The IC50 and apparent inhibitory constant (Ki) values were determined by non-
linear regression using PRISM software version 4.0 (GraphPad Software, Inc., San Diego, CA, 
USA).  Different models of enzyme inhibition (i.e., competitive, noncompetitive, uncompetitive, 
and mixed-type inhibition) were fitted to the data and the best fit was determined by analysis of 
the residuals, the standard error and the 95% confidence interval of the parameter estimates, and 
the Akaike’s information criterion. 
Results 
Rosiglitazone was well-tolerated and no adverse events were noted when the drug was given 
alone.  One of the eight subjects developed a rash two days after completing trimethoprim 
therapy.  The rash resolved without therapeutic intervention within two days. 
   Mean log concentration versus time profiles of eight subjects administered rosiglitazone in the 
presence and absence of trimethoprim are shown in Figure 14.  Trimethoprim administration 
increased rosiglitazone AUC by 31% (p = 0.01) and t1/2 by 27% (p = 0.006), but had no effect on 
Cmax, tmax, and Vd/F (Table 13, Figure 15).  There were no differences in para-O-sulfate-
rosiglitazone or N-desmethylrosiglitazone AUC (Table 13), but the ratio of metabolite AUC to 
rosiglitazone AUC was decreased by 22% for para-O-sulfate-rosiglitazone (p = 0.02) and by 
38% for N-desmethylrosiglitazone (p = 0.004) (See Appendix A, Figure 23).  Trimethoprim 
administration decreased N-desmethylrosiglitazone Cmax by 22% (p = 0.02) but did not 
significantly affect para-O-sulfate-rosiglitazone Cmax (p = 0.19). 
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Figure 14 Log concentration versus time profile of rosiglitazone in the presence and absence of trimethoprim 
Mean (± S.D.) log concentration versus time profile of rosiglitazone in the presence (closed 
triangles) and absence (closed squares) of trimethoprim, 200 mg given twice daily for five days.  
Data are from 8 healthy subjects.  
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 Table 13   Mean pharmacokinetic parameters for rosiglitazone and metabolites in the presence and absence 
of trimethoprim, 200 mg given twice daily for five days to 8 healthy subjects. 
 
Parameter Control Trimethoprim 
Mean difference between 
control and trimethoprim 
(CI 95%) 
P 
value 
Rosiglitazone 
AUC (hr µg l-1) 2774 ± 645 3643 ± 1051 869 (189, 1549) 0.01 
Cmax (µg l-1) 674.3 ± 235.4 591.9 ± 62.2 -82.4 (-265.4, 100.7) 0.32 
Tmax (hr) 0.75 (0.5 – 4.0) 0.88 (0.5 – 2.0)  0.58 
t1/2 (hr) 3.3 ± 0.5 4.2 ± 0.8 0.9 (0.36, 1.5) 0.006 
Vd/F (l) 14.9 ± 3.1 14.1 ± 2.9 -0.8 (-2.4, 0.75) 0.26 
Para-O-sulfate-rosiglitazone 
AUC (U hr l-1) 14.9 ± 3.0 14.2 ± 3.3 -0.61 (-2.4, 1.2) 0.45 
AUC Ratio  
(POS: 
rosiglitazone) 
5.5 ± 1.1 4.3 ± 1.7 -1.2 (-2.2, -0.3) 0.02 
N-desmethylrosiglitazone 
AUC (U hr l-1) 15.6 ± 2.4 13.1 ± 4.8 -2.5 (-5.9, 1.0) 0.14 
AUC Ratio  
(NDR: 
rosiglitazone) 
6.0 ± 1.7 3.7 ± 1.2 -2.2 (-3.5, -1.0) 0.004 
Key: POS: para-O-sulfaterosiglitazone; NDR: N-desmethylrosiglitazone 
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  Subjects were genotyped as CYP2C8*1/*1 (n=4), CYP2C8*1/*2 (n=1) and 
CYP2C8*1/*3 (n=3).  Genotype did not appear to affect rosiglitazone metabolism, as there were 
no significant differences between subjects with heterozygous and homozygous wild type 
genotypes (See Appendix A, Figure 24).  However, there was a trend for the fold increase in 
rosiglitazone AUC to be greater in wild type subjects versus subjects carrying an allelic variant 
(1.49 ± 0.26 vs. 1.16 ± 0.22, p = 0.1; See Appendix A, Figure 25). 
 Trimethoprim reached steady-state in all subjects with an observed mean Cssave of 9.14 ± 
1.83 µmol l-1.  The mean Cssmax observed was 13.98 ± 2.43 µmol l-1 and the Cssmin 6.78 ± 1.79 
µmol l-1.  The mean AUC observed for each 12 hour dosing interval was 109.6 ± 24.6 µmol hr l-
1.  There was a significant relationship between the Cssave trimethoprim plasma concentration 
and the fold increase in rosiglitazone AUC in subjects having the CYP2C8*1/*1 or *1/*2 
genotype (r2 = 0.97, p=0.0021; Figure 16).  The relationship was not significant when subjects 
with the CYP2C8*1/*3 genotype were included (r2 = 0.08, p=0.48).  There was no relationship 
between trimethoprim Cssmax or Cssmin values and the fold increase in rosiglitazone AUC. 
 In human liver microsomes, the apparent Km determined for rosiglitazone (mean 
(standard error)) was 11.9 µM (1.8).  It should be noted that only one of the six substrate 
concentrations used in the incubations was below the estimated Km value.  The inhibition 
profiles of rosiglitazone (10 µM) in the presence of trimethoprim and gemfibrozil at various 
concentrations are depicted in Figure 17.  The apparent Ki and IC50 values calculated for 
trimethoprim were 29.0 µM (1.4) and 51.5 µM (2.8), respectively.  The apparent Ki and IC50 
values determined for gemfibrozil were 69.0 µM (1.1) and 119 µM (2.0), respectively.  The 
mechanism of inhibition of CYP2C8 mediated metabolism of rosiglitazone was competitive and 
noncompetitive for trimethoprim and gemfibrozil, respectively (See Appendix A, Figure 26). 
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Figure 16 Relationship between the fold increase in rosiglitazone AUC and the trimethoprim Cssave 
concentration.  The linear regression line is based on data from subjects having the CYP2C8*1/*1 
or *1/*2 genotype (closed squares; r2 = 0.97, p=0.0021).  The relationship was not significant when 
subjects with the CYP2C8*1/*3 genotype (open triangles) were included (r2 = 0.08, p=0.48). 
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Discussion 
Plasma rosiglitazone concentrations were increased in the presence of trimethoprim.  Whereas 
the AUC and half-life were significantly increased, trimethoprim administration did not appear 
to affect rosiglitazone absorption, since tmax, Cmax, and Vd/F were not different.  In vitro, 
trimethoprim competitively inhibited the CYP2C8 catalyzed para-hydroxylation of rosiglitazone.  
Thus, the in vitro and in vivo results demonstrate that trimethoprim is an inhibitor of the 
CYP2C8 mediated metabolism of rosiglitazone. 
 The in vitro inhibition data for trimethoprim in the present study are consistent with 
previous reports (Wen et al., 2002).  Since gemfibrozil administration has been shown to 
increase rosiglitazone plasma concentrations in healthy human subjects (Niemi et al., 2003a), the 
effect of gemfibrozil on rosiglitazone metabolism in vitro was also evaluated.  Apparent Ki and 
IC50 values for gemfibrozil (69 µM and 119 µM) were comparable to the previously reported 
values of 69 µM and 91 µM, respectively (Wang et al., 2002).  These data indicate that 
trimethoprim is a more potent in vitro inhibitor of CYP2C8 compared to gemfibrozil, which 
suggests that trimethoprim may be more suitable as an in vivo inhibitor for this enzyme.  
However, gemfibrozil appears to be the more effective in vivo inhibitor of CYP2C8.  Niemi et 
al., found that the AUC of rosiglitazone after a single dose (4 mg) was increased 2.3 fold in the 
presence of gemfibrozil (600 mg given twice daily for three days) (Niemi et al., 2003a).  The 
difference in the magnitude of inhibition observed with trimethoprim and gemfibrozil may be 
due to the combined inhibition of CYP2C9 and CYP2C8 by the latter (Wen et al., 2001; Wang et 
al., 2002), although rosiglitazone is only metabolized by CYP2C9 to a minor extent (Baldwin et 
al., 1999), or may be related to the plasma concentrations of the inhibitors.  In the previous 
study, subjects achieved a mean peak total gemfibrozil concentration of 110 µM, which is 
 greater than the apparent Ki (69 µM), and a mean average total gemfibrozil concentration of 31 
µM.  Thus, based on total drug concentration, gemfibrozil would be expected to inhibit CYP2C8 
(Niemi et al., 2003a) to a greater extent than trimethoprim, since the maximum and average total 
concentrations of trimethoprim attained in plasma with normal therapeutic doses are less than the 
apparent Ki.  Using the equation AUCI/AUC = 1+ [I]/ Ki (Ito et al., 2004) and the apparent Ki (69 
µM), the predicted fold-increase in rosiglitazone plasma AUC would be 2.6 and 1.5, based on 
peak and average total plasma gemfibrozil concentrations (inhibitor or I), respectively.   
 In the present study, the mean average total trimethoprim concentration (Cssave) after 
administration for 5 days was 9.14 µM, which is similar to the previously reported value of 10.7 
µM (Watson et al., 1983).  The mean peak total concentration was 13.98 µM, and this and Cssave 
are less than the apparent Ki (29-32 µM).  Wen et al., based on the liver/plasma partition ratio of 
6.5 to 1 observed in the rhesus monkey (Craig and Kunin, 1973) and an estimated peak total 
plasma concentration of 20 µM, predicted that subjects would achieve peak hepatic trimethoprim 
concentrations of approximately 130 µM, which would produce CYP2C8 inhibition of greater 
than 80% (Wen et al., 2002).  In the present study the rosiglitazone AUC was increased by only 
1.3 fold.  However, the predicted magnitude of CYP2C8 inhibition as expressed by the fold 
increase in rosiglitazone AUC would be 1.3 based on the average total plasma concentration.  
Factoring in estimated hepatic accumulation and plasma protein binding (trimethoprim fraction 
unbound=0.55), the predicted increase in AUC would be 2.7 or 2.1 fold based on peak or average 
unbound plasma concentration, respectively.  Thus, these data suggest that hepatic accumulation 
during short term trimethoprim administration is not important and that the magnitude of 
inhibition is more closely related to the average total plasma concentration.  Since the plasma 
concentrations of trimethoprim that are achieved with normal therapeutic doses are less than the 
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 apparent Ki, the use of trimethoprim as an in vivo CYP2C8 inhibitor may be limited.  Although 
gemfibrozil inhibits both CYP2C8 and CYP2C9 in vitro (Wen et al., 2001; Wang et al., 2002), it 
may still have utility as a selective CYP2C8 inhibitor, since in vivo studies have demonstrated a 
more pronounced effect on the metabolism of CYP2C8 substrates (e.g., cerivastatin, repaglinide, 
and rosiglitazone) compared to CYP2C9 substrates (e.g., glimepiride) (Niemi et al., 2001b; 
Backman et al., 2002; Niemi et al., 2003b). 
 The trimethoprim-rosiglitazone interaction may have clinical relevance.  The most 
common serious adverse effects associated with the thiazolidinediones rosiglitazone and 
pioglitazone are related to volume expansion (e.g., congestive heart failure, pulmonary oedema, 
and pleural effusions) (Niemeyer and Janney, 2002), which appears to be concentration-
dependent (Idris et al., 2003).  Thus, patients taking rosiglitazone who are then treated with 
trimethoprim may be at greater risk of adverse effects such as oedema.  The dosage of 
trimethoprim used in this study (200 mg twice daily for 5 days) is similar to the usual dosage of 
trimethoprim (160 mg twice daily) administered in combination with sulfamethoxazole for the 
treatment of common infections.  Since the administration of trimethoprim with rosiglitazone 
may increase the risk of adverse events, the former should be used with caution, especially in 
patients treated with a high rosiglitazone dose (e.g., 8 mg daily), or who will receive 
trimethoprim for a prolonged period of time. 
 Although the sample size in this study is small, CYP2C8 genotype did not appear to 
affect the metabolism of rosiglitazone (in the absence of trimethoprim), as there was no 
significant difference in rosiglitazone exposure in the subjects with a variant allele compared to 
the wild-type subjects (Figure 15A, control).  However, the data suggest that the magnitude of 
inhibition by trimethoprim may be influenced by genotype, as wild type subjects tended to have 
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 a greater increase in rosiglitazone AUC relative to control compared to subjects carrying either 
the CYP2C8*2 or CYP2C8*3 allele (See Appendix A, Figure 25).  In addition, there was a strong 
correlation between the magnitude of inhibition, expressed as the fold increase in rosiglitazone 
AUC, and the average trimethoprim plasma concentration (Cssave), but only in the subjects 
having the CYP2C8*1/*1  or *1/*2 genotype ( ).  Differences in activity associated with 
the CYP2C8*2 and CYP2C8*3 alleles may contribute to these observations.  In vitro, the 
CYP2C8*2 polymorphism is associated with decreased affinity (increased Km) for paclitaxel 
with no change in Vmax, resulting in a two-fold lower 6α-hydroxypaclitaxel intrinsic clearance.  
The CYP2C8*3 variant is associated with markedly decreased paclitaxel turnover (Dai et al., 
2001).  Niemi et al., recently evaluated the effect of CYP2C8 genotype on the pharmacokinetics 
of the CYP2C8 and CYP3A4 substrate repaglinide.  They found that subjects possessing the 
CYP2C8*3 allele had lower repaglinide exposure compared to the control group, which suggests 
that the CYP2C8*3 allele may result in greater CYP2C8 activity (Niemi et al., 2003c).  Data 
from this study suggest that genotype may influence the ability of trimethoprim to inhibit 
CYP2C8 and those individuals carrying the CYP2C8*3 allele may be less sensitive to the 
inhibitory effects of trimethoprim on rosiglitazone metabolism.   
Figure 16
 Overall, this study demonstrates that trimethoprim competitively inhibits the CYP2C8 
mediated metabolism of rosiglitazone in vitro and significantly increases rosiglitazone exposure 
in healthy subjects during short term administration.  Therefore, trimethoprim should be used 
with caution in patients with type 2 diabetes who are taking rosiglitazone. 
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 Chapter 6 
Effect of St. John’s Wort Administration on Rosiglitazone  
Pharmacokinetics in Relation to CYP2C8 genotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Hruska MW, Cheong JA, Langaee TY, and Frye RF.  Effect of St. John’s wort Administration 
on Rosiglitazone Pharmacokinetics in Relation to CYP2C8 genotype. Submitted.] 
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 Abstract 
Objective: The objectives of this study were (1) to investigate the effect of St. John’s wort on 
rosiglitazone pharmacokinetics and (2) to evaluate whether the effect is influenced by CYP2C8 
genotype. 
Methods: This fixed sequence design study involved twenty-seven subjects sequentially selected 
with the following CYP2C8 genotypes: CYP2C8*1/*1  (n = 8), CYP2C8*1/*2  (n = 4), 
CYP2C8*1/*3 (n = 7), CYP2C8*1/*4 (n = 6), CYP2C8*2/*2 (n = 1), and CYP2C8*3/*3 (n = 1).  
The pharmacokinetics of rosiglitazone (8 mg) was evaluated after single dose administration in 
the absence and presence of St. John’s wort 900 mg daily for fourteen days. 
Results: St. John’s wort administration induced the CYP2C8 mediated metabolism of 
rosiglitazone as the area under the plasma concentration-time curve (AUC) decreased by 26%, 
from 3190 ± 641 µg*hr/L to 2375 +/- 537 µg*hr/L (p < 0.0001, 90% Confidence Interval [CI], 
71% - 78%) and apparent oral clearance (CL/F) increased by 35 % from 2.6 ± 0.6 L/hr to 3.5 +/- 
0.7 L/hr (p < 0.0001, 90% CI, 128% - 142%).  CYP2C8 genotype had no effect on induction by 
St. John’s wort as the rosiglitazone AUC ratio (St. John’s Wort/control, %) was not significantly 
different between CYP2C8*1/*1 , 71% (90% CI, 60% - 83%) and heterozygous carriers of 
CYP2C8*2, 78% (90% CI, 69% - 88%), CYP2C8*3, 70% (90% CI, 62% - 79%), and 
CYP2C8*4, 75% (90% CI, 67% - 84%). 
Conclusions: Administration of St. John’s wort significantly increases the CYP2C8 mediated 
clearance of rosiglitazone after single dose administration, but the magnitude of induction is not 
influenced by CYP2C8 genotype.  St. John’s wort use should be monitored when patients are 
administered rosiglitazone or other CYP2C8 substrates. 
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 Introduction 
Rosiglitazone is used in the treatment of type 2 diabetes and belongs to the thiazolidinedione 
class of antihyperglycemic agents (Balfour and Plosker, 1999; Cox et al., 2000).  These agents 
exert their clinical effects via the peroxisome proliferator-activated receptor γ (PPARγ), by 
facilitating the expression of genes responsible for glucose and lipid metabolism (Balfour and 
Plosker, 1999; Vamecq and Latruffe, 1999).  Rosiglitazone is primarily metabolized by 
Cytochrome P450 (CYP) 2C8 with a minor contribution by CYP2C9 (Baldwin et al., 1999).  
Rosiglitazone is metabolized extensively with essentially no parent drug excreted unchanged in 
the urine.  The two major metabolites produced are para-O-sulfate-rosiglitazone and N-
desmethyl rosiglitazone, which account for > 80% of all metabolic products isolated in human 
plasma (Cox et al., 2000).  To date, rosiglitazone pharmacokinetics have been shown to be 
modified by the CYP2C8 inhibitors gemfibrozil (Niemi et al., 2003a) and trimethoprim (Niemi 
et al., 2004a; Hruska et al., 2005), as well as the classical CYP inducer, rifampin (Niemi et al., 
2004a; Park et al., 2004a). 
 Rifampin and hyperforin, a primary constituent of the herbal remedy St. John’s wort, 
have been shown in vitro to induce CYP enzymes (e.g., CYP3A4 and CYP2C9) through 
interaction with the pregnane X receptor (PXR) (Moore et al., 2000; Wentworth et al., 2000; 
Gerbal-Chaloin et al., 2001; Rae et al., 2001; Raucy et al., 2002).  Induction of CYP 
transcription by PXR begins when a ligand binds to PXR, causing a translocation of the ligand-
PXR complex into the nucleus and the heterodimerization with the retinoic X receptor α 
(RXRα).  The PXR-RXRα heterodimer binds to the xenobiotic response element initiating 
transcription and CYP enzyme production (Rae et al., 2001).  In vivo, rifampin and St. John’s 
wort have been shown to increase the clearance of multiple drugs including S-mephenytoin 
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 (CYP2C19) (Feng et al., 1998; Wang et al., 2004b), S-warfarin (CYP2C9) (Heimark et al., 1987; 
Jiang et al., 2004), and midazolam (CYP3A) (Backman et al., 1996; Wang et al., 2001).  
Collectively, these data demonstrate that St. John’s wort (hyperforin) is an important modulator 
of CYP enzyme activity.  The effect of St. John’s wort on in vivo CYP2C8 activity is not known, 
but may be relevant since PXR activators (e.g., rifampin) have been shown to induce CYP2C8 
expression in human hepatocytes (Gerbal-Chaloin et al., 2001; Rae et al., 2001; Raucy et al., 
2002).   
 Although not studied extensively, there is evidence to support that the magnitude of a 
drug interaction may be influenced by the CYP genotype.  For example, induction of CYP2C19 
activity by St. John’s wort and rifampin is markedly different in extensive metabolizers (EM) 
and poor metabolizers (PM) (Feng et al., 1998; Wang et al., 2004a; Wang et al., 2004b).  St. 
John’s wort administration causes an increase in the urinary excretion of 4′-hydroxymephenytoin 
(151%) and 5′-hydroxyomeprazole AUC (50%) in EMs, but has no effect on these parameters in 
PMs, which would be expected since PMs do not have a functional copy of the CYP2C19 gene 
(Wang et al., 2004b).  Also, the effect of rifampin on mephenytoin metabolism is much greater 
in homozygous as compared to heterozygous EMs (Feng et al., 1998).  Consequently, it may be 
important to evaluate drug interactions in association with genotype.  CYP2C8 has at least two 
functionally relevant polymorphisms in vitro: CYP2C8*2 and CYP2C8*3 (Dai et al., 2001).  The 
CYP2C8*2 polymorphism encoding an Ile269Phe substitution is associated with a two-fold 
lower intrinsic clearance of paclitaxel and a decreased affinity for 6α-hydroxypaclitaxel, a major 
metabolite of paclitaxel; whereas CYP2C8*3, which encodes Arg139Lys and Lys399Arg 
substitutions, is associated with decreased paclitaxel turnover (Dai et al., 2001).  Allelic 
frequencies have been estimated as 0.18 for CYP2C8*2 in African-Americans and 0.13 for 
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 CYP2C8*3 in Caucasians (Dai et al., 2001).  A third polymorphism, CYP2C8*4, which encodes 
an Ile264Met substitution and has an allelic frequency of 7.5% in the Caucasian population, may 
also have functional significance (Bahadur et al., 2002).  A previous study conducted by our 
laboratory demonstrated that CYP2C8 genotype may contribute to the ability of the selective 
inhibitor trimethoprim to modulate CYP2C8 activity.  In that study, there was a strong 
correlation between the fold-increase in rosiglitazone AUC and the average trimethoprim plasma 
concentration, but only in the subjects having the CYP2C8*1/*1 or *1/*2 genotype (Hruska et 
al., 2005).  Therefore, it would be of interest to determine whether genotype modifies the extent 
to which the CYP inducer St. John’s wort may alter CYP2C8 activity.  Thus, the purpose of this 
study is to evaluate the effect of St. John's wort on CYP2C8 activity and to assess the impact of 
CYP2C8 genetic variability on any change in CYP2C8 activity as measured by rosiglitazone 
pharmacokinetics. 
Methods 
Human Subjects:  
This study was approved by the Institutional Review Board at the University of Florida.  One 
hundred eleven healthy, non-smoking subjects (47 male, 64 female), 18 years of age or older 
provided written informed consent to participate.  Subjects self-reported their racial background 
and past medical history, and were screened on the basis of CYP2C8 genotype.  Subjects were 
enrolled into genotype groups with a maximum of eight subjects (four men and four women) per 
group.  Subjects asked to continue in the experimental phase of the study were determined to be 
healthy on the basis of past medical history, a physical examination and routine clinical 
laboratory tests.  Subjects were excluded if they had any evidence of abnormal renal or hepatic 
function, had a BMI > 31 kg m-2, had preexisting medical conditions, or used dietary/herbal 
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 supplements or any medications other than oral contraceptives.  Women of child bearing age 
were tested for pregnancy prior to enrollment and on admission to each study phase for 
exclusionary purposes.   
Study Design:  
This study was a fixed sequence design and subjects were stratified based on their CYP2C8 
genotype into one of 4 groups, CYP2C8*1, CYP2C8*2, CYP2C8*3, or CYP2C8*4.  Subjects 
were administered rosiglitazone as follows: (1) rosiglitazone 8 mg alone, and (2) rosiglitazone 8 
mg during St. John's wort 300 mg three times daily.  Subjects abstained from alcohol, caffeine 
containing foods and beverages, grapefruit or grapefruit juice, and over-the-counter medications 
for 48 hours prior to each study visit.  After an overnight fast, subjects were administered 
rosiglitazone 8 mg (Avandia, GlaxoSmithKline, Research Triangle Park, NC, USA) with 8 oz 
(240 ml) of water at approximately 8:00 AM on study day 1.  Subjects fasted for approximately 2 
hours after rosiglitazone dosing.  Blood samples (10 ml) were obtained before and 0.25, 0.5, 
0.75, 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24 hours after drug administration.  After the 24 hour blood 
sample was obtained on study day 2, subjects began self-administering St. John’s wort extract 
300 mg (Kira, “LI 160”, Lichtwer Pharma AG, Berlin, Germany), three times daily for 14 days.  
Rosiglitazone was administered at approximately 8:00 AM on the fourteenth day of St. John’s 
wort dosing (study day 15), and blood samples were obtained as above.  Blood samples were 
drawn in EDTA tubes, kept on ice, and centrifuged within two hours of collection at 2500 g, 4oC, 
for 15 minutes.  Plasma was harvested and stored at -70oC until analysis.  Urine was collected 
from 0 to 24 hours after rosiglitazone administration and aliquots were stored at -20°C or colder 
until analyzed. 
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 Sample Analysis: 
Rosiglitazone:  
Rosiglitazone plasma samples were analyzed as described previously (Hruska and Frye, 2004b).  
Briefly, 200 µL of plasma was placed into microcentrifuge tubes, 250 ng of betaxolol (internal 
standard) was added, and briefly vortexed.  Acetonitrile (600 µl) was added to precipitate 
proteins and samples were vortexed and centrifuged at 3000 g for 10 minutes.  Supernatant was 
transferred and evaporated to dryness at 45°C under a stream of nitrogen and reconstituted in 200 
µl of mobile phase.  Analytes were monitored using HPLC linked with fluorescence detection.  
Monitoring conditions for rosiglitazone were excitation wavelength (λex) of 247 nm and an 
emission wavelength (λem) of 367 nm and an λex of 235 nm and an λem of 310 nm for betaxolol.  
Separation was achieved with an Alltima Phenyl 5µ 250 mm × 4.6 mm column (Alltech 
Associates Inc., Deerfield, IL, USA), and an isocratic mobile phase of 10 mM sodium acetate 
(pH 5): acetonitrile (60:40) delivered at a flow rate of 1 ml min-1.  Intra- and inter-day precision 
ranged from 3.1% – 8.5% and 2.3% – 5.7%, respectively. 
Cortisol and 6β-hydroxycortisol:  
Urinary concentrations of cortisol and 6β-hydroxycortisol were determined by liquid 
chromatography-tandem mass spectrometry (Ohno et al., 2000).  Urine samples (1 ml) were 
extracted with ethyl acetate (5 ml) after the addition of the internal standard, fluorocortisone 
(1000 ng).  The organic layer was transferred to a clean test tube and evaporated to dryness at 
45°C under a stream of nitrogen gas.  Samples were reconstituted with 200 µl of methanol:water 
(70:30, v/v) and placed into autosampler vials for injection.  Separation was achieved using a 
Symmetry C18 5 µm, 3.0 x 150 nm, column (Waters Corporation, Milford, MA, USA).  The 
mobile phases consisted of (A) water:methanol (80:20, v/v) and (B) methanol and were delivered 
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 in a gradient with a total flow rate of 500 µl/min.  The gradient was as follows: 100:0 (A:B) for 
0.2 minutes, increased to 45:55 over 1.0 minutes, increased to 10:90 over 3.8 minutes, 
maintained at 10:90 for 0.5 minute, decreased to 100:0 over 0.5 minutes, and held at 100:0 for 
1.5 minutes for a total of 7.5 minutes.  Analytes were detected by tandem-mass spectrometry 
with positive-ion atmospheric pressure chemical ionization (TSQ Quantum Triple Quadrupole 
Mass Spectrometer, Thermo Electron, San Jose, CA, USA).  Precursor [M + H]+ and product 
ions detected were 363.3/327.1, 379.3/325.1, and 423.3/239.1 for cortisol, 6β-hydroxycortisol, 
and fluorocortisone, respectively.  Inter and intra day variability for both cortisol and 6β-
hydroxycortisol were less than 5%.     
Determination of CYP2C8 Genotype:  
CYP2C8 genotype was determined as previously described (Hruska et al., 2004) (Chapter 4).  
Briefly, a blood sample (approximately 10 ml) was withdrawn from each study subject and DNA 
was extracted using QIAamp® DNA Mini Kit (Qiagen, Valencia, CA, USA) according to 
manufacturer protocol.  PCR reaction mixtures (25 µl) consisted of 12.5 µl HotStarTaq® Master 
Mix (Qiagen, Valencia, CA, USA), 1.5 µl DMSO, PCR primers (10 pmol each), 7 µl of water, 
and 40 ng DNA.  PCR conditions were as follows: 95°C for 15 minutes, 40 cycles consisting of 
(1) denaturation at 94°C for 30 seconds, (2) annealing at 56°C (58°C for Exon 8) for 30 seconds, 
and (3) extension at 72°C for 45 seconds, followed by final extension at 72°C for 7 minutes.  
Genotyping was performed using manufacturer protocol (Biotage AB, Uppsala, Sweden).  
Briefly, PCR products (10 µl) were immobilized with streptavidin-coated Sepharose beads, 
incubated at room temperature, and were isolated and treated with 70% ethanol, denaturation 
buffer, and wash buffer.  Beads were released into a mixture of annealing buffer and 10 pmol 
sequencing primer, heated at 80°C for 2 minutes and cooled to room temperature.  Genotyping 
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 analysis was carried out using a PSQ HS 96 System (Biotage AB, Uppsala, Sweden) and data 
was captured with PSQ HS 96 SNP software (Biotage AB, Uppsala, Sweden).   
Data Analysis 
Rosiglitazone Pharmacokinetics:   
The rosiglitazone concentration-time data were analyzed using noncompartmental methods.  The 
terminal elimination rate constant (λz) was estimated by nonlinear least squares regression 
analysis of the terminal portion of the concentration-time data.  Apparent elimination half-life 
was calculated as 0.693/λz.  The area under the concentration time curve (AUC) was calculated 
by the linear trapezoidal rule with extrapolation to infinity.  The Cmax and time to reach Cmax 
(tmax) were determined by visual inspection of the plasma concentration versus time curves.  
Apparent oral clearance (CL/F) was determined as [Dose / AUC0-∞] and the apparent volume of 
distribution (Vd/F) was calculated from the expression Dose/(λz × AUC). 
6β-hydroxycortisol and cortisol:   
The ratio of endogenous 6β-hydroxycortisol to cortisol in urine is a noninvasive biomarker of 
CYP3A induction.(Ohno et al., 2000)  Since PXR ligands, such as rifampin and hyperforin, 
induce both CYP2C8 and CYP3A,(Raucy et al., 2002; Park et al., 2004a) the urinary 6β-
hydroxycortisol to cortisol ratio serves as a positive control of CYP enzyme induction by St. 
John’s wort.   
Statistical analysis:  
Rosiglitazone pharmacokinetic parameters were log-transformed where appropriate and 
rosiglitazone pharmacokinetics in the presence and absence of St. John’s wort were compared by 
paired t-test.  Tmax was compared using the Wilcoxon matched pairs test.  To examine 
differences in CYP2C8 induction by genotype, differences in the geometric mean AUC ratio 
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 between wild type (CYP2C8*1/*1 ) and heterozygous (CYP2C8*1/*2 , CYP2C8*1/*3, and 
CYP2C8*1/*4) genotype groups were compared using a one-way ANOVA with Dunnett’s 
multiple comparison test.   A two-sided p ≤ 0.05 was considered significant and all calculations 
were performed using PRISM software version 4.0 (GraphPad Software, Inc., San Diego, CA, 
USA). 
Results 
Study Subjects:   
A total of twenty-seven subjects completed the study (13 male, 14 female); three subjects 
withdrew during the first rosiglitazone pharmacokinetics study visit due to adverse events.  The 
age, weight, and body mass index of the twenty-seven subjects who completed the study were 
24.9 ± 7.8 years (19 – 56), 67.6 ± 12.3 kg (45.5 – 96.2), and 23.3 ± 3.1 kg m-2 (18.8 – 29.6), 
respectively (Mean ± SD (range)).  The self reported racial background of the study subjects is as 
follows: six were African-American, nineteen were Caucasian, and two were Hispanic.  Seven of 
the female subjects were taking oral contraceptives and none of the subjects took complimentary 
medicine or over the counter medications during the study visits. 
 Rosiglitazone was tolerated relatively well and the most common adverse event was 
severe headache.  The incidences of severe headache occurred during the control phase of the 
study in four separate individuals causing three subjects to withdraw from the study.  The fourth 
subject completed the study with no further adverse effects noted.  According to subject diaries, 
all but one dose of St. John’s wort (1133/1134 doses, 99.9%) were taken by the 27 individuals.  
St. John’s wort was well tolerated with the most common observed adverse events being 
dizziness, increased tiredness, and headache.  No subjects withdrew from the study due to 
adverse events associated with St. John’s wort. 
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 Rosiglitazone Pharmacokinetics:  
Mean log concentration versus time profiles of single dose rosiglitazone (8 mg) in the presence 
and absence of St. John’s wort administration (900 mg daily) are shown in .  St. John’s 
wort administration significantly affected the disposition of rosiglitazone as the mean AUC and 
t1/2 decreased by 26% (p < 0.0001) and 17 % (p < 0.0001), respectively, and CL/F increased by 
37% (p < 0.0001), while the tmax and Cmax were not different (Figure 19, Table 14).  The Vd/F 
increased (p = 0.01) between control and St. John’s Wort phases, 14.0 L versus 15.8 L, 
respectively, but the mean change was only 12%.  Subject genotype and sex had no effect on the 
inducibility of CYP2C8 in the presence of St. John’s wort as the magnitude of change in AUC 
(Figure 20), t1/2, and CL/F did not differ between genotype groups.   
Figure 18
6β-hydroxycortisol to cortisol ratio:  
The urinary 6β-hydroxycortisol to cortisol ratio significantly increased 1.5 fold, from 7.4 to 11.2 
(p < 0.0001), in the presence of St. John’s wort, providing evidence of CYP induction (See 
Appendix B, Figure 27).  This magnitude of change is similar to previous reports of CYP3A 
induction due to St. John’s wort administration (Roby et al., 2000; Frye et al., 2004).  A 
correlation between CYP2C8 induction, as measured by a change in rosiglitazone AUC, and 
change in 6β-hydroxycortisol to cortisol ratio was not observed. 
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Table 14  Mean pharmacokinetic parameters of rosiglitazone in the absence and presence of St. John’s wort 
extract, 300 mg three times daily for fourteen days in 27 subjects 
 
SJW / Control 
Parameter Control St. John’s Wort p value Geometric 
Mean 
90% CI  
AUC (hr*µg/l) 3190 ± 641 2375 ± 537 < 0.0001 0.74 0.71 – 0.78 
Cl/F (l/hr) 2.6 ± 0.6 3.5 ± 0.7 < 0.0001 1.35 1.28 – 1.42 
t1/2 (hr) 3.8 ± 0.9 3.2 ± 0.7 < 0.0001 0.83   0.80 – 0.86 
Cmax (µg/l) 613.6 ± 151.0 568.4 ± 139.7 0.18 0.92 0.85 – 1.00 
tmax (hr) 0.75 (0.5 – 4)* 0.75 (0.25 – 2)* 0.40 - - 
 
* tmax given as median and range 
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Discussion 
In the present study, we have shown that St. John’s wort increases elimination of the CYP2C8 
substrate rosiglitazone.  Rosiglitazone exposure was decreased as the plasma AUC and half-life 
were decreased and the apparent oral clearance was increased in the presence of St. John’s wort.  
St. John’s wort administration did not affect rosiglitazone absorption as Cmax and tmax were not 
different between study visits.  Thus, the results of this study demonstrate that St. John’s wort 
induces CYP2C8 activity as determined by rosiglitazone pharmacokinetics.   
 The results of this study are consistent with previous reports in that St. John’s wort 
administration (900 mg daily for 14 days) has been shown to induce the activities of CYP3A 
(Durr et al., 2000; Roby et al., 2000; Markowitz et al., 2003), CYP2C9 (Jiang et al., 2004), and 
CYP2C19 (Wang et al., 2004a; Wang et al., 2004b).  Notably, the effect of St. John’s wort 
appears to be greatest for substrates that are metabolized by intestinal CYP enzymes, such as 
midazolam (Wang et al., 2001; Dresser et al., 2003; Hall et al., 2003) and verapamil (Tannergren 
et al., 2004).  For example, Dresser et al., showed that St. John’s wort increased the clearance of 
midazolam by 2.7 fold after oral administration but only 1.5 fold after intravenous administration 
(Dresser et al., 2003).  St. John’s wort appears to have a smaller effect on CYP3A substrates that 
have low first pass metabolism and high bioavailability, such as imatinib and alprazolam, for 
which there was an increase in oral clearance of 1.4 and 2.0 fold, respectively (Markowitz et al., 
2003; Frye et al., 2004).  Thus, the comparatively modest 1.4 fold increase in oral clearance 
observed with rosiglitazone is probably due to its limited first pass metabolism (Cox et al., 2000) 
and that CYP2C8 is found primarily in the liver with virtually no expression in the intestine 
(Lapple et al., 2003). 
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 Previously, Park et al., showed that the PXR ligand rifampin decreased rosiglitazone 
AUC by greater than 60% and increased its clearance three fold (Park et al., 2004a), which is 
greater than the 26% decrease in AUC and 35% increase in CL/F reported in the present study.  
The difference in magnitude of CYP2C8 induction observed with St. John’s wort and rifampin is 
similar to previous reports evaluating CYP3A and CYP2C19 substrates in the presence of these 
inducers.  Rifampin decreases oral midazolam AUC by 96% (Backman et al., 1996), whereas St. 
John’s wort decreases midazolam AUC by only 50% to 65% (Wang et al., 2001; Hall et al., 
2003).  Similar differences have been shown for imatinib, with an AUC reduction of 54% 
(Bolton et al., 2004) and 30% (Frye et al., 2004), for rifampin and St. John’s wort, respectively.  
The urinary excretion of 4′-hydroxymephenytoin, the CYP2C19 mediated metabolite of S-
mephenytoin, was increased by 2 fold in subjects exposed to rifampin (Feng et al., 1998) versus 
1.5 fold in subjects administered St. John’s wort (Wang et al., 2004b).  Our findings are 
consistent with previous reports that demonstrate St. John’s wort is a weaker inducer of CYP 
enzymes as compared to rifampin. 
 The ability of St. John’s wort to induce CYP2C8 activity is not affected by CYP2C8 
genotype as there were no differences in the magnitude of change in rosiglitazone 
pharmacokinetics after treatment with St. John’s wort.  Genotype has been shown to be 
important for induction of CYP2C19, as the excretion of 4'-hydroxymephenytoin was increased 
204% in homozygous wild type subjects but only 70% in heterozygous subjects (Feng et al., 
1998).  However, our data suggest that St. John’s wort induction is not dependent on CYP2C8 
genetic makeup.  This may be due to the nature of the polymorphisms in that the CYP2C8 variant 
alleles encode amino acid changes while the CYP2C19 polymorphisms result in no enzyme 
formation.  In contrast, we showed in a previous study that rosiglitazone inhibition by the 
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selective CYP2C8 inhibitor trimethoprim was modified in subjects possessing the CYP2C8*3 
allele.  There was a close relationship between trimethoprim plasma concentration and extent of 
CYP2C8 inhibition in subjects genotyped as CYP2C8*1/*1 or *1/*2, while there was no 
relationship when subjects expressing the CYP2C8*3 allele were included (Hruska et al., 2005). 
 The magnitude of induction by St. John’s wort may affect the clinical outcome of 
rosiglitazone therapy since its blood glucose lowering effect is dose- and concentration-
dependent (Balfour and Plosker, 1999).  Therefore, patients with type 2 diabetes utilizing 
rosiglitazone should exercise caution when self administering St. John’s wort as it may influence 
the pharmacodynamic response and clinical outcome of rosiglitazone therapy. 
 In conclusion, we have demonstrated that CYP2C8 activity, as determined by 
rosiglitazone pharmacokinetics, is induced by the herbal supplement St. John’s wort and that the 
magnitude of induction is not affected by CYP2C8 genotype.  The use of St. John’s wort with 
CYP2C8 substrates, such as rosiglitazone, should be monitored with caution since concomitant 
administration may lead to suboptimal therapy.  
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Effect of CYP2C8 Genotype on Rosiglitazone Metabolism  
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 Abstract 
Objective: The purpose of this study was to evaluate the pharmacokinetics of rosiglitazone in 
subjects with the CYP2C8 polymorphisms CYP2C8*2, CYP2C8*3, and CYP2C8*4. 
Methods: This single dose pharmacokinetic study involved thirty-eight subjects with the following 
CYP2C8 genotypes: CYP2C8*1/*1  (n = 14), CYP2C8*1/*2  (n = 5), CYP2C8*1/*3 (n = 11), 
CYP2C8*1/*4 (n = 6), CYP2C8*2/*2 (n = 1), and CYP2C8*3/*3 (n = 1).  Subjects participated in 
two previous drug interaction studies (Chapters 5 and 6) in which they were administered a single 
dose of rosiglitazone 8 mg.  Non-compartmental rosiglitazone pharmacokinetic parameter estimates 
were compared between wild type and heterozygous genotype groups. 
Results: CYP2C8 genotype did not affect rosiglitazone exposure as the area under the plasma 
concentration-time curve (AUC) did not differ between wild type (CYP2C8*1/*1), 3164 +/- 625 
µg*hr/L (95% Confidence Interval [CI], 2871 – 3457) and heterozygous individuals, CYP2C8*1/*2, 
3290 +/- 867 µg*hr/L (95% CI, 2464 – 4116), CYP2C8*1/*3, 2933 µg*hr/L +/- 519 (95% CI 2654 – 
3212) and CYP2C8*1/*4, 3230 +/- 658 µg*hr/L (95% CI, 2689 – 3771) (p = 0.71).  The individual 
genotyped as CYP2C8*3/*3 had the second lowest observed AUC (1896 µg*hr/L); whereas the 
subject having the CYP2C8*2/*2 genotype had a higher than average AUC (3733 µg*hr/L), 
consistent with decreased rosiglitazone clearance. The AUC and formation rate of the metabolites N-
desmethylrosiglitazone (AUC, p = 0.45; AUCNDR: AUCrosiglitazone, p = 0.57) and para-O-sulfate-
rosiglitazone (p = 0.36, p =0.13) were not different between genotype groups. 
Conclusions: The effect of allelic variation on in vivo CYP2C8 activity appears to be substrate 
specific as the pharmacokinetic profile of rosiglitazone is not influenced by heterozygous genotypes.  
Additional studies are necessary to investigate the influence of homozygous expression of the 
CYP2C8*2 and CYP2C8*3 alleles and the relative contribution of CYP2C8 and CYP2C9 
polymorphisms on rosiglitazone metabolism. 
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 Introduction 
Cytochrome P450 (CYP) 2C8 is an important enzyme in drug metabolism as it metabolizes the 
substrates, paclitaxel (Rahman et al., 1994), repaglinide (Bidstrup et al., 2003), amodiaquine (Li 
et al., 2002), R-(-)-ibuprofen (Hamman et al., 1997), rosiglitazone (Baldwin et al., 1999), and 
amiodarone (Soyama et al., 2002a), and the endogenous compounds retinoic acid (Nadin and 
Murray, 1999) and arachidonic acid (Dai et al., 2001).  This enzyme exhibits polymorphic 
expression with five allelic variants discovered to date, CYP2C8*1 (wild type), CYP2C8*2, 
CYP2C8*3 (Dai et al., 2001), CYP2C8*4 (Bahadur et al., 2002), and CYP2C8*5 (Nakajima et 
al., 2003).  The CYP2C8*2 allele, which is due to Ile269Phe substitution, is primarily found in 
African Americans at an allele frequency of 0.18, and causes a decreased intrinsic clearance of 
paclitaxel (Dai et al., 2001).  CYP2C8*3 results from Arg139Lys and Lys399Arg substitutions, 
is found primarily in Caucasians at an allele frequency from 0.13 to 0.17 (Dai et al., 2001; 
Martinez et al., 2004), and exhibits decreased in vitro CYP2C8 activity (Dai et al., 2001).  
CYP2C8*4 is found at a frequency of approximately 0.075 in the Caucasian population, is the 
consequence of an Ile264Met substitution, and demonstrates a trend towards decreased CYP2C8 
activity (Bahadur et al., 2002).  The deletion of adenine at nucleotide 475 produces the 
CYP2C8*5 allele, which is found in the Japanese population at an allele frequency of 0.0025, 
and may cause decreased CYP2C8 activity (Nakajima et al., 2003; Ishikawa et al., 2004).  Two 
other variants, CYP2C8*1A and CYP2C8*1B, are found in the promoter regions and do not 
affect CYP2C8 activity (Bahadur et al., 2002).    
 To date, CYP2C8*3 and CYP2C8*4 are the only CYP2C8 alleles that have been 
investigated in vivo.  Niemi et al. demonstrated that individuals with the CYP2C8*1/*3 genotype 
had greater clearance of the oral insulin secretagogue repaglinide than those with the 
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 CYP2C8*1/*1  genotype, while clearance was not different in subjects with the CYP2C8*1/*4 
genotype (Niemi et al., 2003c).  Conversely, two studies have shown that carriers of the 
CYP2C8*3 allele have decreased clearance of R-(-)-ibuprofen.   Martínez et al., determined that 
carriers of the CYP2C8*3 allele had significantly increased AUC and decreased oral clearance 
values for R-(-)-ibuprofen in a gene-dose effect manner (Martinez et al., 2004).  García-Martín et 
al. demonstrated that subjects who possess both the CYP2C8*3 and CYP2C9*3 alleles have 
decreased clearance of R-(-)-ibuprofen and racemic ibuprofen as compared to wild type 
individuals.  The investigators determined that polymorphisms of both CYP2C8 and CYP2C9 
contribute to variable ibuprofen pharmacokinetics (Garcia-Martin et al., 2004).  These studies 
demonstrate that the influence of polymorphic expression on CYP2C8 activity may be substrate 
specific, which is similar to what has been shown for CYP2C9 activity (Takanashi et al., 2000).  
CYP2C9*3 causes decreased clearance of the CYP2C9 substrates warfarin and flurbiprofen in 
vitro (Yamazaki et al., 1998; Takanashi et al., 2000) and in vivo (Takahashi et al., 1998; Lee et 
al., 2003a), but has no effect on diclofenac clearance (Shimamoto et al., 2000; Takanashi et al., 
2000).  Since CYP2C8 may exhibit substrate dependent metabolism, it would be important to 
determine rosiglitazone disposition in the presence of CYP2C8 polymorphisms.  Therefore, the 
purpose of this study is to evaluate the effect of the CYP2C8 polymorphisms, CYP2C8*2, 
CYP2C8*3 and CYP2C8*4 on rosiglitazone pharmacokinetics. 
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 Methods 
Study Subjects  
The studies were approved by the Institutional Review Boards at the University of Pittsburgh and 
University of Florida.  Subjects were recruited as previously reported (See Chapters 5 and 6).  
Briefly, eight subjects were recruited to complete the rosiglitazone with trimethoprim study and 
one-hundred eleven subjects were screened to select thirty subjects to complete the rosiglitazone 
and St. John’s wort study.  Thus, a total of thirty-eight subjects (18 male, 20 female) are 
available for this analysis.  Subjects were determined to be healthy on the basis of past medical 
history, a physical examination and routine clinical laboratory tests, and were excluded if they 
had any evidence of abnormal renal or hepatic function, had a BMI > 31 kg m-2, had preexisting 
medical conditions, or used dietary/herbal supplements or any medications other than oral 
contraceptives.  Women of child bearing age were tested for pregnancy prior to enrollment and 
on admission for the study visit for exclusionary purposes.  Subject age, weight, and body mass 
index of the thirty-eight subjects who completed the study were 25.6 ± 8.7 years (19 – 57), 68.6 
± 13.2 kg (45.5 – 101.0), and 23.4 ± 3.1 kg m-2 (18.8 – 29.6), respectively (Mean ± SD (range)).  
The self reported racial background of the study subjects are as follows: African-American 7, 
Asian 1, Caucasian 28, and Hispanic 2.  Eight of the female subjects were taking oral 
contraceptives and none of the subjects took complimentary medicine or over the counter 
medications during the study visit.  
Study Design  
Subjects from the previous studies were stratified based on their CYP2C8 genotype into one of 4 
groups, CYP2C8*1, CYP2C8*2, CYP2C8*3, or CYP2C8*4, containing at least 5 subjects and 
were administered a single oral dose of rosiglitazone 8 mg.  Subjects abstained from alcohol, 
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 caffeine containing foods and beverages, grapefruit or grapefruit juice, and over-the-counter 
medications for 48 hours prior to the study visit.  After an overnight fast, subjects were 
administered rosiglitazone 8 mg (Avandia, GlaxoSmithKline, Research Triangle Park, NC, 
USA) with 8 oz (240 ml) of water at approximately 8:00 AM on study day 1.  Subjects fasted for 
approximately 2 hours after rosiglitazone dosing.  Blood samples (10 ml) were obtained before 
and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24 hours after drug administration.  Blood 
samples were drawn in EDTA tubes, kept on ice, and centrifuged within two hours of collection 
at 2500 g, 4oC, for 15 minutes.  Plasma was harvested and stored at -70oC until analysis. 
Sample Analysis 
Rosiglitazone: Rosiglitazone plasma samples were analyzed as described previously (See 
Chapter 2) (Hruska and Frye, 2004b).  Acetonitrile (600 µl) was added to plasma samples (200 
µl) spiked with 250 ng of betaxolol (internal standard).  Samples were vortex-mixed, centrifuged 
at 3000 g for 10 minutes, and supernatant was transferred and evaporated to dryness at 45°C 
under a stream of nitrogen, followed by reconstitution with mobile phase (200 µl).  Analytes 
were monitored with HPLC linked with fluorescence detection under the following conditions: 
rosiglitazone: excitation wavelength (λex) of 247 nm, emission wavelength (λem) of 367 nm; 
betaxolol: λex of 235 nm, λem of 310 nm.  Separation was achieved with an Alltima Phenyl 5µ 
150 mm × 4.6 mm column (Alltech Associates Inc., Deerfield, IL, USA), and an isocratic mobile 
phase of 10 mM sodium acetate (pH 5): acetonitrile (60:40) delivered at a flow rate of 1 ml/min. 
Rosiglitazone metabolites:  Determination of rosiglitazone metabolites was described previously 
(Hruska et al., 2005).  Briefly, plasma samples (100 µl) were processed with 96-well 0.45µ 
Captiva® filter plates (Varian Inc, Lake Forest, CA, USA) preloaded with 300 µl of acetonitrile.  
Internal standard (250 ng) was added to each sample and the plates were vortex-mixed, inverted, 
 112
 and filtered under vacuum, followed by addition of water (300 µl) to the filtrate.  Aliquots (10 
µl) were injected onto a Surveyor HPLC system connected to a TSQ Quantum MS/MS system 
(Thermo, Woburn, MA, USA).  Detection was achieved with positive electrospray ionization and 
data output was captured with Xcalibur® software (Thermo, San Jose, CA, USA).  Precursor and 
product ions [M + H]+ detected were m/z 374.2/151 and 344.2/121, for para-O-sulfate-
rosiglitazone and N-desmethylrosiglitazone, respectively.  The internal standard was detected 
with single ion monitoring [M + H]+ at 308.3.  Chromatographic separation was performed with 
a Symmetry C8 5µm, 2.1 × 150 mm column (Waters Corp., Milford, MA, USA) and gradient 
elution with a mobile phase consisting of (A) 0.1% formic acid in water and (B) 0.1% formic 
acid in methanol, delivered at a flow rate of 200 µl/min.  Metabolite concentrations were 
calculated in arbitrary units (U/l) relative to the internal standard peak area. 
Determination of CYP2C8 Genotype: CYP2C8 genotype was determined as previously 
described (See Chapter 4) (Hruska et al., 2004).  Briefly, DNA was extracted from blood or 
buccal swab with QIAamp® DNA Mini Kits (Qiagen, Valencia, CA, USA), according to 
manufacturer protocol.  Target DNA was amplified with PCR and products (10 µl) were isolated 
with streptavidin-coated Sepharose beads.  Genotyping analysis and data capture was carried out 
with a PSQ HS 96 System (Biotage AB, Uppsala, Sweden) and PSQ HS 96 SNP software 
(Biotage AB, Uppsala, Sweden).    
Data Analysis 
Rosiglitazone Pharmacokinetics:  The rosiglitazone concentration-time data was analyzed using 
non-compartmental methods.  The terminal elimination rate constant (λz) was estimated by 
nonlinear least squares regression analysis of the terminal portion of the concentration-time data.  
Apparent elimination half-life was calculated as 0.693/λz.  The area under the concentration time 
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 curve (AUC) was calculated by the linear trapezoidal rule with extrapolation to infinity.  
Apparent oral clearance (CLO) was determined as [Dose / AUC0-∞] and the apparent oral volume 
of distribution (Vd/F) was calculated from the expression Dose/(λz × AUC).  For both 
rosiglitazone metabolites, the area under the concentration time curve (AUC) was calculated by 
the linear trapezoidal rule from 0 to 24 hours.   Pharmacokinetic calculations were performed 
with WinNonlin 2.1 (Pharsight Corp., Mountain View, CA, USA). 
Statistical analysis: Rosiglitazone pharmacokinetic parameters were log-transformed where 
appropriate and wild type (CYP2C8*1/*1) subjects were compared to heterozygous carriers of 
variant alleles using a one-way ANOVA, with Dunnett’s multiple comparison test.  Tmax was 
compared using the Kruskal-Wallis test.  A p value ≤ 0.05 was considered significant and all 
calculations were performed using PRISM software version 4.0 (GraphPad Software, Inc., San 
Diego, CA, USA). 
Results 
Study Subjects: Allele frequencies of all subjects are reported in Table 15.  Adverse event data 
was reported previously (See Chapters 5 and 6).  Briefly, four subjects developed severe 
headache after ingestion of rosiglitazone, causing three to drop out of the study before blood 
sampling was completed.  Extrapolation of AUC to infinity was less than 5% for these subjects 
so early withdrawal did not influence characterization of rosiglitazone pharmacokinetics. 
Rosiglitazone Pharmacokinetics:   The mean log concentration versus time profiles of 
rosiglitazone, N-desmethylrosiglitazone, and para-O-sulfate-rosiglitazone in wild type subjects 
and carriers of CYP2C8 allelic variants are shown in .  Rosiglitazone pharmacokinetic 
data are shown in Table 16.  CYP2C8 genotype did not affect the disposition or absorption of 
rosiglitazone as the AUC (p = 0.71), Cl/F (p = 0.97), t1/2 (p = 0.45), Cmax (p = 0.39), Vd/F (p = 
Figure 21
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 0.39), and tmax (p = 0.15) were not different between heterozygous and wild type genotype 
groups ( , ).  The subjects with the CYP2C8*2/*2 genotype had a higher than 
average (CYP2C8*1/*1) AUC, while the subject with the CYP2C8*3/*3 genotype had the 
second lowest rosiglitazone AUC value observed.  The AUC of N-desmethylrosiglitazone (p = 
0.45) and para-O-sulfate-rosiglitazone (p = 0.36) did not differ between heterozygous and wild 
type genotype groups (Figure 22).  The formation rate of metabolites as determined by the ratio 
of metabolite AUC0-24: rosiglitazone AUC0-24, was not different between wild type and variant 
CYP2C8 alleles for N-desmethylrosiglitazone (p = 0.57) and para-O-sulfate-rosiglitazone (p = 
0.13) (See Appendix C, Figure 28). 
Table 16 Figure 22
 
 
 
Table 15 Allele frequencies of CYP2C8*1, CYP2C8*2, CYP2C8*3, and CYP2C8*4 for subjects (n = 119) 
recruited at the University of Pittsburgh and the University of Florida. 
 
  Allele Frequency 
Racial Background n CYP2C8*1 CYP2C8*2 CYP2C8*3 CYP2C8*4 
African American 14 0.643 0.286 0.036 0.036 
Asian 8 1.00 0.00 0.00 0.00 
Caucasian 79 0.842 0.00 0.089 0.07 
Hispanic 17 0.853 0.00 0.147 0.00 
Other 1 1.00 0.00 0.00 0.00 
Total 119 0.832 0.034 0.084 0.050 
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Figure 21 The mean log concentration versus time profile of rosiglitazone, N-desmethylrosiglitazone, and 
para-O-sulfate-rosiglitazone in subjects after a single dose of rosiglitazone, 8 mg, with the 
genotypes: CYP2C8*1/*1, n = 14 (closed squares), CYP2C8*1/*2, n = 5 (open triangles), 
CYP2C8*2/*2, n = 1 (closed triangles), CYP2C8*1/*3, n = 11 (open circles), CYP2C8*3/*3, n = 1 
(closed circles), and CYP2C8*1/*4, n = 6 (open diamonds). 
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Figure 22 The area under the concentration time curve (AUC) of rosiglitazone, N-desmethylrosiglitazone, and 
para-O-sulfate-rosiglitazone in subjects with the genotypes: CYP2C8*1/*1 (n = 14), CYP2C8*1/*2 
(n = 5), CYP2C8*2/*2 (n =1), CYP2C8*1/*3 (n = 11), CYP2C8*3/*3 (n = 1), and CYP2C8*1/*4 (n = 
6).  Horizontal lines indicate mean AUC. 
 118
 Discussion 
The present study is the first to evaluate rosiglitazone metabolism in the presence of CYP2C8 
polymorphisms and to evaluate the effect of the CYP2C8*2 allele in vivo.  Rosiglitazone 
biotransformation is not affected by CYP2C8 polymorphisms as rosiglitazone pharmacokinetics 
and metabolite formation after single dose administration does not differ between wild-type 
individuals and the heterozygote carriers of CYP2C8 variants.  Further investigation is necessary 
to determine whether homozygous expression of the CYP2C8*2 and CYP2C8*3 alleles has any 
effect on rosiglitazone metabolism.  
 The results of the present study differ from previous reports, which suggest that the 
CYP2C8*3 allele influences the metabolism of repaglinide and R-(-)-ibuprofen.  Niemi et al., 
demonstrated that the clearance of repaglinide, a CYP2C8 and CYP3A4 substrate (Bidstrup et 
al., 2003), is significantly increased in the presence of the CYP2C8*1/*3 genotype (Niemi et al., 
2003c).   Conversely, the clearance of R-(-)-ibuprofen, which is metabolized by CYP2C8 and 
CYP2C9 (Hamman et al., 1997), was decreased in a gene-dose manner relative to the CYP2C8*3 
allele.  Subjects carrying this allele had significantly lower clearance than wild-type individuals 
with a more profound effect observed for homozygous carriers of CYP2C8*3 (Martinez et al., 
2004).  In the present study, no difference in rosiglitazone AUC was observed for the 
CYP2C8*1/*3 genotype, but the CYP2C8*3/*3 genotype could have a larger impact on 
rosiglitazone AUC.   
 The lack of variability in rosiglitazone metabolism in relation to CYP2C8 genotype 
suggests that CYP2C8 activity, like CYP2C9 and CYP2D6, may be substrate specific (Takanashi 
et al., 2000; Wennerholm et al., 2002).  The metabolism of the CYP2C9 substrate, flurbiprofen, 
is significantly decreased in vitro (Yamazaki et al., 1998) and in vivo (Lee et al., 2003a) in the 
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 presence of the CYP2C9*3 allele; however, diclofenac, another CYP2C9 substrate, is not 
affected by this allele in vitro (Yamazaki et al., 1998; Takanashi et al., 2000) or in vivo 
(Shimamoto et al., 2000).   Wennerholm et al. investigated the metabolism of four probes of 
CYP2D6 activity in the presence of the CYP2D6*17 allele and found that carriers of this variant 
allele had altered metabolism for only two of these probes, debrisoquin and dextromethorphan 
(Wennerholm et al., 2002).  CYP2C8 appears to follow a similar pattern of substrate specificity 
as in vitro studies have demonstrated that the metabolism of paclitaxel (Dai et al., 2001; Soyama 
et al., 2001), but not the N-deethylation of amiodarone (Soyama et al., 2002a) is decreased in the 
presence of the CYP2C8*3 allele.  In vivo, the CYP2C8*3 allele appears to increase repaglinide 
clearance (Niemi et al., 2003c), but in the present study this allele does not influence 
rosiglitazone clearance. 
 Although CYP2C8 variants do not appear to effect rosiglitazone pharmacokinetics, the 
presence of CYP2C9 variants may have an effect since this enzyme contributes to a minor extent 
to rosiglitazone metabolism (Baldwin et al., 1999).  Metabolism of R-(-)-ibuprofen, which is 
unidirectionally converted up to 63% in vivo (Lee et al., 1985) to the CYP2C9 substrate, S-(+)-
ibuprofen (Hamman et al., 1997), demonstrates the impact of CYP2C9 variants.  García-Martín 
et al., determined the metabolism of racemic ibuprofen, R-(-)-ibuprofen, and S-(+)-ibuprofen 
were dependent on both CYP2C8 and CYP2C9 polymorphisms, as the CYP2C8*3 and 
CYP2C9*3 alleles both contributed to the reduced clearance of these substrates (Garcia-Martin et 
al., 2004).  Individuals with the CYP2C8*1/*1 genotype and at least one copy of the CYP2C9*3 
allele exhibited a reduction of racemic and R-(-)-ibuprofen clearance; whereas CYP2C8*3 
carriers, who were CYP2C9*1/*1, exhibited no changes in R-(-)-ibuprofen clearance (Garcia-
Martin et al., 2004).  Further, in the study by Martinez et al., all of the subjects presenting with 
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 the CYP2C8*3 allele had at least one copy of the CYP2C9*2 allele, but none of the CYP2C8 
wild type individuals carried a CYP2C9 mutation (Martinez et al., 2004).  These results suggest 
the pharmacokinetics of substrates metabolized by both CYP2C8 and CYP2C9, such as 
rosiglitazone and ibuprofen, are impacted by the polymorphic expression of both enzymes.  
Further, linkage of the CYP2C8*3 and CYP2C9*2 alleles, which occurs in approximately 96% of 
CYP2C8*3 carriers (Yasar et al., 2002), may also influence rosiglitazone pharmacokinetics.  
Further evaluation of rosiglitazone metabolism by CYP2C8 and CYP2C9 variants is warranted 
to determine the genetic contribution of each of these enzymes.  
 Rosiglitazone metabolism by individuals with CYP2C8*1/*2 genotype is not consistent 
with the in vitro literature, which demonstrated CYP2C8*2 has a reduced intrinsic clearance of 
paclitaxel (Dai et al., 2001).  Like the CYP2C8*3/*3 genotype, the CYP2C8*2/*2 genotype may 
have a greater effect on rosiglitazone AUC than observed in heterozygous individuals, but 
further study is required.  If the CYP2C8*2/*2 genotype does present with decreased activity, it 
may cause unwanted adverse events, such as edema during rosiglitazone therapy (Idris et al., 
2003), or exaggerated pharmacodynamic effects of other CYP2C8 substrates.  Additional studies 
evaluating the in vivo activity of CYP2C8*2 variants, especially homozygous carriers is 
necessary.   
 Finally, the present study supports previous in vitro (Bahadur et al., 2002) and in vivo 
(Niemi et al., 2003c) data demonstrating CYP2C8*4 does not influence CYP2C8 activity as the 
mean rosiglitazone AUC in this sample population was approximately the same as the wild type 
individuals.  It appears that this variant allele, although present at an allele frequency of 
approximately 7.5% (Bahadur et al., 2002), does not influence CYP2C8 mediated metabolism.    
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  In conclusion, this study demonstrates the influence of polymorphic expression on 
CYP2C8 activity may be substrate specific as rosiglitazone pharmacokinetics, unlike other 
CYP2C8 substrates, are not different between heterozygous and wild type individuals.  
Additional studies investigating the influence of homozygous expression of the CYP2C8*2 and 
CYP2C8*3 alleles and the relative contribution of CYP2C8 and CYP2C9 polymorphisms would 
be necessary to fully understand their role in rosiglitazone metabolism. 
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 Chapter 8 
Conclusions and Future Directions 
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 The purpose of this research was to investigate the utility of rosiglitazone as an in vivo probe of 
CYP2C8 activity.  To accomplish this goal, novel methods were developed to determine 
rosiglitazone and trimethoprim plasma concentrations and to identify CYP2C8 polymorphisms.  
The disposition of rosiglitazone was utilized as a marker of CYP2C8 activity in the presence of 
the CYP2C8 inhibitor, trimethoprim, and the CYP inducer, St. John’s wort extract, and the 
impact of CYP2C8 genotype on these interactions was evaluated.  Finally, basal rosiglitazone 
pharmacokinetic parameters were compared between genotype groups to determine the influence 
of CYP2C8 polymorphisms on in vivo rosiglitazone metabolism.  
 To measure CYP2C8 activity through the evaluation of rosiglitazone metabolism, a 
method utilizing fluorescence detection was developed to detect rosiglitazone plasma 
concentrations.  Advantages of this method relative to published methods include the use of 
protein precipitation, which simplifies sample processing, the use of small volumes of plasma, 
and the application of a commercially available internal standard.  To determine trimethoprim 
plasma concentrations and their correlation with CYP2C8 inhibition, an assay employing 
ultraviolet detection was developed.  Advantages include the use of simple protein precipitation, 
which does not require further preparation, consistent recovery, and direct applicability to the 
determination of trimethoprim plasma concentrations in pharmacokinetic studies or after 
administration of high dose therapy.  To ascertain the influence of CYP2C8 genotype on 
rosiglitazone metabolism, a genotyping method was developed as a screening tool for CYP2C8 
allelic variants.  This method utilizes Pyrosequencing technology, which offers the primary 
advantage over other genotyping methods of determining the direct sequence of target DNA.  
Pyrosequencing is a cost effective and less time consuming genotyping method that allows for 
high throughput analysis and precise determination of CYP2C8 variants.   
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  The first interaction study, which evaluated the in vitro and in vivo effects of 
trimethoprim on rosiglitazone metabolism, determined that trimethoprim is an effective CYP2C8 
inhibitor in vitro and significantly inhibits rosiglitazone metabolism in vivo.  Trimethoprim, a 
competitive inhibitor, is more potent in vitro compared to the CYP2C8/9/19 inhibitor, 
gemfibrozil, which inhibits CYP2C8 by a noncompetitive mechanism; however, in vivo 
trimethoprim has a less profound effect on rosiglitazone metabolism.  The difference in extent of 
inhibition observed between trimethoprim and gemfibrozil is most likely related to the inhibitor 
steady state concentration, which for gemfibrozil exceeds the inhibition constant (Ki) but for 
trimethoprim does not.  Finally, carriers of the CYP2C8*3 allele did not exhibit inhibition by 
trimethoprim in a concentration dependent manner, whereas non-carriers of this did.   
 The second study evaluated the effect of St. John’s wort extract administration on 
rosiglitazone metabolism in healthy subjects genotyped for CYP2C8 polymorphisms.  St. John’s 
wort administration significantly decreases rosiglitazone exposure, but the magnitude of 
induction (AUCcontrol/AUCSt. John’s wort) was not dependent on CYP2C8 genotype.  This study 
illustrates St. John’s wort extract induces rosiglitazone metabolism and may influence the 
pharmacodynamic response of rosiglitazone.   
 Finally, analysis of basal rosiglitazone pharmacokinetic parameters for all subjects was 
conducted to determine the effect of genotype on rosiglitazone metabolism.  Exposure to 
rosiglitazone was not different between wild type and heterozygous carriers of CYP2C8 variant 
alleles, which differs from previous reports of substrates in the presence CYP2C8 variants.  
Interestingly, homozygous carriers of the CYP2C8*2 and CYP2C8*3 alleles appear to have a 
more profound affect on rosiglitazone metabolism, but further investigation is necessary.  
Therefore, the effect of CYP2C8 genotype on in vivo activity may be substrate specific, resulting 
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 in no effect on rosiglitazone metabolism, or the effect of genotype on rosiglitazone metabolism 
may only be relevant in carriers of two allelic variants. 
 Rosiglitazone is a suitable probe to evaluate drug interactions involving CYP2C8, as the 
pharmacokinetic parameters of rosiglitazone are affected by the CYP2C8 modulators 
trimethoprim, gemfibrozil, rifampin, and St. John’s wort extract.  Rosiglitazone is a more 
suitable probe of hepatic CYP2C8 activity versus other potential in vivo CYP2C8 probes, 
paclitaxel and repaglinide.  Paclitaxel, an antineoplastic agent, cannot be safely administered to 
healthy volunteers and CYP3A contributes to the metabolism of repaglinide, which may 
complicate the interpretation of CYP2C8 induction studies, since both enzymes are induced via 
the orphan nuclear receptor PXR.  Rosiglitazone offers advantages over these substrates as it has 
a favorable pharmacokinetic profile and has close to complete bioavailability allowing its use as 
an in vivo probe of CYP2C8 activity in drug-drug and drug-herb interaction studies.   
The major polymorphisms of CYP2C8, unlike CYP2C19 and CYP2D6, do not abolish 
enzyme production.  Since there are no major changes in CYP2C8 production, there are no 
apparent PM and EM phenotypes.  However, like CYP2C9 and CYP2D6*17, changes in 
CYP2C8 activity in the presence of allelic variants appear to be substrate specific as only some 
substrates are affected by polymorphic expression.  Since the major CYP2C8 allelic variants do 
not abolish enzyme production, changes in the amino acid structure may affect the enzyme active 
site and influence metabolism in a substrate-dependent manner.  These alterations of the 
CYP2C8 active site may help explain why paclitaxel metabolism in vitro and repaglinide 
metabolism in vivo are affected by polymorphic expression, but amiodarone metabolism in vitro 
and rosiglitazone metabolism in vivo are not.  The location of these amino acid substitutions in 
the CYP2C8 protein may also help explain why the inhibitory effects of trimethoprim, but not 
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 the inductive effects of St. John’s wort extract, appear to be affected by CYP2C8 genotype.  
Since CYP2C8 variants do not eliminate enzyme production, induction is not affected by 
CYP2C8 genotype, but changes of the enzyme active site may affect the efficacy of a 
competitive inhibitor, such as trimethoprim.  Therefore, rosiglitazone may not be a suitable probe 
to investigate CYP2C8 polymorphisms as no changes in the pharmacokinetic profile of 
rosiglitazone in the presence of these mutations are observed. 
 Future research is required to confirm the findings of this work and better characterize 
CYP2C8 polymorphisms in vitro and in vivo.  In vitro, the role of CYP2C8 variants on the 
metabolism of the substrates R-(-)-ibuprofen, rosiglitazone, and repaglinide should be 
investigated.  By evaluating these substrates in the presence of CYP2C8 polymorphisms, the 
possibility of substrate dependent CYP2C8 metabolism may be explored.  Further, the 
orientation of each substrate in the CYP2C8 enzyme active site should be investigated to better 
understand the probable cause of substrate specific effects.  In vivo, rosiglitazone metabolism in 
the presence of CYP2C8 homozygous variant carriers should be assessed to determine if a 
relationship exists.  The extent of rosiglitazone metabolism by CYP2C9 should be evaluated to 
determine the relative contributions of CYP2C8 and CYP2C9, which would further support the 
use of rosiglitazone as an in vivo CYP2C8 probe.  Finally, the individual and combined effects of 
CYP2C8 and CYP2C9 polymorphisms should be evaluated to determine their role in 
rosiglitazone metabolism.       
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  In summary, the results of the present work indicate that rosiglitazone is suitable for use 
as an in vivo probe of CYP2C8 activity in the presence of potential CYP2C8 inducers and 
inhibitors; however, it may not be a suitable probe of CYP2C8 activity in the presence of the 
known CYP2C8 polymorphisms.  The clinical effect of CYP2C8 substrates may be influenced by 
inhibitors and inducers and the use of rosiglitazone as a CYP2C8 probe may lead to the 
identification of these potential drug interactions. 
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 Table 17 Individual rosiglitazone pharmacokinetic parameters in the presence and absence of trimethoprim 
200 mg twice daily for five days in 8 subjects 
Rosiglitazone Pharmacokinetic Parameters 
SN Control Trimethoprim SN Control Trimethoprim 
AUC (µg*h/L)  Cmax (µg/L)  
1 3377 3883 1 1104.2 603.1 
2 3286 4616 2 766.9 688.2 
3 1948 2490 3 660.5 513.1 
4 2318 2547 4 388.3 500.5 
5 2735 5117 5 381.2 585.6 
6 3281 4624 6 697.3 635.3 
7 3368 3118 7 809.6 584.3 
8 1886 2753 8 586.3 625.4 
Mean 2774 3643 Mean 674.3 591.9 
S.D. 645 1051 S.D. 235.4 62.2 
t1/2 (h)   
1 2.6 3.9 1 0.75 2.00 
2 3.4 4.2 2 0.50 1.00 
3 2.7 3.2 3 0.50 0.75 
4 3.4 4.2 4 1.00 0.50 
5 3.6 5.4 5 4.00 2.00 
6 4.0 5.4 6 0.50 0.75 
7 3.7 3.3 7 0.75 2.00 
8 3.0 4.0 8 0.75 0.75 
Mean 3.3 4.2 Median 0.75 0.88 
S.D. 0.5 0.8 Range (0.5 – 4.0) (0.5 – 2.0)  
Vd (L)     
1 9.5 12.0    
2 12.5 10.8    
3 16.5 15.4    
4 18.4 19.4    
5 15.7 12.2    
6 14.4 13.7    
7 13.3 12.4    
8 18.9 16.8    
Mean 14.9 14.1    
S.D. 3.1 2.9    
tmax (h) 
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 Table 18 Individual rosiglitazone metabolite pharmacokinetic parameters in the presence and absence of 
trimethoprim 200 mg twice daily for five days in 8 subjects 
Rosiglitazone Metabolite Pharmacokinetic Parameters 
SN Control Trimethoprim SN Control Trimethoprim 
Para-O-sulfate-rosiglitazone (POS) 
AUC (U*h/L)  AUC Ratio (POS:Rosiglitazone) 
1 16.9 17.6 1 5.0 4.5 
2 19.1 15.5 2 5.9 3.4 
3 10.8 12.5 3 5.5 5.0 
4 17.9 19.4 4 7.8 7.6 
5 14.0 12.8 5 5.2 2.6 
6 13.9 10.0 6 4.3 2.2 
7 15.0 15.3 7 4.5 4.9 
8 11.1 10.6 8 5.8 3.9 
Mean 14.9 14.2 Mean 5.5 4.3 
S.D. 3.0 3.3 S.D. 1.1 1.7 
N-desmethylrosiglitazone (NDR) 
AUC (U*h/L)  AUC Ratio (NDR:Rosiglitazone) 
1 14.3 18.2 1 4.2 4.7 
2 17.8 18.2 2 5.5 4.0 
3 12.8 7.2 3 6.5 2.9 
4 15.8 11.0 4 6.9 4.3 
5 16.9 18.1 5 6.3 3.7 
6 18.2 9.3 6 5.7 2.1 
7 11.7 8.0 7 3.5 2.6 
8 17.3 15.1 8 9.1 5.5 
Mean 15.6 13.1 Mean 6.0 3.7 
S.D. 2.4 4.8 S.D. 1.7 1.2 
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Figure 24 Rosiglitazone AUC in subjects with CYP2C8*1/*1, CYP2C8*1/*2, and CYP2C8*1/*3 genotypes.  
Line indicates mean. 
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Figure 25 Fold increase of rosiglitazone AUC in the presence trimethoprim in subjects with CYP2C8*1/*1 
and CYP2C8*1/*2 or CYP2C8*1/*3 genotypes.  Horizontal lines indicate mean. 
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Figure 26 Michaelis-Menten plots of rosiglitazone in the presence of trimethoprim and gemfibrozil in human 
liver microsomes. 
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APPENDIX B 
 
 
 
Individual Subject Data and Additional Figures from  
Rosiglitazone-St. John’s wort Interaction Study 
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 Table 19 Individual AUC (µg*h/L) and Cl/F (L/h) of rosiglitazone 8 mg in the presence and absence of St. 
John’s wort extract, 300 mg three times daily for fourteen days in 27 subjects 
 
SN Control St. John’s wort SN Control St. John’s wort 
AUC (µg*h/L)  Cl/F (L/h)  
573-003 3749 2883 573-003 2.1 2.8 
573-004 2759 2328 573-004 2.9 3.4 
573-005 3832 2284 573-005 2.1 3.5 
573-006 2879 2181 573-006 2.8 3.7 
573-007 1896 2402 573-007 4.2 3.3 
573-011 2789 1803 573-011 2.9 4.4 
573-013 2569 1927 573-013 3.1 4.2 
573-017 3733 2687 573-017 2.1 3.0 
573-025 3125 2344 573-025 2.6 3.4 
573-029 3331 1991 573-029 2.4 4.0 
573-034 4266 2016 573-034 1.9 4.0 
573-035 2998 3079 573-035 2.7 2.6 
573-036 3561 1812 573-036 2.2 4.4 
573-037 3020 2051 573-037 2.6 3.9 
573-038 2794 1881 573-038 2.9 4.3 
573-042 4417 3432 573-042 1.8 2.3 
573-046 3130 2423 573-046 2.6 3.3 
573-055 2358 1843 573-055 3.4 4.3 
573-062 3910 2786 573-062 2.0 2.9 
573-065 3535 2942 573-065 2.3 2.7 
573-069 2682 2427 573-069 3.0 3.3 
573-072 3838 3385 573-072 2.1 2.4 
573-074 4155 3453 573-074 1.9 2.3 
573-077 2879 1742 573-077 2.8 4.6 
573-091 2791 2323 573-091 2.9 3.4 
573-094 2320 1624 573-094 3.4 4.9 
573-099 2821 2085 573-099 2.8 3.8 
Mean 3190 2375 Mean 2.6 3.5 
S.D. 641 537 S.D. 0.6 0.7 
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 Table 20 Individual t1/2 (h) and Vd (L) of rosiglitazone 8 mg in the presence and absence of St. John’s wort 
extract, 300 mg three times daily for fourteen days in 27 subjects 
 
SN Control St. John’s wort SN Control St. John’s wort 
t1/2 (h)   Vd (L)   
573-003 3.3 2.7 573-003 10.2 10.6 
573-004 4.2 3.0 573-004 17.7 14.7 
573-005 2.8 2.4 573-005 8.6 12.1 
573-006 3.3 2.6 573-006 13.2 13.7 
573-007 2.0 2.2 573-007 12.2 10.6 
573-011 4.2 4.9 573-011 17.5 31.5 
573-013 3.2 2.8 573-013 14.2 17.0 
573-017 5.6 4.5 573-017 17.2 19.2 
573-025 4.2 3.5 573-025 15.7 17.5 
573-029 3.2 2.8 573-029 11.1 16.4 
573-034 3.3 2.5 573-034 9.0 14.5 
573-035 4.8 4.0 573-035 18.4 15.1 
573-036 5.4 3.2 573-036 17.5 20.3 
573-037 4.4 3.6 573-037 16.8 20.5 
573-038 3.1 2.5 573-038 12.9 15.5 
573-042 4.8 4.5 573-042 12.5 15.1 
573-046 4.2 3.2 573-046 15.6 15.4 
573-055 3.2 2.5 573-055 15.7 15.8 
573-062 4.1 3.3 573-062 12.1 13.6 
573-065 3.4 2.7 573-065 11.0 10.4 
573-069 3.8 3.4 573-069 16.3 16.4 
573-072 4.7 4.2 573-072 14.3 14.3 
573-074 4.4 3.6 573-074 12.2 11.9 
573-077 3.4 2.6 573-077 13.8 17.5 
573-091 4.0 3.0 573-091 16.6 14.9 
573-094 2.5 2.6 573-094 12.7 18.4 
573-099 3.3 2.5 573-099 13.4 13.7 
Mean 3.8 3.2 Mean 14.0 15.8 
S.D. 0.9 0.7 S.D. 2.8 4.1 
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 Table 21 Individual Cmax (µg/L) and tmax (h) of rosiglitazone 8 mg in the presence and absence of St. John’s 
wort extract, 300 mg three times daily for fourteen days in 27 subjects 
SN Control St. John’s wort SN Control St. John’s wort 
Cmax (µg/L)  tmax (h)   
573-003 703.2 644.2 573-003 0.75 2.00 
573-004 501.3 550.1 573-004 0.75 0.50 
573-005 884.5 791.2 573-005 0.50 0.25 
573-006 683.0 619.2 573-006 0.50 1.00 
573-007 436.1 615.4 573-007 2.00 0.50 
573-011 816.2 240.6 573-011 0.50 0.50 
573-013 476.1 581.4 573-013 2.00 0.50 
573-017 491.2 521.8 573-017 0.75 0.50 
573-025 489.9 570.6 573-025 2.00 0.75 
573-029 694.0 726.1 573-029 0.50 0.50 
573-034 910.4 545.4 573-034 0.50 0.50 
573-035 651.3 613.3 573-035 0.75 0.75 
573-036 546.4 326.8 573-036 0.75 2.00 
573-037 471.9 410.2 573-037 1.00 1.00 
573-038 573.9 475.2 573-038 0.75 1.00 
573-042 775.0 532.6 573-042 1.00 2.00 
573-046 641.6 551.8 573-046 0.50 1.00 
573-055 302.2 419.8 573-055 4.00 2.00 
573-062 805.7 761.5 573-062 0.50 0.50 
573-065 626.0 731.7 573-065 1.00 1.00 
573-069 632.3 401.2 573-069 0.50 2.00 
573-072 509.5 690.7 573-072 2.00 1.00 
573-074 787.0 829.8 573-074 0.50 0.75 
573-077 508.0 469.2 573-077 0.75 0.50 
573-091 504.9 514.2 573-091 1.00 0.50 
573-094 678.3 568.4 573-094 0.75 0.25 
573-099 468.3 644.2 573-099 2.00 0.75 
Mean 613.6 568.4 Median 0.75 0.75 
S.D. 151.0 139.7 Range (0.5 – 4.0) (0.25 – 2.0) 
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Figure 27 CYP3A induction as measured by the ratio of 6β-hydroxycortisol: cortisol in the presence (SJW) 
and absence (Control) of St. John’s wort extract, 300 mg for fourteen days.   
 
 140   
  
 
 
 
 
 
APPENDIX C 
 
 
 
Individual Subject Data for Rosiglitazone-Trimethoprim and Rosiglitazone-St. John’s wort 
Interaction Studies Sorted by Genotype 
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 Table 22 Individual rosiglitazone pharmacokinetic parameters for subjects presenting with the CYP2C8*1/*1 
genotype 
  
SN AUC (µg*h/L) SN Cl/F (L/h) SN  t1/2 (h) 
573-003 3749 573-003 2.1 573-003 3.3 
573-004 2759 573-004 2.9 573-004 4.2 
573-005 3832 573-005 2.1 573-005 2.8 
573-006 2879 573-006 2.8 573-006 3.3 
573-009 2728 573-009 2.9 573-009 3.3 
573-010 3893 573-010 2.1 573-010 5.5 
573-013 2569 573-013 3.1 573-013 3.2 
573-029 3331 573-029 2.4 573-029 3.2 
573-034 4266 573-034 1.9 573-034 3.3 
573-035 2998 573-035 2.7 573-035 4.8 
RT2 3282 RT2 2.4 RT2 3.4 
RT3 1987 RT3 4.0 RT3 3.2 
RT5 2737 RT5 2.9 RT5 3.8 
RT6 3288 RT6 2.4 RT6 4.4 
Mean 3164 Mean 2.6 Mean 3.7 
S.D. 619 S.D. 0.6 S.D. 0.7 
SN Vd/F (L) SN Cmax (µg/L) SN tmax (h) 
573-003 10.2 573-003 703 573-003 0.75 
573-004 17.7 573-004 501 573-004 0.75 
573-005 8.6 573-005 885 573-005 0.50 
573-006 13.2 573-006 683 573-006 0.50 
573-009 14.0 573-009 562 573-009 0.50 
573-010 16.2 573-010 759 573-010 0.50 
573-013 14.2 573-013 476 573-013 2.00 
573-029 11.1 573-029 694 573-029 0.50 
573-034 9.0 573-034 910 573-034 0.50 
573-035 18.4 573-035 651 573-035 0.75 
RT2 11.8 RT2 767 RT2 0.50 
RT3 18.3 RT3 661 RT3 0.50 
RT5 16.1 RT5 381 RT5 4.00 
RT6 15.3 RT6 697 RT6 0.50 
Mean 13.9 Mean 666 Median 0.50 
S.D. 3.4 S.D. 148 Range (0.5 – 4.0)  
Key: RT: Subjects who participated in rosiglitazone-trimethoprim interaction study 
 142   
  
 
 
Table 23 Individual rosiglitazone pharmacokinetic parameters for subjects presenting with the CYP2C8*1/*2 
genotype  
 
SN AUC (µg*h/L) SN Cl/F (L/h) SN  t1/2 (h) 
573-025 3125 573-025 2.56 573-025 4.2 
573-042 4417 573-042 1.81 573-042 4.8 
573-062 3910 573-062 2.05 573-062 4.1 
573-069 2682 573-069 2.98 573-069 3.8 
RT4 2317 RT4 3.45 RT4 3.6 
Mean 3290 Mean 2.57 Mean 4.1 
S.D. 866 S.D. 0.67 S.D. 0.4 
SN Vd/F (L) SN Cmax (µg/L) SN tmax (h) 
573-025 15.7 573-025 490 573-025 2.00 
573-042 12.5 573-042 775 573-042 1.00 
573-062 12.1 573-062 806 573-062 0.50 
573-069 16.3 573-069 632 573-069 0.50 
RT4 18.1 RT4 388 RT4 1.00 
Mean 15.0 Mean 618 Median 0.50 
S.D. 2.6 S.D. 180 Range (0.5 – 4.0) 
Key: RT: Subjects who participated in rosiglitazone-trimethoprim interaction study 
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 Table 24 Individual rosiglitazone pharmacokinetic parameters for subjects presenting with the CYP2C8*1/*3 
genotype  
 
SN AUC (µg*h/L) SN Cl/F (L/h) SN  t1/2 (h) 
573-001 2968 573-001 2.70 573-001 4.0 
573-011 2789 573-011 2.87 573-011 4.2 
573-036 3561 573-036 2.25 573-036 5.4 
573-038 2794 573-038 2.86 573-038 3.1 
573-065 3535 573-065 2.26 573-065 3.4 
573-091 2791 573-091 2.87 573-091 4.0 
573-094 2320 573-094 3.45 573-094 2.5 
573-099 2821 573-099 2.84 573-099 3.3 
RT1 3387 RT1 2.36 RT1 2.7 
RT7 3374 RT7 2.37 RT7 4.2 
RT8 1931 RT8 4.14 RT8 3.2 
Mean 2934 Mean 2.81 Mean 3.6 
S.D. 511 S.D. 0.57 S.D. 0.8 
SN Vd/F (L) SN Cmax (µg/L) SN tmax (h) 
573-001 15.7 573-001 652 573-001 0.75 
573-011 17.5 573-011 816 573-011 0.50 
573-036 17.5 573-036 546 573-036 0.75 
573-038 12.9 573-038 574 573-038 0.75 
573-065 11.0 573-065 626 573-065 1.00 
573-091 16.6 573-091 505 573-091 1.00 
573-094 12.7 573-094 678 573-094 0.75 
573-099 13.4 573-099 468 573-099 2.00 
RT1 9.0 RT1 1104 RT1 0.75 
RT7 14.4 RT7 810 RT7 0.75 
RT8 19.1 RT8 586 RT8 0.75 
Mean 14.5 Mean 670 Median 0.75 
S.D. 3.1 S.D. 182 Range (0.5 – 2.0) 
Key: RT: Subjects who participated in rosiglitazone-trimethoprim interaction study 
 144   
  
 
Table 25 Individual rosiglitazone pharmacokinetic parameters for subjects presenting with the CYP2C8*1/*4 
genotype 
 
SN AUC (µg*h/L) SN Cl/F (L/h) SN  t1/2 (h) 
573-037 3020 573-037 2.65 573-037 4.4 
573-046 3130 573-046 2.56 573-046 4.2 
573-055 2358 573-055 3.39 573-055 3.2 
573-072 3838 573-072 2.08 573-072 4.7 
573-074 4155 573-074 1.93 573-074 4.4 
573-077 2879 573-077 2.78 573-077 3.4 
Mean 3230 Mean 2.56 Mean 4.1 
S.D. 658 S.D. 0.53 S.D. 0.6 
SN Vd/F (L) SN Cmax (µg/L) SN tmax (h) 
573-037 16.8 573-037 472 573-037 1.00 
573-046 15.6 573-046 642 573-046 0.50 
573-055 15.7 573-055 302 573-055 4.00 
573-072 14.3 573-072 510 573-072 2.00 
573-074 12.2 573-074 787 573-074 0.50 
573-077 13.8 573-077 508 573-077 0.75 
Mean 14.7 Mean 537 Median 0.75 
S.D. 1.6 S.D. 164 Range (0.5 – 4.0) 
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Figure 28 Formation rate of para-O-sulfate-rosiglitazone and N-desmethylrosiglitazone as measured by the 
metabolite AUC: rosiglitazone AUC. 
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Rosiglitazone-Trimethoprim Drug Interaction Study Protocol, Informed Consent, 
Advertisement, and Approval Letter 
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 A.  Principal Investigator: Reginald F. Frye, Pharm.D., Ph.D. 
Co-Investigators: Matthew Hruska, Pharm.D., Janet Amico, M.D. 
 
B. Protocol Title: Effect of CYP2C8 inhibition by trimethoprim on the 
pharmacokinetics of rosiglitazone. 
 
C. Hypothesis and Specific Aims 
The primary aim of this study is to test the hypothesis that the selective CYP2C8 inhibitor 
trimethoprim will decrease the clearance (increase the AUC) of rosiglitazone and decrease formation 
of its para-hydroxylated metabolite.  We will accomplish this aim by characterizing the 
pharmacokinetics of rosiglitazone in the absence and presence of trimethoprim in healthy volunteers.  
A secondary, exploratory aim of this study is to describe rosiglitazone pharmacokinetics in 
individuals expressing the CYP2C8*2 or *3 allelic variants.  
 
D. Background 
In humans, the cytochrome P450 (CYP) 2C subfamily, which includes the four isoenzymes 2C8, 
2C9, 2C18, and 2C19, is responsible for the metabolism of several drugs including non-steroidal 
anti-inflammatory drugs, tolbutamide, phenytoin, omeprazole, and diazepam [1-3].  CYP2C8 is 
primarily distributed in the liver [3], and is involved in the metabolism of paclitaxel [4], retinoic acid 
[4], and rosiglitazone [5-7].  Two polymorphisms have been identified in the CYP2C8 enzyme: 
CYP2C8*2 and CYP2C8*3 [8].  The CYP2C8*2 polymorphism is associated with a two-fold lower 
intrinsic clearance of paclitaxel and a decreased affinity for 6α-hydroxypaclitaxel, a major metabolite 
of paclitaxel; whereas CYP2C8*3 is associated with decreased paclitaxel turnover [3, 8].  Allelic 
frequencies have been reported to be 0.18 for CYP2C8*2 in African-Americans and 0.13 for 
CYP2C8*3 in Caucasians [8].  Identification of these polymorphisms serves as a basis to investigate 
variability associated with CYP2C8 in vivo enzymatic activity. 
Rosiglitazone is a thiazolidinedione antihyperglycemic agent used in the treatment of type 2 
diabetes [6, 7].  Thiazolidinediones exert their clinical effects via the peroxisome proliferator-
activated receptor γ (PPARγ) [9, 10], which facilitates the expression of genes responsible for 
glucose and lipid metabolism.  Rosiglitazone has a half-life in humans of approximately 3 to 4 hours, 
a volume of distribution of approximately 18 liters, and it is 99.8% bound to plasma proteins.  The 
maximum plasma concentration is reduced and the time at which the maximum concentration is 
achieved is delayed in the presence of food.  Age and renal function exert no effect on rosiglitazone 
pharmacokinetics [9].  Rosiglitazone undergoes extensive metabolism with essentially no parent drug 
excreted unchanged in the urine.  The two major metabolites of rosiglitazone isolated via microsomal 
and animal studies are para-hydroxy rosiglitazone and N-desmethyl rosiglitazone, both of which are 
produced by CYP2C8 [5, 6].  The sulfate conjugated para-hydroxy metabolite, para-O-sulfate-
rosiglitazone, has been shown in humans to be the major metabolite isolated in plasma [7].  Based on 
these characteristics, conversion of rosiglitazone to the para-O-sulfate-rosiglitazone metabolite may 
be useful as an isoform specific index of CYP2C8 enzyme activity.   
An important consideration when evaluating a potential probe drug is whether the probe suitably 
detects variation in activity of the target enzyme.  Thus, it has been suggested that one means by 
which an enzyme-specific probe can be validated is to evaluate the pharmacokinetics of the probe 
drug in subjects who are treated with an inhibitor of the target enzyme [10].  The CYP inhibitor to be 
administered in this study is trimethoprim, an antibiotic predominantly used in the treatment of 
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 respiratory and urinary tract infections.  Trimethoprim possesses antimicrobial activity against such 
organisms as Streptococcus pyogenes, Staphylococcus epidermis, Haemophilus influenzae, 
Escherichia coli, Proteus mirabilis, and Klebsiella spp.  The mechanism of action of trimethoprim is 
through competitive inhibition of the enzyme dihydrofolate reductase, a key enzyme in the folate 
pathway, which blocks DNA synthesis and leads to cellular death [11].  Basic pharmacokinetic 
parameters of trimethoprim include peak plasma concentrations occurring in 1-4 hours after single 
dose, bioavailability of 95%, t1/2 of ~10 hours, protein binding of 44%, a volume of distribution 
ranging from 70 -100 L, and excretion primarily renally as unchanged drug [11-14].  Trimethoprim 
has been shown in vitro to selectively inhibit CYP2C8 at concentrations ranging from 5 to 100 µM 
(1.45 – 29 µg/ml), with 80% inhibition anticipated to occur at a concentration at the enzyme site of 
20µM (5.8 µg/ml) [15].  Trimethoprim 200 mg administered twice daily reaches an average steady 
state (Cssave) plasma concentration of 3.1 µg/ml [14].  The associated hepatic concentration (enzyme 
site), based on the liver to plasma partition of 6.5:1 determined in the rhesus monkey, is expected to 
be approximately 20 µg/ml, thereby yielding an anticipated inhibition of CYP2C8 greater than 80% 
[16].   
The purpose of this study is to characterize the pharmacokinetics of rosiglitazone in the absence and 
presence of trimethoprim in healthy volunteers.  In addition, we will begin to gather preliminary data 
on the effect of genetic variation in CYP2C8 on the pharmacokinetics of rosiglitazone.  Due to the 
allele frequencies, we do not anticipate having an adequate number of individuals with allelic 
variants to determine the impact of the noted polymorphisms, but this will generate important 
preliminary data to support subsequent evaluation under a separate study. 
E. Progress and Preliminary Studies 
No studies to date have been performed.   
 
F.  Design and Methods 
 
Design Overview:  This study will be conducted in 8 subjects (4 men /4 women), who are 18 to 65 
years of age, and will involve rosiglitazone administration as follows:  (1) rosiglitazone 8 mg alone 
and (2) rosiglitazone 8 mg during trimethoprim 200 mg twice-daily.  The order of administration will 
be randomized in a cross-over design to avoid any bias or sequence related effect.  The visits will be 
separated by a washout period of one to two weeks.  
Screening Visit:  Subjects will be asked to read and sign the informed consent at the screening visit 
prior to the performance of any study-related procedures.  The screening visit lasts approximately 
one (1) hour and 10 ml of blood will be withdrawn.  Age, height, and weight will be recorded in a 
demographic record.  To participate, the subjects must not have any evidence of abnormal renal 
function (i.e., creatinine clearance as estimated by the Cockroft-Gault equation < 80 ml/min) or 
hepatic function (i.e., ALT or AST greater than 2.0-times the upper limit of normal or total bilirubin 
out of the normal range).  Women of childbearing potential will be given a pregnancy test to exclude 
pregnancy.  Once subjects are determined eligible they will return to the GCRC for study visit 1.  
Study Visit Procedures:  Subjects will be asked to abstain from alcohol and caffeine containing 
foods and beverages for 24 hours and from grapefruit or grapefruit juice for 48 hours prior to each 
study visit.  Subjects will also be asked to abstain from any over-the-counter medications, including 
non-steroidal anti-inflammatory drugs (e.g., naproxen and similar drugs), for 48 hours prior to each 
study visit.  Subjects will report to the GCRC by 6 PM the evening prior to each rosiglitazone dosing 
day.  They will fast from midnight the night before dosing until 2 hours (approximately 10:00 AM) 
after rosiglitazone administration.  Prior to dosing, an intravenous catheter will be inserted into an arm 
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 vein for the purpose of obtaining blood samples.  At approximately 12:00 PM, subjects may eat a 
standardized lunch, and after approximately 4:00 PM subjects may eat per normal schedule. 
Standardized lunch and dinner meals will be provided while at the GCRC. The subjects may drink 
water as needed.  All subjects will be genotyped for CYP2C8 allelic variants using a portion of the 
baseline blood sample collected for pharmacokinetic studies.  
Rosiglitazone Pharmacokinetics:  Blood samples (N=14; 10 ml or 2 teaspoons each, 140 ml total) 
will be obtained before and 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24 hours after drug 
administration.  Total voided urine will be collected via clean catch method before and at the 
following time intervals after the rosiglitazone administration: 0-8 hr and 8-24 hr.  Blood samples 
will be drawn in EDTA tubes, kept on ice, and centrifuged within two hours of collection at 2800 
rpm, 4oC, for 15 minutes.  Plasma will be harvested and stored at -70oC or colder until analysis.  
Urine will be refrigerated throughout the study day.  At the completion of each collection interval, the 
total volume of urine will be recorded and multiple aliquots will be stored at –70oC or colder until 
analysis.  Subjects will remain in the GCRC until the last blood draw; the total time required for 
subjects to remain in the GCRC is approximately 40 hours.   
Study Visits 
Rosiglitazone alone: Subjects will come to the General Clinical Research Center (GCRC) and will 
be given a single oral dose of rosiglitazone 8 mg at approximately 8 AM.  Blood and urine 
collection will occur as described above.  Subjects will be discharged after the last blood draw at 
24 hours.   
Rosiglitazone and trimethoprim: Subjects will be given five trimethoprim 200mg tablets to self-
administer as trimethoprim 200 mg twice daily at approximately 7:30 AM and 7:30 PM for three 
days.  On the third day, subjects will report to the GCRC by 6:00 PM, give a blood sample (10 ml) 
at approximately 7:00 PM, and will be given trimethoprim 200 mg at approximately 7:30 PM.  
Subjects will be administered 3 more doses of trimethoprim 200 mg every 12 hours for a total of 
ten doses (Table 1).  We anticipate that trimethoprim 200mg twice daily will yield an average 
plasma concentration of 3.1 µg/ml.  Subjects will then undergo the same procedure as in 
rosiglitazone alone with additional blood draws (10 ml) at 30, 36, and 48 hours after rosiglitazone 
dosing and additional urine collection from 24 to 36 hours.  Subjects will be discharged after the 
last blood draw at 36 hours, but must return for a 48-hour blood sample; the total time required for 
subjects to remain in the GCRC is approximately 50 hours.  A total of seventeen (17) blood 
samples (170 ml) will be obtained during this study period. 
Table 1 
Day -3 -2 -1 1 2 
Rosiglitazone 8 mg    X  
Trimethoprim 200 mg BID X X X X X 
 
A portion of the blood sample obtained prior to rosiglitazone dosing will be used for CYP2C8 
genotyping, which will allow a preliminary comparison of para-O-rosiglitazone formation rate 
between the genotypes CYP2C8*1/*2  and CYP2C8*1/*3 versus wild type CYP2C8*1/*1 . 
The total amount of blood to be collected over the duration of the study, including screening labs, is 
approximately 320 milliliters (22 tablespoonfuls).   
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 Sample Analysis 
Rosiglitazone and para-O-rosiglitazone will be measured using high performance liquid 
chromatography (HPLC) with fluorescence detection based on a method reported by Cox et al [7].  
Trimethoprim will be measured in plasma by an HPLC ultraviolet detection assay reported by Ronn 
et al [17]. 
 
Data Analysis 
Rosiglitazone.  The rosiglitazone concentration-time data will be analyzed by noncompartmental 
methods.  The terminal elimination rate constant (λz) will be estimated by nonlinear least squares 
regression analysis of the terminal portion of the concentration-time data.  Apparent elimination half-
life will be calculated as 0.693/ λz.  The area under the concentration time curve (AUC) and the area 
under the first moment of the concentration time curve (AUMC) will be calculated by the linear 
trapezoidal rule with extrapolation to infinity.  Mean residence time (MRT) will be calculated as 
[AUMC0-∞ / AUC0-∞].  Apparent oral clearance (CLO) will be determined as [Dose / AUC0-∞] and the 
apparent steady-state volume of distribution will be determined as [CLO × MRT].  The formation 
clearance of para-O-rosiglitazone will be calculated as the amount of each metabolite recovered in the 
urine, divided by the plasma rosiglitazone AUC from the same time interval. 
Trimethoprim.  The trimethoprim concentration-time data will be analyzed by non-compartmental 
methods.  The area under the concentration time curve (AUC) will be calculated by the linear 
trapezoidal rule over the duration of rosiglitazone blood sampling. 
CYP2C8 Genotyping.  CYP2C8 genotype data will be used to generate preliminary data on the effect 
of CYP2C8 allelic variants on rosiglitazone pharmacokinetics.  The DNA obtained from a single 
blood sample will be stored in Dr. Frye’s laboratory and will not be made available to anyone for 
purposes other than those of this study.  Samples will be stored without personal identifiers, using a 
unique study code, and destroyed within one year after the conclusion of this study.  Subjects may 
request at any time that their samples be destroyed or released to a designee of their choosing, but 
only with written permission.  Samples will be destroyed within one week. 
 
G. Biostatistical Design and Analysis 
Sample Size and Power: The objective of this study is to determine whether rosiglitazone clearance 
and para-hydroxylation are inhibited in the presence of trimethoprim.  This study is a randomized 
two-way, crossover design and the primary endpoints are rosiglitazone AUC and para-O-
rosiglitazone formation clearance, which serve as surrogate estimates of CYP2C8 activity.  Subjects 
will be randomized by randomly permuted blocks (8 subjects randomized in 2 blocks).  There will 
not be any stratifying factors employed.  Sample size calculations were performed using PASS 
(version 6.0, Kaysville, UT) and are based on the within-subject coefficient of variation (CV) 
reported for rosiglitazone AUC, which was 18% [18].  Using this within-subject CV, the proposed 
sample size of N = 8 subjects will allow for the detection of an effect size of 1.5 (90% power, α = 
0.05, two-sided), which translates into a 27% difference.  The expected magnitude of difference is 
more than 100%. 
Statistical Analysis Plan: Rosiglitazone AUC and para-O-rosiglitazone formation clearance will be 
compared by paired t-test.  Parameter values will be log-transformed prior to analysis since these 
values exhibit log-normal distribution.  A two-sided p ≤ 0.05 will be considered significant and all 
calculations will be performed using SAS software version 8.02 (SAS, Cary, NC).  The expected 
outcomes are that rosiglitazone AUC and para-O-rosiglitazone formation clearance, surrogate 
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 markers of CYP2C8 activity, will be decreased in the presence of trimethoprim as a result of enzyme 
inhibition. 
 
H. Human Subjects 
1. Subject Population.  Eight (8) healthy subjects aged between 18 and 65 years will complete 
this study.  Based on past experience, we anticipate a screening failure rate of approximately 25%, 
thus the proposed number of subjects enrolled per IRB guidelines will be ten (10), which allows for 
potential dropouts.  An even number of men and women will be recruited and will give written 
informed consent.  As defined by NIH, this study will enroll children aged 18 to 21 years; children 
less than 18 years of age will be excluded from study participation since this study poses greater than 
minimal risk and there is no potential for direct benefit to the subject. 
 
   Each subject will have to pass a screening evaluation based on history, physical examination and 
the following biochemical and urinalysis tests: BUN, creatinine, electrolytes, liver function tests, 
total protein, albumin, complete blood count, urine pH, hemoglobin, protein, glucose, specific gravity 
and microscopic examination of sediment.  Pregnant women, or women who are currently breast-
feeding an infant, will not be allowed to take part in this study.  Women of childbearing potential will 
be tested to exclude pregnancy using a urine pregnancy test.  Use of oral contraceptives or hormonal 
replacement therapy will be permitted.  Abstinence from alcohol (in any form) and caffeine for 24 
hours and grapefruit/grapefruit juice for 48 hours before and during the period of the rosiglitazone 
pharmacokinetic studies is also required. 
Minority Inclusion Statement:  Women or men of all races will be eligible and recruited for this 
study.  Women and men will be balanced.  The racial and age mix of the study will be representative 
of the population of Western Pennsylvania. There will be no exclusion based on race, sex, or 
ethnicity. 
Total Planned Enrollment: 8 
TARGETED/PLANNED ENROLLMENT: Number of Subjects 
Sex/Gender Ethnic Category Females Males Total 
 Hispanic or Latino 0 0 0 
 Not Hispanic or Latino 4 4 8 
 Ethnic Category Total of All Subjects* 4 4 8
Racial Categories  
 American Indian/Alaska Native 0 0 0 
 Asian 0 0 0 
 Native Hawaiian or Other Pacific Islander 0 0 0 
 Black or African American  1 1 2 
 White 3 3 6 
 Racial Categories: Total of All Subjects * 4 4 8
 
Inclusion Criteria 
1. Non-smokers (self-reported) aged between 18 and 65 years. 
2. Body Mass Index (BMI) < 31. 
3. Signed Informed Consent. 
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 Exclusion Criteria 
1. Any evidence of renal dysfunction (estimated creatinine clearance < 80ml/min). 
2. Any evidence of impaired hepatic function (liver enzymes greater than two times the 
upper limit of normal or bilirubin outside the normal range). 
3. Taking any medications other than oral contraceptives or hormonal replacement therapy. 
4. Women who are pregnant or are currently breastfeeding. 
5. Prior hypersensitivity to trimethoprim and/or co-trimoxazole (i.e. Bactrim or Septra) 
 
2. Sources of Research Material:  During this study, thirty-one blood samples (310 ml) will be 
collected during the pharmacokinetics studies.  A portion of a single blood sample will be used to 
obtain DNA for genotyping.  Urine will be collected in intervals for 24-36 hours after 
rosiglitazone administration.  The blood and urine will be obtained specifically for research 
purposes in order to meet our specific aim.   
3. Recruitment Methods and Consent Procedures:  Subjects will be recruited through an 
advertisement that will be placed in the Pitt News (See Appendix A).  Informed Consent will be 
obtained prior to any screening procedures.  Subjects considering enrollment in the study will be 
provided with an IRB approved consent form to read, and the study protocol will be explained to 
them.  Any questions that potential subjects have will be answered by a physician co-
investigator; if interested in study participation subjects will be required to sign the consent form 
and have that witnessed.  A copy will be maintained in the subject’s GCRC chart and a copy 
retained by the investigator.  A physician co-investigator will obtain consent and sign the 
Investigator’s Certification.  Eligible subjects will then undergo a screening assessment based on 
history, physical examination and laboratory tests to assess their suitability for the study.   
4. Potential Risks:  Side effects are listed below for each of the drugs used in this study.  These 
medications may cause all, some, or none of the side effects listed below.  Furthermore, there is 
always the risk of very uncommon or previously unknown side effects occurring.  Side effects 
that are considered likely occur in more than 10 out of every 100 (10%) people who take the 
drug, common side effects occur in approximately 1 to 10% of people, and rare side effects occur 
in less than 1% of people.  
 
Rosiglitazone has been well-tolerated in several drug interaction studies conducted in healthy 
volunteers [18-21].  Unlike other anti-diabetic agents, rosiglitazone has not been shown to cause 
hypoglycemia in healthy volunteers.  Rosiglitazone has been shown to be associated with 
hepatocellular injury in men greater than 60 years of age after 2 to 3 weeks of daily therapy. 
Rosiglitazone (8 mg) is a FDA approved anti-diabetic agent used alone or in combination in 
the treatment of Type 2 diabetes mellitus. 
Likely: Weight gain. 
Common: Upper respiratory tract infection, headache, peripheral edema, back pain or injury, 
fatigue, hyperglycemia, diarrhea, and anemia. 
Rare: Exacerbation of CHF, elevated transaminases, hepatic failure, hepatitis, increased 
bilirubin, pulmonary edema. 
Trimethoprim, 200 mg twice daily, has been administered safely for five days in the treatment of 
urinary tract infection and yielded a lower incidence of adverse effects versus the 
sulfamethoxazole/trimethoprim combination product (e.g., Co-trimoxazole).  The most frequent 
events reported were gastrointestinal disturbances such as nausea, vomiting, and diarrhea [22].  
Healthy volunteers tolerated doses of 12 mg/kg/day and reported nausea and headaches as the 
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 most frequent adverse events [23].  Large doses up to 23 mg/kg/day have been utilized in the 
treatment of Pneumocystis carinii Pneumonia (PCP) in AIDS patients, with the most frequent 
adverse events reported as gastrointestinal disturbances, followed by LFT abnormalities, 
neutropenia, and thrombocytopenia [24, 25].  The frequency of these events increases with the 
duration of therapy and sustained plasma concentrations greater than 5 µg/ml [25].   It is 
anticipated in this study that subjects administered 200 mg twice daily for 5 days will achieve 
steady-state concentrations of 3.0 µg/ml and maximum concentrations of ~4.0 µg/ml, which are 
below the threshold of 5 µg/ml [14].    
Trimethoprim (200 mg) is an FDA approved antibiotic used in the treatment of infections of 
the urinary and respiratory tracts. 
Likely: None. 
Common: Rash, pruritis, megablastic anemia (with chronic high dose). 
Rare: Fever, exfoliative dermatitis, nausea, vomiting, epigastric distress, thrombocytopenia, 
neutropenia, leukopenia, hyperkalemia, cholestatic jaundice, increased LFTs, elevated 
BUN/serum creatinine   
The risks involved with this study include the discomfort and inconvenience of having an 
intravenous catheter placed and blood samples collected with potential for pain, bruising, 
bleeding and infection.   
Due to the genetic component of this study, there is a risk for breach of confidentiality, which 
could impact future insurability, employability or reproduction plans, or have a negative impact 
on family relationships, and/or result in paternity suits or stigmatization.  The DNA obtained will 
be stored in Dr. Frye’s laboratory and will not be made available to anyone for purposes other 
than those of this study.  Samples will be stored without personal identifiers, using a unique study 
code, and destroyed in one year after the conclusion of this study.  Subjects may request at any 
time that their samples be destroyed or released to a designee of their choosing, but only with 
written permission. 
5 Risk Management Procedures: The risk of adverse experiences in this study will be minimized 
by utilizing only qualified individuals to conduct the study, the staff in GCRC in UPMC-MUH.  
Appropriate attention to detail in the experimental setting will be emphasized.  Moreover, this 
study will use small, single doses of rosiglitazone and short-term exposure to trimethoprim and 
thus, the likelihood of dose-related adverse events should be minimized.  Immediate medical 
treatment will be provided for any illness or injury resulting from this study.  Trained nursing 
staff are present in the GCRC at all times and the physician co-investigator will also be available 
to evaluate the subject.  In the event that a subject experiences an intolerable side effect, the subject 
will be withdrawn from the study and followed for resolution of the effect(s).  A subject may also 
be removed from the study if in the opinion of the physician investigator, it is in the subject’s best 
interest. 
Data Safety Monitoring Plan.  This study involves a small number of subjects who will be 
closely monitored by the Investigators and research personnel on the General Clinical Research 
Unit.  The data and safety information obtained in each study subject is reviewed at a weekly or 
biweekly meeting held by the Investigators.  As a part of these meetings, the research team will 
monitor data, confidentiality, and recruitment in addition to adverse events. A summary report 
from the meetings will be submitted to the IRB at the time of annual renewal.  If a serious life-
threatening event occurs, the event will be reported immediately (i.e., within 24 hours) to both 
the FDA and the IRB.  Unexpected reactions of moderate or greater severity will be reported to 
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 the IRB within 10 calendar days of the reaction.  Minor events will be reported to the IRB at the 
time of annual review. 
6.  Evaluation of the Risk/Benefit Ratio: No personal benefit will result from this study; however, 
this study may provide important information on the use of rosiglitazone as a CYP2C8 enzyme 
selective probe drug.  The risk to benefit ratio of this study is considered low. 
7.  Cost and Payment:  All procedures necessary for the completion of these studies will be 
performed at no cost to the study subjects (or their insurance providers).  The subjects will be 
paid for study participation.  Subjects will be paid $500 for completion of the entire study.  If 
only one of the two study visits is completed, subjects will be paid $200.  Other than the payment 
and their contribution to our knowledge of drug action, there are no benefits to the subjects for 
participating in this study. 
 
I. Justification for Utilization of GCRC Resources 
The GCRC use is being requested to take advantage of the facilities and expertise available there to 
ensure proper conduct of the study.  It will ensure that drugs are given under medical supervision and 
samples are collected by qualified professionals with experience in the conduct of research studies.  
These factors are important to obtain results that are valid and interpretable. 
 
J. Study Size and GCRC Resources 
  1. Number of subjects     10 (8 to complete) 
  2. Annual number of research patient days  32 
  3. Annual number of outpatient visits 18 (screening, 8 outpatient 
blood draws ) 
  4. Estimated Ancillary Costs Per Patient Days   
  5. Estimated Ancillary Costs Per Outpatient Visit  
  6. Description of Other GCRC Resources Required None 
 
K. Research needs to be provided by Investigator’s laboratory 
Analytical assays required for the determination of concentrations of rosiglitazone, para-O-
rosiglitazone, and trimethoprim will be conducted by Dr. Frye.  Labeled storage containers for 
plasma/urine samples will be provided. 
 
L. Funding Support: Pharmacodynamic Research Center 
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N. Qualifications of Investigators 
 
Reginald F. Frye, Pharm.D., Ph.D. is an Assistant Professor in the Department of Pharmaceutical 
Sciences, School of Pharmacy, and a member of the Center for Clinical Pharmacology.  He is also 
Director of the Clinical Pharmacology Analytical Facility.  He has expertise in the evaluation of drug 
metabolism in humans. 
Matthew W. Hruska, Pharm.D, is a Ph.D. student in the Clinical Scientist Program in the School of 
Pharmacy and has experience in the conduction of clinical research studies.  He will serve as the 
study coordinator.  
Janet A. Amico, M.D. is a Professor of Pharmaceutical Sciences and Medicine in the Department of 
Pharmaceutical Sciences and Division of Endocrinology.  She is active in both clinical and research 
endeavors that focus on endocrinology.   
 157   
  PROTOCOL APPENDIX A 
 
 
 
ADVERTISEMENT 
 
Healthy men and women 18-65 years old are needed for a research study 
evaluating how one drug affects the break down of another drug.   
The study requires two 2-night stays (1 or 2 weeks apart) in UPMC-Montefiore.   
Participants will be paid $500.00 upon study completion.  Contact Matthew Hruska, School of 
Pharmacy.  mwhst12@pitt.edu or 412-624-8105. 
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CONSENT TO ACT AS A SUBJECT IN AN EXPERIMENTAL STUDY 
 
TITLE: Effect of CYP2C8 inhibition by trimethoprim on the pharmacokinetics of 
rosiglitazone. 
 
Principal Investigator: Reginald F. Frye, Pharm.D., Ph.D. 
 Associate Professor, School of Pharmacy 
 807 Salk Hall 
 (412) 624-4683 
Co-Investigators: Janet A. Amico, M.D. 
 Matthew W. Hruska, Pharm D 
 School of Pharmacy 
 904 Salk Hall 
    412-648-8430 
 
SOURCE OF SUPPORT: Pharmacodynamic Research Center  
 
TO PERSONS BEING ASKED TO PARTICIPATE IN THIS STUDY: 
The following information is provided to inform you about a research study that you are being asked to 
participate in.  Please read this form carefully.  Any questions you may have about this study will be 
answered.  Please feel free to ask any questions you may have about this study and/or about the 
information given below. 
 
Why is this research being done? 
   You are being asked to participate in this study because you are a healthy man or woman between the 
ages of 18 and 65 years old.  The purpose of this study is to determine if the antibiotic trimethoprim 
changes how the body metabolizes (breaksdown) the drug rosiglitazone.  If you agree to participate in this 
study, you will receive on two separate occasions, a single doses of rosiglitazone 8 mg (a drug normally 
used to assist the body with adjusting sugar in the blood).  Rosiglitazone is taken by mouth as a tablet to 
treat diabetes and has been approved for use by the US Food and Drug Administration (FDA).  In 
addition, you will be asked to take an antibiotic twice a day for 5 days.  You will take it at home for 3 of 
the days.  The antibiotic you will be given is trimethoprim, 200 mg twice daily, an FDA approved 
antibiotic used in the treatment of respiratory and urinary tract infections.  Both rosiglitazone and 
trimethoprim will be given by mouth.
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Who is being asked to take part in this research study? 
 You are being invited to take part in this research study because you are a healthy volunteer.  A total of 
up to ten healthy men and women will participate in this study.  This study will require two (2) two-night 
stays in the General Clinical Research Center (GCRC) in UPMC-Montefiore Hospital.  One visit will last 
for approximately 40 hours and the other visit will last for approximately 50 hours. 
   
What procedures will be performed for research purposes? 
If you agree to be one of the ten study subjects, you understand that the following will be required of you: 
 
• You will have a physical exam and laboratory tests (requiring 10 mL or two teaspoonfuls of 
blood) to determine if you are eligible to participate in the study.  The purpose of the blood 
sample is for the screening laboratory tests (to check how your kidney and liver are working).  
The exam and laboratory tests will be done within four (4) weeks prior to the start of the study.  
These examinations and screenings will require one to two hours of your time and are not 
designed for the purpose for your personal health care, but only for qualification to enter the 
study. 
• If you are a woman of childbearing age, you will have a pregnancy test.  If this is positive, you 
will not be eligible to participate in this study.  Pregnant women, or women who are currently 
breast-feeding an infant, will not be allowed to take part in this study. 
• To be eligible to participate in this study, you should not be taking any medications other than 
birth control pills or hormone replacement therapy.  You will not be permitted to drink any 
alcoholic or caffeine containing food or beverages for 24 hours prior to the study visits.  You will 
not have any grapefruit or grapefruit juice 48 hours prior to or during the study.  You will be 
asked to abstain from taking any over the counter medications 48 hours prior to the study day and 
throughout your participation in this study (requiring an additional 50 hours). 
Experimental Procedures: 
 
If you qualify to take part in this research study, you will undergo the following experimental procedures: 
 
1. There will be two overnight study visits at the GCRC.  On one visit you will be given 
rosiglitazone alone and on the other visit you will be given trimethoprim and rosiglitazone.  The 
second study visit will occur at either one (1) or two (2) weeks after the first study visit.  The 
order in which these visits occur will be assigned by chance (like flipping a coin).   
2. For the rosiglitazone alone study visit, you will report to the GCRC by 6:00 PM, the night prior to 
rosiglitazone administration.  If you are female and capable of bearing children, a urine 
pregnancy test will be performed.  If the pregnancy test is positive, you will not be allowed to 
participate in this study.  The next morning, a catheter (thin plastic tube inserted into a vein) will 
be placed in a forearm vein of one of your arms for the purpose of blood collection.  You will 
give a pre-dose blood sample (10 ml or two teaspoonfuls) from your catheter.  At approximately 
8:00 AM, you will be given a rosiglitazone tablet (8 mg) by mouth with 8 ounces of water.  A 10 
ml blood sample (two teaspoonfuls) will be obtained at 15, 30, and 45 minutes, 1, 2, 4, 6, 8, 10, 
12, 16, 20, and 24 hours after rosiglitazone administration.  You will be allowed to eat regularly, 
with the exception of caffeine, two hours after you take rosiglitazone.  You will remain in the 
GCRC overnight. Total voided urine will be collected before and at the following time intervals 
after rosiglitazone administration: 0-8 hr and 8-24 hr. The catheter will be removed after the 24-
 160 Subject Initials _________ 
Approval Date: 11/18/2002 
Renewal Date: 11/17/2003 
University of Pittsburgh 
IRB#020971 
Consent version: 11/14/2002 
 
hour blood sample is collected.  You may leave the GCRC after collection of the 24-hour blood 
and urine samples.   
3. For the rosiglitazone and trimethoprim study visit, you will be given five (5) trimethoprim 200 
mg tablets to take at home.  You will take one (1) trimethoprim 200 mg tablet twice daily, at 
approximately 7:30 AM and 7:30 PM, with a full glass of water for 3 days.  A study coordinator 
will contact you to ask about taking the study drugs and to ask you if you are experiencing any 
side effects from the drug.  On the evening of the third day of taking trimethoprim, you will 
report to the GCRC by 6:00 PM and receive another dose of trimethoprim at approximately 7:30 
PM and continue to be given trimethoprim every 12 hours for a total of five (5) more times.  You 
will be given rosiglitazone 8 mg at approximately at 8:30 AM.  The blood draws will follow the 
same procedures as above with additional blood samples taken at 30, 36, and 48 hours and 
additional urine collection from 24-36 hours after taking rosiglitazone.  You may leave the GCRC 
after collection of the 36-hour blood sample, but must return to the GCRC at 48 hours after 
rosiglitazone administration and give a 10 ml blood sample to measure the concentration of 
rosiglitazone. 
4. A portion of one of the blood samples obtained will be collected to obtain deoxyribonucleic acid 
or DNA (genetic material).  The DNA will be used to screen for genetic differences in drug 
metabolizing enzymes that break down drugs. The activities of these enzymes vary between 
individuals due to both genetic and environmental factors.  The DNA obtained will be stored in 
the Principal Investigator’s Laboratory in Salk Hall for use in the current study only.  The 
samples will contain only a study code number and not your name or any other information 
identifying you.  You can request at any time that the samples be destroyed.  The blood samples 
will be under the control of the principal investigator listed on the first page of this form, and will 
be destroyed in one (1) year, at the conclusion of the study. 
5. A total of thirty-one (31) blood samples will be obtained during the rosiglitazone study days for a 
total amount of 310 ml (about 10 ounces or 21 tablespoonfuls). 
6. The total blood withdrawn from you during the study, including screening labs, will be 
approximately 22 tablespoonfuls or 320 ml.  The amount of blood withdrawn when someone 
donates a unit of blood is approximately 30 tablespoonfuls or 450 ml. 
 
What are the possible risks, side effects, and discomforts of this research study? 
As with any investigational study, there may be adverse events or side effects that are currently unknown 
and it is possible that certain of these unknown risks could be permanent, serious or life-threatening.  You 
will not experience any personal benefits to your health as a result of your participation in this study.  You 
will receive a total of two (2) doses of rosiglitazone and ten (10) doses of trimethoprim for this study and 
that they may cause all, some, or none of the side effects listed below.  You may experience previously 
unknown side effects or you may have an allergic reaction to the drug.  You will be asked if you have 
received the study drugs in the past and, specifically, if you have experienced any side effects.  If you 
have, you may not be able to participate in this study.  If you are a woman capable of becoming pregnant, 
a pregnancy test will be conducted before you take the study drug.  If you are pregnant, you will not be 
allowed to continue with this study.  If you think you are experiencing a side effect from rosiglitazone or 
trimethoprim, you must let the research nurse at the GCRC and one of the investigators know 
immediately. 
 
Side effects are listed below for each of the drugs used in this study.  Side effects that are considered 
LIKELY, occur in more than 10% of people (more than 10 out of every 100 people) who take the drug, 
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COMMON side effects occur in approximately 1% to 10% of people (1 to 10 out of 100 people), and 
RARE side effects occur in less than 1% of people (less than 1 in 100 people). 
 
Risks of the study drugs. 
Rosiglitazone (8 mg) is an FDA approved drug used to lower blood sugar to treat Type 2 diabetes.  
Rosiglitazone has not been shown to cause hypoglycemia (low blood sugar, symptoms include sweating, 
lightheadedness, weakness, nausea, confusion or loss of consciousness) in healthy volunteers. 
Likely (occurs in more than 10 out of every 100 people): Weight gain (usually seen with chronic use). 
Common (occurs in approximately 1 to 10 out of every 100 people): Upper respiratory tract infection 
(fever, stuffy or runny nose), headache, peripheral edema (swelling of the feet or legs), back pain, injury, 
high blood sugar, diarrhea, anemia (decreased red blood cells; symptoms include dizziness, 
lightheadedness). 
Rare (occurs in less than 1 out of every 100 people): Worsening of congestive heart failure, elevated liver 
enzymes, liver failure, hepatitis, increased bilirubin (a pigment released when the liver processes waste), 
pulmonary edema (increased fluid in the lungs). 
 
Trimethoprim (200 mg) is an FDA approved antibiotic used to treat urinary and respiratory tract 
infections. 
Likely (occurs in more than 10 out of every 100 people): None. 
Common (occurs in approximately 1 to 10 out of every 100 people): Rash, itchiness, and with chronic 
high doses, megaloblastic anemia (large red blood cells, symptoms include dizziness, lightheadedness). 
Rare (occurs in less than 1 out of every 100 people): (usually occur with duration of treatment greater 
than 10 days) Fever, exfoliative dermatitis (inflamed skin, which falls off in scales or layers), nausea, 
vomiting, epigastric distress (gastrointestinal discomfort such as epigastric pain (heartburn-like feeling), 
increased blood potassium levels, yellowing of the skin, elevated liver enzyme levels associated with liver 
failure, elevated blood urea nitrogen/serum creatinine (breakdown products of blood, muscle, and 
protein), neutropenia (low neutrophil counts), leukopenia (low leukocyte counts), thrombocytopenia (a 
decrease in platelet count), and abnormal liver function tests (an increase in the liver enzymes that is 
associated with liver damage).  Neutrophils and leukocytes are white blood cells that fight infections.  
Platelets are cells responsible for blood clotting.   
To avoid risk to the fetus, it is important that you not be pregnant when we conduct this study. We also 
advise that you (or your female sexual partner) not become pregnant for one week after ingestion of the 
study drugs. Avoiding sexual activity is the only certain method to prevent pregnancy. However, if you 
choose to be sexually active, you should use an appropriate “double barrier” method of birth control (such 
as female use of a diaphragm, intrauterine device (IUD), or contraceptive sponge, in addition to male use 
of a condom) or the female should be using prescribed “birth control” pills, injections, or implants. If you 
choose to be sexually active during this study, pregnancy could still result even with the use of these birth 
control methods. The risks of receiving the study drug while pregnant include potential loss of pregnancy 
or possible birth defects. 
 
Risks of the Blood Tests: 
Bruising, soreness, or rarely, infection may occur as a result of the needle sticks to obtain blood from your 
vein. 
 
Risks of the Genetic Tests: 
There is a possibility that if the results of a research study involving genetic material were to become 
generally known, this information could affects one’s ability to be insured, employed, future plans for 
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children, or family relationships.  In this study, all genetic data are stored without personal identifying 
information (all samples are stored with a unique study code number). 
 
What are possible benefits from taking part in this study? 
You will receive no direct benefit from taking part in this research study.  Information from the DNA 
contained in the blood sample will not provide any immediate benefit to you.  Since there are no 
established links between the information obtained and possible genetic changes, you will not be 
informed of the results of any gene testing.  The DNA obtained will be stored in Dr. Frye’s laboratory in 
Salk Hall for use in the current study only.  The samples will be stored indefinitely for use in the current 
study only.  You can request at any time that the samples be destroyed. 
If I agree to take part in this research study, will I be told of any new risks that may be found during 
the course of the study? 
You will be promptly notified if any new information develops during the course of this study which may 
cause you to change your mind about continuing to participate. 
Will my insurance provider or I be charged for the costs of any procedures performed as part of this 
research study? 
Neither you, nor your insurance provider, will be charged for the costs of any of the procedures 
performed for the purpose of this research study (i.e., the Screening Procedures and Experimental 
Procedures described above). 
Will I be paid if I take part in this research study? 
Participation in this study is voluntary.  If you decide to participate in this study, all procedures performed 
and medications given will be at no cost to you. Upon successful completion of the requirements of the 
study, you will be paid the sum of $500 for your participation. If, for whatever reason, you only complete 
the first of the two study visits, you will be paid $200.  Parking fees related to your participation in this 
study will not be paid for by the study.  
Your blood sample and its DNA used in this research study may contribute to a new invention or 
discovery.  In some instances, these inventions or discoveries may be of commercial value and may be 
sold, patented, or licensed by the investigators and the University of Pittsburgh for use in other research 
or the development of new products.  If you agree to participate in this research study, there are currently 
no plans to share with you any money that may result from the development of such products.  You retain 
the right to have your blood samples and its DNA destroyed should you decide to withdraw from this 
research study. 
Who will pay if I am injured as a result of taking part in this study? 
University of Pittsburgh researchers and their associates who provide services at the UPMC Health 
System (UPMC HS) recognize the importance of your voluntary participation in their research studies. 
These individuals and their staffs will make reasonable efforts to minimize, control, and treat any injuries 
that may arise as a result of this research. If you believe that you are injured as a result of the research 
procedures being performed, please contact immediately the Principal Investigator or one of the co-
investigators listed on the first page of this form.  
Emergency medical treatment for injuries solely and directly related to your participation in this research 
study will be provided to you by the hospitals of the UPMC HS. It is possible that the UPMC HS may bill 
your insurance provider for the costs of this emergency treatment, but none of these costs will be charged 
directly to you. If your research-related injury requires medical care beyond this emergency treatment, 
 163 Subject Initials _________ 
Approval Date: 11/18/2002 
Renewal Date: 11/17/2003 
University of Pittsburgh 
IRB#020971 
Consent version: 11/14/2002 
 
you will be responsible for the costs of this follow-up care unless otherwise specifically stated below. 
You will not receive any monetary payment for, or associated with, any injury that you suffer in relation 
to this research. 
Who will know about my participation in this research study? 
   All records related to your involvement in this research study will be stored in a locked file cabinet. 
Your identity on these records will be indicated by a case number rather than by your name, and the 
information linking these case numbers with your identity will be kept separate from the research records. 
Only the researchers listed on the first page of this form and their staff will have access to your research 
records.  Initials and a code number will indicate your identity on donated blood samples and their DNA.  
University policy requires that all research records be kept for a period of not less than 5 years after the 
study ends. 
   Any information about you obtained from this research will be kept as confidential (private) as possible. 
You will not be identified by name in any publication of research results unless you sign a separate form 
giving your permission (release). In unusual cases, your research records may be released in response to 
an order from a court of law. It is also possible that authorized representatives of the Food and Drug 
Administration and/or the University Research Conduct and Compliance Office may inspect your 
research records.  If the researchers learn that you or someone with whom you are involved is in serious 
danger or harm, they will need to inform the appropriate agencies as required by Pennsylvania law. 
Is my participation in this research study voluntary? 
Your participation in this research study is completely voluntary. You do not have to take part in this 
research study and, should you change your mind, you can withdraw from the study at any time. Your 
current and future care at a UPMC HS facility and any other benefits for which you qualify will be the 
same whether you participate in this study or not. 
If I agree to take part in this research study, can I be removed from the study without my consent? 
   It is possible that you may be removed from the research study by the researchers if, for example, your 
pregnancy test proves to be positive, you experience a side effect that is intolerable, or if in the opinion of 
the physician investigator, it is in your best interest to no longer participate in this study. 
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************************************************************************************* 
 
IF I HAVE A QUESTION:  If at any time in the study I wish to contact and discuss any aspect of the 
research study with the investigators I may contact Dr. Frye at (412) 624-4683 or any of the other 
investigators at the phone numbers provided on the front of this Consent Form. 
 
 
VOLUNTARY CONSENT: 
 
I certify that I have read the preceding, or it has been read to me, and I understand its contents. Any 
questions I have pertaining to the research have been, and will continue to be answered by the 
investigators listed at the beginning of this consent form at the numbers given. Any questions I have 
concerning my rights as a research subject will be answered by the Human Subjects Protection Advocate 
at the University of Pittsburgh IRB Office (412-578-8570). A copy of this consent form will be given to 
me. My signature below means I have freely agreed to participate in this project. 
 
 
 
_____________________________________________  ____________________ 
Subject Signature Date and Time 
 
 
 
_____________________________________________  ___________________ 
Witness Date and Time 
 
 
I certify that I have explained to the above individual the nature and purpose, the potential benefits and 
possible risks associated with participating in this research study, have answered any questions that have 
been raised, and have witnessed the above signature. 
 
 
 
_____________________________________________  ____________________ 
Investigator Signature Date and Time
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